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Glycolipids, particularly -galactosylceramides, have gained considerable attention due to 
their ability to modulate immune responses. The discovery of a synthetic glycolipid antigen, 
KRN7000, has enhanced our understanding of iNKT cell function. Since KRN7000 stimulates 
iNKT cells to release both Th1 and Th2 cytokines in relative amounts at which the biological 
activity of either one is antagonized by the other, tremendous effort has been devoted toward 
synthesizing analogues of KRN7000 that bias cytokine release, as such targets may offer new 
approaches to treating viral infections, bacterial infections, cancer, and autoimmune conditions. 
The first part of this proposal describes the synthesis of a series of novel carbohydrate modified 
analogues of -galactosylceramide. These analogues have modifications at C6” of the sugar 
moiety as well as on the sphingoid base. Development of these analogues was aimed at inducing 
Th1 biased cytokine release in iNKT cells.  
For the past two decades, the Howell group has made contributions towards the novel 
synthesis and application of 4-membered heterocyclic compounds such as oxetanes and 2-
methyleneoxetanes. The second part of this dissertation will discuss the development of Lewis 
acid mediated transformations utilizing 2-methyleneoxetanes to access synthetically valuable 
products. Herein, we present the first example of 2-methyleneoxetanes as nucleophiles in carbon-
carbon bond forming reaction. 
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Chapter 1. Synthesis of -GalCer analogues as NKT-cell agonists 
1.1 General introduction to glycosylceramides 
1.1.1 Glycosphingolipids 
Glycosphingolipids (GSLs) are a diverse class of glycolipids found in the lipid membranes 
of plants, animal cells, and bacterial cells. They have varied molecular structures and play key 
roles in cell-cell communication, viral and bacterial infections, immune system activation and 
modulation, and cell proliferation.1 GSLs are comprised of a ceramide backbone covalently linked 
to one or several saccharide residues. GSLs are generally classified into four categories:2 
1. Cerebrosides Containing one sugar residue 
2. Neutral glycosphingolipids Containing one or more uncharged sugar residues 
3. Gangliosides Containing one or more neuraminic acid residues 
4. Sulfatides Containing one sulfated residue on the saccharide 
Ceramides contain a sphingoid base with an amide linkage to a fatty acid chain (Figure 
1A), which can vary in saturation, length, branching, and hydroxylation. Natural sphingoid bases 
consist of sphingosine (2S,3R-D-erythro-2-amino-1,3-octadec-4E-enediol), sphinganine (2S,3R-
D-erythro-2-amino-1,3-octadecanediol) and phytosphingosine (2S,3S,4R-D-ribo-2-amino-1,3,4-
octadecane triol) (Figure 1B).  The sphingoid base of GSLs has a 1”-1’ glycosidic linkage to the 
sugar head group, which is most commonly glucose or galactose (Figure 1C, D). This glycosidic 
linkage of the anomeric carbon (C1”) to the sugar can be in either - or -linkage (Figure 1E). 
Mammalian glycolipids usually exist in the  orientation.3 
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Figure 1. (A) General structure of ceramide; (B) Structures of natural sphingoid bases; (C) Structures of galactose 
and glucose; (D) General structure of galactosylceramide; (E)  and -anomers of D-galactose.  
1.1.2 History of -galactosylceramides 
In 1993, the pharmaceutical division of Kirin Brewery Inc. isolated a series of novel -
galactosylceramides called agelasphins (AGLs) from the marine sponge, Agelas mauritianus.4,5 
Of these agelasphins, agelasphin-9b (Figure 2) exhibited potent anti-tumor activity in in vivo 
models of several murine tumor lines.6 Agelasphins consist of a saccharide that is - or -linked 
to a phytosphingosine-containing ceramide backbone, and diversity in the compositions and 
lengths of the lipid chains lead to different agelasphins (Figure 2). Initial screenings demonstrated 
that -linked galactose-containing agelasphin glycolipids were significantly more potent against 
B16 mouse melanoma cells than -linked agelasphins. 
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Figure 2. Chemical structure of some natural AGLs from the Agelas mauritianus. 
While agelasphin-9b was the most potent agelasphin identified in the marine sponge, it 
could only be isolated in very small amounts. The promising anti-tumor activities of agelasphin-
9b led Kirin Brewery Co.7 to perform a structure-activity relationship (SAR) study with the intention 
of finding a potent, commercially-viable anti-tumor agent. SAR studies led to the synthesis of 
KRN7000 (Figure 3), more commonly referred to as -galactosylceramide (-GalCer), which was 
selected as a candidate for clinical application.8 The strategic simplifications included removing 
the fatty acid C2 hydroxyl group and the terminal branching of the sphingoid base. Importantly, 
by extending the sphingoid base chain to 18-carbons and the fatty acid chain to 26-carbons, the 
stimulatory activity of agelasphin-9b was maintained for -GalCer. In 1997, it was found that 
KRN7000 formed a complex with CD1d and stimulated NKT cells to produce equally high levels 
of both Th1 and Th2 cytokines; these cytokines antagonize each other’s biological functions and 
limit the therapeutic effects of KRN7000.33 
 
Figure 3. Structures of agelasphin-9b and KRN7000. 
1.1.3 Activation of NKT cells by the complex CD1d/Glycolipid/TCR 
-GalCer activates NKT cells (natural killer T cells) in a CD1d-restricted manner.9 First, -
GalCer binds to CD1d, a major histocompatibility complex (MHC) class I-like molecule on the 
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surface of antigen-presenting cells (APCs), to form a glycolipid/CD1d binary complex (Figure 4). 
This -GalCer/CD1d complex is then presented to the T cell receptor (TCR) of the NKT cell, and 
upon recognition, rapid secretion of T helper 1 and 2 (Th1 and Th2) cytokines occurs. Th1 
cytokines include IFN-, IL-2, and TNF-, and the production of these cytokines is associated with 
anti-tumor, anti-viral, antibacterial, and adjuvant effects of -GalCer. Th2 cytokines include IL-4 
and IL-10, and the production of these cytokines is associated with certain autoimmune diseases 
such as type 1 diabetes. In the process of NKT activation, -GalCer induces the secretion of Th1 
and Th2 cytokines indiscriminately.   
 
Figure 4. Activation of NKT cells by CD1d/glycolipid/TCR complexation. 
1.1.3.1 Binary complex 
X-ray crystallography analysis of the mouse10,11 and human12 CD1d/KRN7000 complexes 
revealed both the architecture of CD1d and the binding mode for the glycolipid. The CD1d protein 
consists of a C-terminus 3 domain composed of -sheets in two layers and a more complex N-
terminus domain, which consists of two -helices, 1 and 2 (Figure 5). The 1 and 2 helices 
of CD1d lie on top of seven  strands and form two large hydrophobic pockets, named A’ and C’ 
(F’ for mouse CD1d). The glycolipid specifically binds to CD1d with the 26 carbon acyl chain of 
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-GalCer occupying the longer A’ pocket and the shorter, 18 carbon sphingoid base chain 
occupying the C’ pocket. Thus, hydrophobic interactions are the principle factors generating the 
binding energy between the lipid chains and the CD1d binding groove. Meanwhile, the hydrophilic 
galactose head group protrudes from the CD1d groove for recognition by the TCR of NKT cells.  
 
Figure 5. Crystal structure of hCD1d-KRN7000 binary complex. Figure generated from 1ZT412 with PyMol. 
Analysis of the crystal structure of the hCD1d/KRN7000 complex has identified key 
hydrogen bonds between KRN7000 and CD1d (Figure 6). Notably, three amino acids of the CD1d 
engage in hydrogen bonds with KRN7000. The 2”- and 3”-OH of the galactose hydrogen bond to 
the two oxygen atoms on Asp151 (mouse Asp153), located on the CD1d 2 helix. The glycosidic 
oxygen atom 1”-O on KRN7000 can form a hydrogen bond with the hydroxide group of Thr154 
(mouse Thr156); alternately, Thr154 can act as a hydrogen acceptor with the 2”-NH amide group. 
The 3’-OH of the sphingoid base hydrogen bonds to the oxygen atom on Asp80, located on the 
CD1d 1 helix. However, in mouse CD1d, Asp80 binds to the 3’- and 4’-OH groups of the 
6 
 
sphingoid base.44 These interactions are believed to orient the sugar in a specific position for 
presentation with the TCR of NKT cells.  
 
Figure 6. Hydrogen bonds formed between KRN7000 (blue) and amino acid residues of hCD1d (purple). Figure 
generated from 1ZT412 with PyMol. 
1.1.3.2 Ternary complex 
The X-ray crystallographic structure of the ternary human CD1d/KRN7000/TCR complex, 
published by Rossjohn and co-workers13 in 2007, has been instrumental for understanding the 
interactions that occur within the TCR/CD1d/KRN7000 complex (Figure 7). The crystal structures 
of both human and mouse14 ternary CD1d/KRN7000/TCR complexes showed conformational 
conservation, indicating a lock-and-key style binding mechanism. Even more surprisingly, the 
NKT TCR was bound to the CD1d-antigen binding cleft in a parallel manner, which differed from 
the diagonal footprints observed for MHC class-I-restricted TCRs.15 This now positions the TRC 
-chain above the exposed end of the CD1d binding groove, and the TCR -chain is positioned 
above the enclosed end of the F’ pocket. Consequently, binding of the TCR and KRN7000 
happens solely with the TCR -chain (CDR1 and CDR3 loops).  
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Figure 7. Crystal structure of hCD1d-KRN7000-TCR ternary complex. Figure generated from 2PO613 with PyMol. 
Analysis of the crystal structure of hCD1d/KRN7000/TCR complex identified key hydrogen 
bonds formed when the 2”-, 3”-, and 4”-OH groups on the galactose interact with amino acid 
residues Gly96, Ser30, and Phe29, respectively (mouse 2”- and 3”-OH hydrogen bond with 
Asn30) (Figure 8). Additionally, the 3’-OH of the sphingoid base forms a hydrogen bond with 
Arg95. Formation of these hydrogen bonds appears to be important for the recognition of the TCR 
complex and activation of NKT cells. These results also explain why glycosyl ceramides with other 
sugar head groups, such as -mannosylceramide (-ManCer), do not activate NKT cells.16 The 
orientations of the 2”- and 4”-OH groups in mannose (2”-axial and 4”-equatorial) differs compared 
to those of galactose, resulting in the loss of two hydrogen bonds between CD1d and the TCR of 
the NKT cell. Additionally, the -linkage of KRN7000 was shown to be more important for TCR 
recognition than the -linkage of -galactosylceramide.17 
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Figure 8. Hydrogen bonds formed between KRN7000 (blue), amino acid residues of hCD1d, and the TCR receptor of 
NKT cells. Figure generated from 2PO613 with PyMol. 
1.1.4 Analogues of KRN7000 
The limited positive therapeutic outcome of KRN7000 in clinical trials was believed to be 
due to unbiased production of both Th1 and Th2 cytokines. It is suggested that CD1d-ligands 
must be capable of biasing either a Th1 or Th2 response for therapeutic applications.18 KRN7000 
inspired researchers to design analogues of KRN7000 that bias towards either Th1 or Th2 
cytokine response. Modifications of KRN7000 are mainly based on four types:  (1) nature of the 
ceramide moiety; (2) variation on the lipid chains; (3) modification of the sugar head moiety; and 
(4) nature and configuration of the anomeric bond (Figure 9).19,20,21 The different biological 
activities of various KRN7000 analogues provides a better understanding of the interactions of 
the CD1d/glycolipid/TCR complex and immune response. Below, a brief overview of notable 
and/or relevant analogues is given. 
 
Figure 9. Four commonly modified moieties in KRN7000. 
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1.1.4.1 Modification of the sphingoid base 
To understand the structural requirements of the ceramides necessary for anti-tumor 
activity, Morita and co-workers synthesized different 3’- and 4’-OH analogues, as well as different 
acyl chain length analogues, of -GalCer (Figure 10).22,23,24,25 These initial SAR studies showed 
an -GalCer analogue lacking the 3’- and 4’-OH group (AGL-535) was inactive in stimulating NKT 
cells. However, the four diastereomers of the sphinganine analogues (AGL-555, AGL-556, AGL-
558, and AGL-559) showed only slightly decreased anti-tumor activity, with the natural (2S,3R)-
isomer, AGL-558, having similar effects to KRN7000.23 It was also noted that a longer acyl chain 
enhanced the bioactivity. 
 
Figure 10. Structure of KRN7000 and ceramide modified analogues. 
The importance of the 3’-OH group was later explained by the crystal structure of 
hCD1d/KRN7000/TCR. The crystal structure revealed that the 3’-OH of KRN7000 formed a 
hydrogen bond with Asp80 of the CD1d and with Arg95 of the TCR, whereas the 4’-OH of 
KRN7000 showed no significant interaction with CD1d or the TCR. To further explore the 
importance of the 3’- and 4’-OH groups, modifications at these positions have been prepared 
(Figure 11).26,27 Replacement of the 4’-OH with gem-difluorides (1) provided a compound that 
showed a minimal loss in cytokine production yet had an increased bias toward Th1 cytokine 
polarization.26 This was attributed to the gem-difluorides increasing the hydrogen bond donating 
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ability of the 3’-OH with Asp80 of the CD1d. Furthermore, Van Calenbergh and co-workers 
investigated replacing the 3’- and 4’-OH (H-bond donor) with an amine group (H-bond acceptor).27 
It was found that replacement of the 3’-OH with an amine group (2) (Figure 11) resulted in a 
significant drop in cytokine response compared to KRN7000, despite compound 2 having a good 
affinity for the TCR. Replacement of the 4’-OH with an amino (3) induced a moderate cytokine 
production, however lower than that induced by KRN7000. The 3’-OH analogues (3) was shown 
to be more effective at activating NKT cells than the 4’-OH analogues (2). 
 
Figure 11. Structures of KRN7000 and sphingoid base analogues. 
In 2008, Chung and co-workers28 were able to synthesize and evaluate all eight 
stereoisomers on the phytosphingosine chain of KRN7000 (Figure 12). The biological analysis of 
these eight stereoisomers revealed the S configuration of the amide and 3’-OH group was 
important for NKT cell activation. However, the stereochemistry at the 4’-OH position was not 
significant for the stimulation of NKT cells. Van Calenbergh and co-workers also reported the 
synthesis of three similar diastereoisomers with truncated acyl chains.29 Interestingly, in vitro data 
demonstrate that truncated diastereoisomer (2S,3S,4S)-4 of -GalCer induced similar levels of 
IFN- and IL-4 compared to KRN7000. These results suggest changing the stereochemistry at 
the 4’-OH of the phytosphingosine chain could result in similar NKT cell activation. 
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Figure 12. Structure of the eight KRN7000 stereoisomers and truncated analogue. 
In 2011, Kim and co-workers reported the first synthesis of the 3’-deoxy analogue of -
GalCer.30 Unexpectedly, they found that mouse NKT cell activation by 3’-deoxy--GalCer was 
comparable to activation by both 4’-deoxy--GalCer and KRN7000. Additional docking studies 
with hCD1d/glycolipid/TCR suggested that the 3’-deoxy analogue was able to shift itself lower in 
the CD1d pocket and establish a new hydrogen bond between the 4’-OH and CD1d. This indicates 
that the 4’-OH can also play an important role, and the two hydroxyl groups could play cooperative 
or individual roles in orienting the glycolipid. 
In 2012, a conflicting reports were published on the importance of the 4’-OH.31 Stocker 
and co-workers reported the phytosphingosine, sphinganine, and sphingosine analogues of -
GalCer stimulate human and mouse NKT cells differently (Figure 13). These three glycolipids 
showed similar activation of mouse NKT cells; however, human NKT cells showed a significant 
decrease in activity for the sphinganine and sphingosine analogues in several assay systems. 
These results suggested that the 4’-OH is important for the activation of human NKT cells and 
should be considered when comparing the CD1d-glycolipid binding between different species.  
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Figure 13. Structure of KRN7000 and ceramide modified analogues. 
The importance of the 4’-OH was further explored by Pipelier and co-workers,32 who 
synthesized 3’,4’-dideoxy--GalCer analogues combined with the introduction of a mono or 
difluoro substituent at C3’ position (Figure 14). Biological evaluations were performed in vitro on 
human cells and in vivo on mice. Replacement of the 3’-OH with one isoelectronic fluorine was 
not able to restore the effects lost with the 3’-OH group, but the presence of two fluorine groups 
at the C3’ position significantly restored activation of human NKT cells. Moreover, in support of 
previous reports, human NKT cell response shows a divergence from mice NKT cell response 
and might not be reliable models between species.  
 
Figure 14. Structure of sphinganine and 3’,4’-dideoxy-fluoro--GalCer analogues. 
1.1.4.2 Modification of the sugar head group 
After the discovery of the potent anti-tumor activities of KRN7000, several studies were 
performed to investigate structure-activity relationships (SAR) based on modifications of the sugar 
head group. In 1997, Taniguchi and co-workers33 synthesized a number of disaccharide 
analogues of -GalCer with the second sugar at the 2”-, 3”-, 4”-, and 6”-positions of the galactose 
fragment (Figure 15). Interestingly, the activity for each of the disaccharides was similar to that of 
KRN7000. Following this finding, Kronenberg and co-workers34 showed that disaccharide 
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Gal(1→6)GalCer was able to stimulate NKT cells without lysosomal processing to the 
monosaccharide. In contrast, the corresponding disaccharides of Gal(1→2)GalCer, 
Gal(1→3)GalCer, and Gal(1→4)GalCer35 required enzymatic processing to the 
monosaccharide for NKT cell stimulation.  
 
Figure 15. Disaccharide analogues of KRN7000. 
The importance of hydroxyl groups in positions 2”, 3”, and 4” of the galactose fragment 
was examined by deletion or modification of the functional group (Figure 16). Removal of the 2”-
OH36 or substitution with a methoxy37, fluoro38, or acetamide39 group resulted in a dramatic 
decrease in cytokine response. Modification to the 3”-OH and 4”-OH of the galactose has also 
been explored by evaluation of 3”- or 4”-deoxy40,41 or fluoro41 analogues of -GalCer. Unlike the 
2”-OH analogues that dramatically decreased the immune response, small modifications at the 
3”- and 4”-OH subtly decreased the cytokine response. The 3”-O-sulfate39,42 and 4”-alkylaryl43 
analogues gave a response comparable to KRN7000. 
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Figure 16. Structures of sugar head group modifications of -GalCer. 
Successful modifications of the sugar head group of -GalCer are rather limited and 
mostly restricted to the 6”-position. The crystal structure of the CD1d/-GalCer/TCR complex 
showed hydrogen-bonding between the 2”-, 3”-, and 4”-hydroxyls of the galactose and the amino 
acids of the TCR and/or CD1d.44,45 However, the primary 6”-OH of the galactose is positioned 
away from the TCR/CD1d interface and does not participate in hydrogen bonding, suggesting that 
modification at the 6”-OH may be well tolerated. These findings have led to the design of various 
C6” analogues of -GalCer with diverse properties and applications (Figure 17), including amide 
probes49,54, arylamides57,58,59, disaccharides34, triazole analogues60,61, PEGylated analogues56, 
thio/peptide-conjugates46, and small functional groups47,48,55. 
 
Figure 17. Modifications at the C6”-position of -GalCer. 
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In 2002, Savage and co-workers converted the 6”-OH of -GalCer to an amine group, 
which allowed for efficient coupling of fluorophores such as prodan and dansyl or small molecules 
like biotin (Figure 18).49 These analogues were designed as probes to observe the trafficking of 
glycolipids and to quantify their association with CD1d and NKT cell receptors. Probes for studying 
glycolipid trafficking have been prepared previously (fluorophore,50 biotin,51 and BODIPY52). 
These probes were incorporated on the end of the fatty acyl chain that binds within the deep 
hydrophobic pocket of the CD1d receptor. However, the incorporation of probes on the acyl chain 
is not ideal as the probe may interfere with the association formed between the acyl chain and 
the CD1d receptor. Analogues with incorporation of probes on the C6” galactose were able to 
stimulate NKT cells similarly to KRN7000. Wang and co-workers reported the visibility of a biotin-
labelled -GalCer analogue by flow cytometry.53 Soon after, Stocker and co-workers 
demonstrated the ability of dansyl -GalCer to activate NKT cells and to be used as a fluorescent 
probe with flow cytometry.54 These results, among others, led to further exploration in designing 
C6”--GalCer analogues that can bias cytokine release. 
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Figure 18. Fluorophore-, BODIPY-, and biotin-appended -GalCer analogues. 
One practical limitation of -GalCer is its poor solubility in aqueous and organic solvents. 
Savage and co-workers found that the incorporation of an acetamide group at C6” (PBS-57) with 
the incorporation of a cis-double bond on the acyl chain provided a compound with increased 
solubility in DMSO (Figure 19).55 Also, in vivo and in vitro studies of PBS-57 exhibited increased 
NKT cell activation compared to KRN7000. Gunzán and co-workers demonstrated that the 
solubility of KRN7000 could be improved by the addition of a polyethylene glycol (PEG) group.56 
The PEGylated 6”-analogue of KRN7000 (MPEG--GalCer) had increased solubility and 
stimulated NKT cells more efficiently than KRN7000. Interestingly, MPEG--GalCer skewed the 
cytokine release profile toward a Th2 response, whereas many C6” analogues to date have 
skewed a Th1 cytokine response. 
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Figure 19. Structures of PBS-57 and MPEG--GalCer. 
Another application in modifying the C6” position of KRN7000 was demonstrated when 
Van Calenbergh and co-workers synthesized a number of C6”-analogues of amide- or urea-linked 
aromatic motifs to obtain additional interactions with the CD1d receptor.57 Remarkably, many of 
these analogues provided a skewed Th1 response. In particular, the promising analogue Nu--
GalCer (Figure 20) gave diminished production of IL-4 and increased production of IFN-in vivo 
compared to KRN7000. The significant Th1-skewed cytokine response of Nu--GalCer was later 
explained when Elewaut and co-workers58 obtained the X-ray crystal structure of mouse Nu--
GalCer complexed with CD1d and the TCR. The study revealed that all of the hydrogen bonding 
interactions of -GalCer with CD1d and the TCR are conserved with Nu--GalCer.  In addition to 
these hydrogen bonds, another hydrogen bond was formed between the carbonyl oxygen of the 
urea linker and Thr159 of CD1d. Moreover, the structure revealed that the naphthyl group sat in 
a small hydrophobic pocket on top of the A’ pocket. This induced-fit binding pocket acted as a 
third anchor to the CD1d, along with the A’ and F’ pockets. The addition of the hydrogen bond 
together with the induced-fit binding pocket imparted a higher affinity of Nu--GalCer to CD1d, 
which resulted in a longer interaction with the NKT cell and is thought to account for the Th1 
cytokine bias. Elewaut and co-workers also synthesized three new -GalCer analogues (PyrC--
GalCer, NC--GalCer, and 4ClPhC--GalCer) that were more potent in preventing lung 
metastasis in B16 mice compared to Nu--GalCer and KRN7000. 59 
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Figure 20. Structures of 6”--GalCer analogues. 
The C6” position of galactose has also been explored by Besra and coworkers, who 
designed a series of 1,2,3-triazole moieties (Figure 21).60 1,4-Disubstituted and 1,5-disubstituted 
triazole group are considered as bioisosteres of the amide bond. Using click chemistry, a library 
of 1,2,3-triazole--GalCer analogues was synthesized from a diverse range of aromatic-
substituted alkynes. Surprisingly, these 6”-triazole-substituted -GalCer analogues stimulated 
both IFN- and IL-4 production, which elicited either a Th1 bias similar to KRN7000 or a small Th2 
cytokine biasing result. These results demonstrated that subtle structural changes to the 6”-
position can impart a significant difference in cytokine-biasing response. Besra and coworkers 
further explored utilizing click chemistry to synthesize homodimeric -GalCer analogues (Figure 
21) in hopes of mimicking results that multimeric versions of monomeric ligands have higher 
affinity for target receptors.61 However, homodimeric analogues of -GalCer proved to be less 
active than -GalCer. 
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Figure 21. Structures of 6”-trazole -GalCer analogues. 
1.1.5 Synthesis of -GalCer 
Kirin Brewery co. initially isolated several agelasphins from the extracts of the Okinawan 
marine sponge, Agelas mauritianus.4 The anti-tumor activity of agelaphin-9b prompted Morita and 
co-workers to synthesize agelaphin-9b.5 However, due to the minute amounts of agelasphin-9b 
present in the marine sponge and difficulty in the scale-up, new analogues were probed. This led 
Morita and co-workers to the first synthesis of KRN7000 and other analogues (Scheme 1).6 
Notably, glycosylation was done under Mukaiyma reaction conditions with predominantly -
selectivity. 62 Since then, many synthetic strategies have been developed to optimize the synthesis 
of KRN7000 (-GalCer), including a practical synthesis of it by Kirin Brewery Co.63 
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Scheme 1. Synthesis of KRN7000 (-GalCer). 
-GalCer and its analogues are generally composed of three fragments, the sugar head 
group (galactose), the sphingoid base, and the fatty acyl chain. Typically, one of two strategies is 
implemented when coupling these fragments (Figure 22): (1) incorporation of the acyl chain with 
the sphingoid base for total functionalization of the ceramide moiety before coupling with the 
protected sugar; or (2) coupling of the protected sugar with the sphingoid base moiety, followed 
by N-acylation.19 In the two strategies, the major difficulty in synthesizing KRN7000 and its 
analogues is the formation of the glycosidic bond with high -selectivity. The success of the 
glycosylation depends on many things, including the reactivity of the donor and acceptor (both 
the sugar and ceramide), the substituents on the donor and acceptor (protecting groups and 
amide precursor), and the promotor or catalyst.64 Noteworthy, before the recent commercially 
availability of D-ribo-phytosphingosine, much research focused on constructing the asymmetric 
centers of the sphingoid base. 
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Figure 22. Major pathways for the synthesis of KRN7000. 
From a mechanistic viewpoint, the major challenge in the stereochemical control of 
glycosidic bond formation stems from the formation of an oxocarbenium ion intermediate. 
Glycosylation reactions typically involve four distinct steps (Figure 23): (1) activation of a glycosyl 
donor with an activator or promoter (Lewis acid or Bronsted acid); (2) departure of the leaving 
group results in the formation of a glycosyl cation, which is stabilized as an oxocarbenium ion 
intermediate; (3) nucleophilic attack by the glycosyl acceptor on the top or the bottom face of the 
flattened ring; and (4) proton transfer to provide the neutral 1,2-trans () and/or 1,2-cis () 
glycoside(s).64 
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Figure 23. General mechanisms of glycosylation. 
The formation of a 1,2-trans linkage glycoside can be reliably achieved using the 
participatory effect of the neighboring 2-acyl substituent (Figure 24). For instance, 2-O-acyl 
protected donors often lead to the formation of 1,2-trans glycosides (-linkage) via the formation 
of a bicyclic acyloxonium intermedate. Since the bottom face of the ring is blocked, nucleophilic 
attack from the top face by the glycosyl acceptor would occur. Typically, the use of neighboring 
group assistance leads to very high or complete stereoselectivity of 1,2-trans linkage products. 
Alternatively, the formation of 1,2-cis linkages is typically much more challenging. The use of non-
participating groups at C-2 leads to the formation of the oxocarbenium ion, resulting in the 
formation of 1,2-cis and/or 1,2-trans glycosides. Nonetheless, biasing of the -anomeric 
selectivity has been achieved with appropriate choice of donor, acceptor, promotor/activator, 
solvent, temperature, and protecting groups. 
 
Figure 24. Stereoselective synthesis of 1,2-trans linkage via neighboring group assistance. 
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In recent years, glycosyl bromides and especially glycosyl iodides have been applied to in 
situ anomerization for the synthesis of -glycosides. Lemieux and coworkers discovered that 
tetra-O-benzylated -glycosyl bromide is in equilibrium with the more reactive -glycosyl bromide, 
the equilibrium is catalyzed in the presence of excess bromide ions from tetraalkylammonium 
bromide (tetraethylammonium bromide), and the reaction proceeds in an SN2-like manner to 
afford the -glycosyl product (Scheme 2).65 Mechanistic and kinetic studies have been conducted 
to support an SN2-type mechanism.66 
 
Scheme 2. Lemieux’s in situ anomerization procedure. 
Although the first report of utilizing glycosyl iodides in a glycosylation reaction dates back 
to 1929, these glycosyl donors have been underutilized in comparison to glycosyl bromides.67 
Glycosyl iodides were avoided due to their high level of reactivity, instability, and difficulties in 
purification. Recently, Gervay-Hague and co-workers discovered that glycosyl iodides can be 
utilized in glycosylation reactions with excellent yields and high -selectivity.66a,68,69,70 In the late 
1990s, Gervay-Hague and co-workers reported the synthesis and mechanistic studies of both - 
and -glycosyl iodides using NMR spectrometry (Scheme 3A).66 Treatment of -acetate 7 with 
TMSI at –100 °C resulted in the formation of the -glycosyl iodide (9). However, equilibration to 
the -anomer occurs rapidly as the temperature is raised. Formation of -glycosyl iodide (9) 
from both - and -acetates (7 and 7) likely occurs via O-silylation of the acetyl group to afford 
the trimethylsilyl acetoxonium ion intermediates (8 and 8), followed by SN2-like displacement 
to afford the glycosyl iodide. This technique is highly useful for the formation of glycosyl iodides 
because the byproduct, trimethylsilyl acetate, is volatile and easily removed. This methodology 
was also utilized to generate glycosyl iodides (11) directly from per-O-silylated sugar with TMSI 
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(Scheme 3B).71 Subsequent treatment with TBACN (CN-) provided intermediate -
cyanoglucoside (12). The reaction with TMS ether is also advantageous since the byproducts 
are volatile, and multiple reactions can be carried out in one pot without isolation of intermediates. 
Thus, per-O-silylated -cyanoglucoside (12) was converted to per-O-acetylated -
cyanoglucoside (13) in a one-pot, four-step process. 
 
Scheme 3. (A) Proposed mechanism of glycosyl iodide formation; (B) Synthesis of per-O-acetylated -cyanoglucose 
in a one-pot, four-step process. 
This methodology was effectively used by Gervay-Hague and co-workers for the synthesis 
of -GalCer analogues (Scheme 4). Many glycosylation methods involve installation of the amide 
linkage of the fatty acyl chain after glycosylation due to the poor nucleophilicity of the primary 
hydroxyl group as a result of intramolecular hydrogen bonding. Thus, azides have proven to be 
functionally useful amine surrogates without the deactivation of intramolecular hydrogen bonding. 
Gervay-Hague and co-workers utilized azido sphingosine analogues with per-O-benzylgalactosyl 
iodide (14) in efficient syntheses of -galactosyl ceramides (Scheme 4A). 68 The stereoselectivity 
was achieved from the in situ anomerization of the -glycosyl iodide to the more reactive -
anomer by the addition of TBAI, which subsequently undergoes an SN2-type reaction to 
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exclusively produce -glycoside. Correlation between the yields and protecting groups on the 
secondary alcohol(s) of the sphingoid base was observed. Protecting the secondary hydroxyl 
groups with electron withdrawing groups, such as benzoates (Bz), gave a 30% yield. Electron 
donating groups, such as benzyl (Bn) and p-methoxybenzyl (PMB), as protecting groups provided 
higher yields (67% and 94%, respectively). Similarly, changing the protecting groups on the 
galactose from benzyl to trimethylsilane groups increased the reactivity of the donor. These per-
O-TMS glycosides are particularly attractive due to their ease of synthesis, scalability, and 
deprotection under methanolysis conditions. Gervay-Hague and co-workers demonstrated a one-
pot process for the synthesis of -glycosides with removal of the TMS groups (Scheme 4B). 68 
Shortly after, Gervay-Hague and co-workers were able to achieve glycosylation between glycosyl 
iodides with fully functionalized ceramide acceptors (Scheme 4C). 69,70 In a one-pot, three-step 
process, -linked glycosyl ceramides were efficiently synthesized in good yields. 
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Scheme 4. Progress towards a one-pot synthesis of -linked glycolipids; A) First-generation synthesis with azido 
sphingosine and per-O-benzylated galactosyl iodide; B) Second-generation synthesis with azido sphingosine and 
per-O-silylated galactosyl iodide; C) Second-generation synthesis with fully functionalized ceramide and per-O-
silylated galactosyl iodide.  
1.2 Aims and objectives 
It is widely accepted that a stronger glycolipid-CD1d interaction provides a proportionally 
higher release of Th1-cytokines, which is important in treating infectious diseases and cancer.  In 
an effort to simplify SAR studies, the Howell research group designed and synthesized a 
sphinganine analogue of KRN7000, AH03-1 (Figure 25).72  This analogue was able to activate 
mice NKT cells; in addition, it induced a Th1 biased response. However, it did not show a 
noticeable effect on the activity of human NKT cells.  
27 
 
 
Figure 25. Sphingoid base and C6” modified analogues of -GalCer. 
Many analogues of -GalCer in which the 6”-hydroxyl(methyl) group is modified have been 
developed. As mentioned previously PBS-5755, NU--GalCer58, NC--GalCer59, and PyrC-
GalCer59 showed potent Th1-type immunostimulatory activities. Previous work in the Howell 
group led to the design and synthesis of a set of carbohydrate-modified analogues of AH03-1 and 
KRN7000 that incorporated aromatic rings at varying distances from C6” and C4” of the galactose 
moiety. An initial biological study of these compounds showed that AH10-7 (Figure 25) elicited a 
strong Th1 bias. Current efforts have centered on further exploration of compounds related to 
AH10-7. Thus, we decided to synthesize four new target compounds (Figure 26) of different length 
linkers between a C6” amide bond and the aromatic moiety. These compounds will also provide 
further information about the role of 4’-OH group on the ceramide for NKT cell activation in mice 
and human cells. The route towards the synthesis of 6”-N-derivatized -galactosyl ceramides is 
described.  
 
Figure 26. Target molecules 15-18. 
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1.3 Results and discussion 
1.3.1 Synthetic routes to target compounds 
In devising a synthetic route to access targets 15-18 compounds, many aspects were 
evaluated. Firstly, the most important aspect in the synthetic strategy is to obtain -
stereoselectivity in the glycosylation process. Stereoselectivity in the anomeric bond formations 
can effectively be controlled by the choice of glycosyl donor and suitable reaction conditions. 
Ideally, a short route that involves minimal protecting group manipulations is desired, as protecting 
group manipulations can factor into poor overall yields. It is also ideal to incorporate the C6”-
amide functionality at a later stage to avoid completely repeating the synthetic sequence for each 
target compound. With this in mind, the retrosynthesis of our target compounds is shown in Figure 
27. It was envisioned that the compounds 15-18 could be accessed by reduction and acylation of 
an azide at the C6” of galactose. Key azides 19 could be obtained by global deprotection and 
acylation of glycosylated sphingoid bases 20. The fully protected azide 20 could be accessed via 
a Mitsunobu reaction from the selective monodeprotection of primary hydroxyl 21. -Glycosides 
21 could be obtained via a Gervay-Hague glycosylation of glycosyl donor 22 and acceptors 23.  
 
Figure 27. Retrosynthetic strategy for target compounds. 
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The three protecting groups (TMS, TBS, and Boc) were chosen for many reasons; (1) their 
ease of attachment and removal; (2) TMS incorporation on the galactose sugar donor increases 
reactivity in glycosylation reactions; (3) selective monodeprotection of the primary silyl ether; (4) 
removal of the protecting groups in a one step process; (5) excellent stereoselectivity in 
glycosylation. 
1.3.2 Synthesis of 6”-N-derivatized -galactosyl ceramide 
1.3.2.1 Synthesis of glycosyl acceptor 
The synthesis of sphingoid base fragment 23 was achieved in three steps using a 
procedure similar to that developed by Besra and co-workers (Scheme 5).73 First, commercially 
available phytosphingosine (24) was Boc-protected using di-tert-butyldicarbonate to provide 25, 
in excellent yields. Next, both the primary and secondary hydroxyl groups were silylated with 
TBSOTf in the presence of 2,6-lutidine to give silyl ether 26. Selective monodeprotection of the 
primary silyl ether using HF-pyridine provided glycosyl acceptor 23 in 86% yield. Noteworthy, 
monodeprotection of primary silyl ether using TFA-H2O mixture resulted in complete deprotection 
of all silyl ethers or much lower yields obtained for the glycosyl acceptor. 
 
Scheme 5. Synthesis of glycosyl acceptor. 
1.3.2.2 Synthesis of glycosyl donor and glycosylation reaction 
The glycosyl donor 22 (per-O-silylated galactose) was obtained in one step from 
commercially available D-galactose (27) in quantitative yield (Scheme 6). The key step in the 
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synthesis of the target glycolipids employed Gervay-Hague’s glycosylation methodology, in which 
the glycosyl iodide donor 28 was generated in situ by treating per-O-silylated galactose 22 with 
iodotrimethysilane (TMSI).68 The stereoselectivity was achieved from the in situ anomerization of 
the -glycosyl iodide to the more reactive -anomer (28) by the addition of TBAI, which 
subsequently undergoes SN2-type reaction with glycosyl acceptor 23 to provide high -selectivity 
of glycoside 29 in up to 75% yield.  
 
Scheme 6. Synthesis of glycosyl donor 22 and -glycoside 29. 
1.3.2.3 Synthesis of 6”-N-derivatized -galactosyl ceramide targets 15-18 
With -glycoside 29 in hand, attempts were made to perform the selective 
monodeprotection of the primary silyl ether group. To this end, following the literature procedure 
of Besra and co-workers, treatment of -glycoside 29 with acetic acid in acetone/methanol was 
not a success (Scheme 7). 73 Many reactions gave deprotection of TMS groups from both primary 
and secondary alcohols. Reaction conditions such as concentration, equivalents of acetic acid, 
temperature, and time were probed without formation of the product 30. However, one reaction 
gave the desired compound in 48% yield without reproducibility. 
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Scheme 7. Selective monodeprotection of the primary silyl ether group of -glycoside 30. 
With the small amount of product acquired, alcohol 30 was converted to azide 31 (Scheme 
8) by a Mitsunobu reaction using diphenylphosphoryl azide (DPPA), triphenylphosphine (PPh3), 
and diisopropyl azodicarboxylate (DIAD).74 Azide 31 was then treated with 10% trifluoroacetic 
acid (TFA) in dichloromethane (DCM) overnight to cleave the Boc, TMS, and TBS-groups in one 
step. The Boc and TMS groups were successfully removed, although surprisingly, the TBS 
group(s) on the secondary alcohol was not removed. Additional attempts to cleave the TBS 
group(s) with neat TFA or TBAF were unsuccessful. Due to the challenges encountered in 
selective monodeprotection and the global deprotection steps, a new synthetic route was 
strategized. 
 
Scheme 8. Attempted synthesis azido -glycoside 32. 
1.3.3 Synthesis of 6”-N-derivatized -galactosyl ceramide (route 2) 
Our new retrosynthetic analysis for the preparation of the four target -GalCer analogues 
is presented in Figure 28. Using a modified procedure from Van Calenbergh and co-workers, we 
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planned to prepare targets 15-18 from the benzyl ether protected 6”-azido--GalCer analogue 
33.57 We chose to protect the secondary hydroxyl groups of the -GalCer as benzyl ethers to 
streamline the final deprotection. Furthermore, to avoid solubility problems, the final debenzylation 
step was performed after modification of the 6”-amino group. The amide functionality could be 
obtained by reduction of azide 33, follow by EDC coupling of the amine with the appropriate acid. 
The fully protected glycolipid 33 could be obtained using a Mukaiyama glycosylation of sugar 
donor 34 with ceramides 35 or 36. By incorporating the acyl chain to the sphingoid base and 
having the amine functionality on the sugar masked as an azide, minimal transformations were 
required after glycosylation. In addition, sugar donor 34 and ceramides 35 and 36 could be 
obtained from readily available starting materials. 
 
Figure 28. New retrosynthetic strategy for target compounds. 
1.3.3.1 Synthesis of sugar donor  
With our synthetic strategy in place, the first goal was the preparation of the azido 
galactose donor.7 The synthesis of the galactose donor was accomplished in accordance with 
published methods (Scheme 9).75 Compound 37 was formed in an excellent yield by the selective 
installation of isopropylidenes at the 1,2 and 3,4 positions of commercially available D-galactose 
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(27). Selective installation of the tosylate at the primary position, followed by azide substitution, 
gave compound 38.  Next, simultaneous cleavage of the isopropylidenes and Fisher glycosylation 
using a 5% solution of AcCl in MeOH furnished compound 39 in 87% yield over three steps. 
Subsequent treatment with NaH, followed by the addition of benzyl bromide, gave compound 40. 
Acetolysis of 40, followed by Zémplen deacetylation, gave hemiacetal 41, which was then 
transformed into fluorides 36 using diethylaminosulfurtrifluoride (DAST).  
 
Scheme 9. Synthesis of glycosyl donor 36. 
1.3.3.2 Synthesis of glycosyl acceptor for targets 15 and 16 
The key phytosphingosine ceramide acceptor 35 (Scheme 10) for glycosylation was 
prepared by use of a method similar to Schmidt’s,76 with modifications. The amino group of 
commercially available phytosphingosine 24 was converted into an azido group (42) in a metal-
catalyzed diazotransfer reaction with freshly prepared TfN3.77 Selective tritylation of the primary 
alcohol, followed by benzylation of the two secondary alcohols with sodium hydride and benzyl 
chloride, gave 43. Deprotection of the primary alcohol was achieved using TsOH, and reduction 
of the azide under Staudinger conditions gave amino alcohol 44. Lastly, acylation of the free 
amine with activated hexacosanic acid (45) furnished glycosyl acceptor 46.  The activated 
hexacosanic acid (45) was accessed in one step via DCC coupling of commercially available 
cerotic acid (46) with para-nitrophenol. 
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Scheme 10. Synthesis of glycosyl acceptor 35. 
1.3.3.3 Synthesis of sphingoid base acceptor for targets 17 and 18 
Sphinganine ceramide 34 was synthesized using a well-developed protocol from the 
Howell group starting from commercially available Boc-L-serine 47 (Scheme 11).72 The serine-
derived Weinreb amide 48 was reacted with isopropylmagnesium bromide (sacrificial base), 
followed by the nucleophilic addition of pentadecyl magnesium bromide, to give moderate yield 
of ketone 49. Silyl protection of the primary hydroxyl group gave compound 50 in 89% yield. 
Diastereoselective reduction of ketone 50 using lithium tri-tert-butoxyaluminum hydride, followed 
by benzyl protection of the secondary alcohol, furnished 51 in good yield. Deprotection of the silyl 
and Boc groups was accomplished in one step by in situ generation of HCl using acetyl chloride 
and methanol; the resulting free amine underwent acylation with an activated ester of cerotic acid 
to give ceramide 34. 
 
Scheme 11. Synthesis of sphingoid base glycosyl acceptor 34. 
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1.3.3.4 Synthesis of targets 15 and 16 
Glycosylation of donor 36 and acceptor 35 was achieved via Mukaiyama glycosylation,78 
using SnCl2/AgClO4 as the activator in anhydrous THF with 4 Å MS, to afford the desired -
glycoside 52 with an / ratio of 4/1 in 52% yield (Scheme 12).  Glycosylation using the -anomer 
of the glycosyl donor (36) gave the desired -glycoside (52) with similar selectivity, but a lower 
yield at 32%. Staudinger reduction of azide 52 provided the free 6”-amino-group (53) in good 
yield. Next, coupling of amine 53 with the appropriate acid and EDC as the coupling reagent 
provided amides 54a and 54b. Removal of the benzyl groups in compounds 54a and 54b by 
hydrogenolysis gave the desired amide targets 15 and 16.  
 
Scheme 12. Synthesis of -GalCer analogues targets 15 and 16. 
1.3.3.5 Synthesis of targets 17 and 18 
Glycosylation was performed on donor 36 and ceramide acceptor 34 using the same 
conditions as those in Sec 1.3.3.4 (Scheme 13). In this case, the glycosylation yields were 
improved to 62-72% of the desired -glycoside (55). Reduction of the azide (55), followed by 
coupling with the appropriate acid and removal of the benzyl groups, gave targets 17 and 18. 
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Scheme 13. Synthesis of -GalCer analogues targets 17 and 18. 
1.3.4 Biological testing 
The evaluation of the target analogues 15-18 is currently under way by our collaborators 
Dr. Weiming Yuan from Keck School of Medicine of USC, CA and Dr. Steven A. Porcelli Albert 
Einstein  College  of  Medicine,  NY.  Preliminary in vitro assay in mice for their ability to stimulate 
NKT cells as measured by IL-2 production demonstrated that all four compounds (15-18) were 
significantly active. Interestingly, compounds 17 and 18 which lack the 4’-OH seem to be more 
potent. Additionally, in vitro assay in human cell lines showed the ability of compounds 17 and 18 
to stimulate IFN- production. The immunostimulatory studies of these analogues (15-18) as well 
as related compounds is currently under investigation by our collaborators. 
1.4 Conclusion  
The synthesis of the four target compounds 15-18 proved to be less straightforward than 
initially expected due to several difficulties encountered during the first synthetic route. 
Nonetheless, an alternative route was devised and target compounds 15-18 were obtained from 
commercially available starting materials. The key glycosylation step of the second route was 
accomplished utilizing a Mukaiyama glycosylation method with high -selectivity. The 
incorporation of the C6” amide functionally in a later stage avoided the need to repeat the synthetic 
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sequence for each target compound. The preliminary biological evaluation of these four glycolipid 
analogues in collaboration with Dr. Steven A. Porcelli and Dr. Weiming Yuan found that these 
compounds were able to stimulate cytokine production of IL-2 and IFN-. Further in vitro and in 
vivo studies will provide a better understanding for the nature of the immune response elicited by 
these compounds.  
1.5 Experimental  
1.5.1 General experimental  
All moisture sensitive reactions were run in a flame-dried flask under an atmosphere of 
N2. Methylene chloride (DCM), dimethylforamide (DMF), toluene, and pyridine were dried over 
CaH2 or over 4 Å molecular sieves (MS). Tetrahydrofuran (THF) was dried using a J. C. Meyer 
Solvent Dispensing System (SDS). Deuterated chloroform was dried over 4 Å MS. Zinc(II) 
chloride was freshly fused prior to use. Commercially available reagents were purchased from 
Acros, Aldrich, Alfa Aesar, or TCI America and were purified as necessary. 
 Flash column chromatography was performed using silica gel, 40 microns flash silica. 
Silica gel was deactivated with trimethylamine when necessary. Thin layer chromatography was 
carried out with silica gel (Silica Gel 60 F254) glass plates, and compounds were visualized by UV 
(254 nm), 0.5% KMnO4 in 0.1 M aqueous NaOH solution, 5% phosphomolybdic acid in EtOH, or 
a 2.5% solution of p-anisaldehyde in 95% EtOH. 1H NMR spectra were recorded on a Bruker 
AVANCE 300, 400, or 500 MHz spectrometer. 13C NMR spectra were recorded on a Bruker 
AVANCE 75, 100, or 125 MHz spectrometer. 1H NMR chemical shifts are reported as  values in 
ppm calibrated to residual CHCl3 (7.26 ppm) or pyridine-d5 (8.71, 7.56 and 7.18 ppm). 1H NMR 
coupling constants (J) are reported in Hertz (Hz). 13C NMR chemical shifts are calibrated to the 
CDCl3 peak at 77.23 ppm or pyridine-d5 at 149.9, 135.5 and 123.5 ppm. Infrared spectra were 
obtained on a FTIR spectrometer. High-resolution mass spectra (HRMS) were obtained using 
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DART AccuTOF or JEOL JMS-AX505HA mass spectometers. Optical rotations were recorded on 
JASCO P-2000 polarimeter in a 5 mL cell. 
1,2:3,4-Di-O-isopropylidene--D-galactopyranose (37) 
 
D-Galactose (5.00 g, 27.7 mmol) was dissolved in dry acetone (125 mL), followed by the addition 
of anhydrous zinc chloride (3.78 g, 27.7 mmol) and concentrated H2SO4 (0.50 mL). The mixture 
was stirred at rt for 20 h. Then potassium carbonate (1.0 g) was added, and the resultant mixture 
was stirred for 10 min. The reaction mixture was filtered through a pad of celite and the filter cake 
washed with acetone (2 × 200 mL). The filtrate and washings were concentrated to afford 1,2:3,4-
di-O-isopropylidene--D-galactopyranose (37) as a colorless syrup (7.01 g, 97%):79 [α]D
23 = ‒56.9 
(c = 1.0, CHCl3); IR (neat) 3441, 2930, 1451, 1375, 1209 cm-1; 1H NMR (400 MHz, CDCl3) 5.57 
(d, J = 5.1 Hz, 1H), 4.62 (dd, J = 8.0, 2.4 Hz, 1H), 4.34 (dd, J = 5.1, 2.4 Hz, 1H), 4.28 (d, J = 8.0 
Hz, 1H), 3.92‒3.71 (m, 2H), 2.45 (dd, J = 10.2, 3.0 Hz, 1H), 2.31 (br s, 1H), 1.54 (s, 3H), 1.46 (s, 
3H), 1.34 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 109.3, 108.6, 92.1, 71.5, 70.6, 70.4, 68.1, 62.2, 
26.0, 25.9, 24.9, 24.1; HRMS (ESI) m/z calcd for C12H20NaO6 [M + Na]+ 283.1157, found 
283.0957. 
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1,2:3,4-Di-O-isopropylidene-6-O-p-toluenesulfonyl-6--D-galactopyranose (38a) 
 
1,2:3,4-Di-O-isopropylidene--D-galactopyranose (37) (3.10 g, 11.9 mmol) was dissolved in dry 
pyridine (25 mL), and the solution was cooled to 0 °C. Then p-toluenesulfonyl chloride (2.72 g, 
14.2 mmol) was added in 3 portions over 20 min. The solution was then allowed to warm to rt. 
After 20 h, the solution was poured into an ice-water mixture (20 g). The solution was extracted 
with CHCl3 (3 × 25 mL), washed with H2O (2 × 20 mL) and dried (MgSO4). Evaporation of the 
solvent gave a black syrup which crystallized from diethyl ether-petroleum ether (1:1) to afford 
1,2:3,4-di-O-isopropylidene-6-O-p-toluenesulfonyl--D-galactopyranose (38a) as a white solid 
(4.34 g, 88%):80 mp = 90‒92 °C; [α]D
23 = ‒67.0 (c = 1.0, CHCl3); IR (neat) 2993, 2958, 2936, 1359, 
1212, 1119, 1067, 956 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 
8.1 Hz, 2H), 5.45 (d, J = 5.0 Hz, 1H), 4.58 (dd, J = 7.9, 2.5 Hz, 1H), 4.29 (dd, J = 5.0, 2.5 Hz, 1H), 
4.22‒4.18 (m, 2H), 4.11‒4.02 (m, 2H), 2.44 (s, 3H), 1.50 (s, 3H), 1.34 (s, 3H), 1.31 (s, 3H), 1.28 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 144.9, 133.1, 130.0, 128.3, 109.8, 109.2, 96.3, 70.8, 70.6, 
70.6, 68.4, 66.1, 26.2, 26.0, 25.1, 24.6, 21.8; HRMS (ESI) m/z calcd for C19H27O8S [M + H]+ 
415.1427, found 415.1424. 
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6-Azido-6-deoxy-1,2:3,4-di-O-isopropylidene--D-galactopyranose (38) 
 
Sodium azide (0.91 g, 13.9 mmol) was added to a solution of 1,2:3,4-di-O-isopropylidene-6-O-p-
toluenesulfonyl--D-galactopyranose (38a) (4.43 g, 10.7 mmol) in dry DMF (78 mL). The mixture 
was heated at 130 °C for 48 h. The mixture was cooled to rt and filtered. The filtrate was 
concentrated to 30 mL, and H2O (35 mL) was added. The solution was extracted with CHCl3 (4 × 
40 mL), and the combined extracts were dried (Na2SO4) and concentrated to give a syrup. 
Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 80:20) afforded 6-
azido-6-deoxy-1,2:3,4-di-O-isopropylidene--D-galactopyranose (38) as a pale yellow oil (2.77 g, 
91%):80 [α]D
23 = –95.1 (c = 1.0, CHCl3); IR (neat) 2988, 2936, 2099, 1210, 1065, 1004 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 5.52 (d, J = 5.1 Hz, 1H), 4.60 (dd, J = 7.8, 2.4 Hz, 1H), 4.29 (dd, J = 
4.8, 2.4 Hz, 1H), 4.15 (dd, J = 7.8, 2.0 Hz, 1H), 3.88 (ddd, J = 7.8, 5.4, 1.9 Hz, 1H), 3.47 (dd, J = 
12.8, 7.8 Hz, 1H), 3.32 (dd, J = 12.7, 5.4 Hz, 1H), 1.51 (s, 3H), 1.42 (s, 3H), 1.30 (s, 6H); 13C NMR 
(100 MHz, CDCl3) δ 109.7, 108.9, 96.5, 71.3, 70.9, 70.5, 67.1, 50.8, 26.1, 26.1, 25.0, 24.5; HRMS 
(ESI) m/z calcd for C12H20N3O5 [M + H]+ 286.1403, found 286.1411. 
6-Azido-6-deoxy-1-O-methyl--D-galactopyranoside (39) 
 
6-Azido-6-deoxy-1,2:3,4-di-O-isopropylidene--D-galactopyranose (38) (4.30 g, 15.1 mmol) was 
dissolved in MeOH (45 mL) and cooled to 0 °C. Acetyl chloride (10.2 mL, 143 mmol) was added 
to the solution dropwise, which was allowed to warm to rt. After 12 h, the solution was 
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concentrated, and the residue was purified by flash chromatography on silica gel (DCM/MeOH, 
90:10), yielding 6-azido-6-deoxy-1-O-methyl--D-galactopyranoside (39) (about 9% -isomer) as 
a white solid (2.87 g, 87%):49 mp = 172.4–173.1 °C; IR (neat) 3371, 3237, 2933, 2092, 1641, 
1460, 1349, 1297 cm-1; 1H NMR (400 MHz, pyridine-d5) δ 6.56 (br s, 3H), 5.18 (d, J = 3.7 Hz, 1H), 
4.60 (dd, J = 10.1, 3.7 Hz, 1H), 4.42 (dd, J = 10.1, 3.3 Hz, 1H), 4.30 (m, 1H), 4.21 (dd, J = 3.3, 
1.1 Hz, 1H), 4.02 (dd, J = 12.8, 8.8 Hz, 1H), 3.58 (dd, J = 12.8, 4.0 Hz, 1H), 3.48 (s, 3H); 13C NMR 
(100 MHz, pyridine-d5) δ 102.3, 71.8, 71.4, 71.4, 70.6, 55.8, 53.0; HRMS (ESI) m/z calcd for 
C7H14N3O5 [M + H]+ 220.0934, found 220.0954. 
6-Azido-2,3,4-tri-O-benzyl-6-deoxy-1-O-methyl--D-galactopyranoside (40) 
 
6-Azido-6-deoxy-1-O-methyl-/-D-galactopyranoside (39) (1.07 g, 4.88 mmol, / ratio 10:1) 
was dissolved in dry THF (65 mL), followed by the addition of benzyl bromide (3.48 mL, 29.3 
mmol), K2CO3 (5.39 g, 39.1 mmol) and 18-crown-6 (90 mg, 0.07 mmol). The suspension was 
stirred for 15 min, and NaH (60% in mineral oil, 1.46 g, 36.6 mmol) was added. After 12 h, brine 
(50 mL) was added and the solution was extracted with Et2O (3 × 50 mL). The combined organic 
extracts were dried (Na2SO4) and concentrated. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc, 80:20) afforded 6-azido-2,3,4-tri-O-benzyl-6-deoxy-1-O-methyl--D-
galactopyranoside (40) as a colorless oil (2.01 g, 84%):49 [α]D
23 = +4.8 (c = 1.0, CHCl3); IR (neat) 
3063, 3030, 2905, 2097, 1092, 1042, 1027, 734, 696 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.46–
7.29 (m, 15H), 5.04 (d, J = 11.4 Hz, 1H), 4.93 (d, J = 11.8 Hz, 1H), 4.85 (d, J = 12.0 Hz, 1H), 4.79 
(d, J = 11.9 Hz, 1H), 4.77 (d, J = 3.6 Hz, 1H), 4.72 (d, J = 12.0 Hz, 1H), 4.15–3.78 (m, 4H), 3.60–
3.53 (m, 1H), 3.43 (s, 3H), 2.97 (dd, J = 12.6, 4.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 138.5, 
138.2, 138.0, 128.2, 128.1, 127.8, 127.6, 127.5, 127.4, 127.3, 127.3, 98.5, 78.6, 76.1, 75.2, 74.4, 
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73.3, 73.2, 69.6, 55.1, 51.2; HRMS (ESI) m/z calcd for C28H31N3NaO5 [M + Na]+ 512.2161, found 
512.2179. 
1-O-Acetyl-6-azido-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranoside (41a) 
 
6-Azido-2,3,4-tri-O-benzyl-6-deoxy-1-O-methyl--D-galactopyranoside (40) (505 mg, 1.03 mmol) 
was dissolved in acetic acid (0.42 mL) and cooled to 0 °C. The suspension was stirred for 10 min, 
and acetic anhydride (0.56 mL, 5.98 mmol) was added, followed by the addition of concentrated 
H2SO4 (9 μL). The mixture was stirred at 0 °C for 8 h, followed by the addition of ice cold H2O (10 
mL). The mixture was extracted with DCM (4 × 15 mL), dried (Na2SO4), and concentrated. 
Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 95:5) afforded 1-O-
acetyl-6-azido-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranoside (41a) as a colorless oil (427 mg, 
80%):81 [α]D
23 = +44.4 (c = 1.0, CHCl3); IR (neat) 3063, 3031, 2874, 2102, 1749, 1227, 1126, 1104, 
737, 698 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35–7.28 (m, 15H), 6.40 (d, J = 3.9 Hz, 1H), 5.03 
(d, J = 11.4 Hz, 1H), 4.90 (d, J = 11.7 Hz, 1H), 4.78 (d, J = 12.0 Hz, 1H), 4.72 (s, 2H), 4.61 (d, J 
= 11.4 Hz, 1H), 4.21–4.16 (m, 1H), 3.94–3.90 (m, 3H), 3.49 (dd, J = 12.3, 7.2 Hz, 1H), 3.17 (dd, 
J = 12.3, 6.3 Hz, 1H), 2.14 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.3, 138.3, 137.9, 137.8, 128.2, 
128.1, 128.0, 127.8, 127.7, 127.6, 127.5, 127.4, 127.3, 90.3, 78.3, 74.8, 74.6, 74.5, 73.0, 72.9, 
71.6, 50.6, 20.6; HRMS (ESI) m/z calcd for C29H31N3NaO6 [M + Na]+ 540.2111, found 540.2101. 
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6-Azido-2,3,4-tri-O-benzyl-6-deoxy-/-D-galactopyranoside (41) 
 
6-Azido-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranoside (41a) (377 mg, 0.728 mmol) was 
dissolved in dry MeOH (3 mL). Then sodium methoxide solution in MeOH (25 wt. %, 0.10 mL) 
was added dropwise, and the solution was stirred at rt for 5 min. The mixture was neutralized with 
1.0 M HCl and extracted with CHCl3 (4 × 5 mL). The combined extracts were washed with water 
(2 × 5 mL), dried (Na2SO4), and concentrated. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc, 85:15 to 70:30) afforded 6-azido-2,3,4-tri-O-benzyl-6-deoxy--D-
galactopyranoside (41) (mixture of anomers, /ratio 3:1)  as a colorless oil (329 mg, 96%):81 -
isomer: [α]D
23 = +8.8 (c = 1.0, CHCl3); IR (neat) 3421 , 3030, 2924, 2102, 1454, 1091, 1063, 1028, 
737, 698 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.42–7.29 (m, 15H), 5.29 (d, J = 3.5 Hz, 1H), 5.00 (d, 
J = 11.4 Hz, 1H), 4.85 (d, J = 11.8 Hz, 1H), 4.84 (d, J = 11.7 Hz, 1H), 4.81 (d, J = 11.2 Hz, 1H), 
4.72 (d, J = 11.7 Hz, 1H), 4.61 (d, J = 11.4 Hz, 1H), 4.07–4.03 (m, 2H), 3.94 (dd, J = 7.7, 2.7 Hz, 
1H), 3.85 (br s, 1H), 3.50 (dd, J = 12.4, 7.5 Hz, 1H), 3.11 (dd, J = 12.5, 4.6 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 138.6, 138.3, 138.2, 128.7, 128.6, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 
127.7, 92.0, 78.7, 76.6, 74.8, 74.7, 73.8, 73.4, 69.9, 51.3; HRMS (ESI) m/z calcd for 
C27H29N3NaO5 [M + Na]+ 498.2005, found 498.2028. 
6-Azido-2,3,4-tri-O-benzyl-6-deoxy-/-D-galactosyl fluoride (36) 
 
6-Azido-2,3,4-tri-O-benzyl-6-deoxy-/-D-galactopyranoside (41)  (500 mg, 1.05 mmol, / ratio 
3:1) was dissolved in dry DCM (8 mL), and the solution was cooled to –30 °C. Then 
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diethylaminosulfur trifluoride (508 mg, 3.15 mmol) was added dropwise, and stirring was 
continued for for 20 min. MeOH (2 mL) was added, and the solution was poured into cold 
saturated aqueous NaHCO3 (6 mL). The mixture was extracted with CHCl3 (3 × 10 mL). The 
combined organic extracts were washed with brine (15 mL), dried (Na2SO4) and concentrated. 
Purification and separation of diastereomers by flash chromatography on silica gel (petroleum 
ether/EtOAc, 90:10) afforded 6-azido-2,3,4-tri-O-benzyl-6-deoxy--galactosyl fluoride (36) as a 
colorless oil (220 mg, 44%):81 -isomer as a colorless oil: IR (neat) 3088, 3064, 3031, 2914, 2872, 
2102, 1454, 1126, 1109, 1049, 738, 698 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.43–7.31 (m, 15H), 
5.61 (dd, J = 53.6, 2.6 Hz, 1H), 5.04 (d, J = 11.3 Hz, 1H), 4.91–4.74 (m, 4H), 4.62 (d, J = 11.3 Hz, 
1H), 4.12–3.96 (m, 3H), 3.91 (br s, 1H), 3.53 (dd, J = 12.4, 7.2 Hz, 1H), 3.17 (dd, J = 12.5, 6.0 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 138.4, 138.1, 128.7, 128.7, 128.6, 128.5, 128.2, 128.2, 
128.1, 128.0, 127.8, 106.2 (d, JC-F = 225.5 Hz), 78.4, 75.8 (d, JC-F = 23.5 Hz), 75.0, 74.5, 74.0, 
73.7, 72.1 (d, JC-F = 2.7 Hz), 51.0; HRMS (ESI) m/z calcd for C27H28FN3NaO4 [M + Na]+ 500.1962, 
found 500.1958: -isomer 6-azido-2,3,4-tri-O-benzyl-6-deoxy--galactosyl fluoride (36) was 
obtained as a colorless oil (220 mg, 44%): IR (neat) 3029, 2881, 2103, 1454, 1101, 1055, 70, 696 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37–7.31 (m, 15H), 5.23 (dd, J = 52.6, 6.3 Hz, 1H), 4.96 (d, J 
= 11.6 Hz, 1H), 4.84–4.72 (m, 4H), 4.61 (d, J = 11.5, 1H), 3.94 (ddd, J = 12.2, 9.0, 6.3 Hz, 1H), 
3.83–3.80 (m, 1H), 3.72–3.58 (m, 3H), 3.51 (s, 2H), 3.27 (dd, J = 11.6, 5.04 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 138.2, 138.1, 138.0, 128.7, 128.6, 128.4, 128.3, 128.2, 128.1, 128.1, 127.8, 
109.9 (d, JC-F = 216.4 Hz), 80.2 (d, JC-F = 9.9 Hz), 78.5 (d, JC-F = 22.0 Hz), 75.0, 74.4, 73.9 (d, JC-F 
= 4.2 Hz), 73.6, 73.1, 51.2; HRMS (ESI) m/z calcd for C27H28FN3NaO4 [M + Na]+ 500.1962, found 
500.1981. 
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(S)-[2-Hydroxy-1-(methoxymethylcarbamoyl)ethyl]-carbamic acid tert-butyl ester (48) 
 
(S)-2-(tert-Butoxycarbonyl)-3-hydroxypropanoic acid (4.00 g, 19.5 mmol) was dissolved in dry 
DCM (77 mL), and the solution was cooled to –15 °C. Next, N,O-dimethylhydroxyl amine 
hydrochloride (1.96 g,  20.0 mmol) was added, followed by N-methylmorpholine (2.21 mL, 20.1 
mmol). After 5 min EDC (3.85 g, 20.1 mmol) was added in 5 equal portions over 30 min (1 portion 
per 6 min). The reaction mixture was allowed to stir an additional 1 h at –15 °C. Then, ice cold 
aqueous HCl (1.0 M, 25 mL) was added, the layers were separated, and the aqueous layer was 
extracted with DCM (3 × 25 mL). The combined organic extracts were washed with saturated 
aqueous NaHCO3 (2 × 25 mL), H2O (2 × 25 mL) and brine (1 × 25 mL). The organic phase was 
dried (MgSO4) and concentrated to give (S)-[2-hydroxy-1-(methoxymethylcarbamoyl)ethyl]-
carbamic acid tert-butyl ester (48) as a white solid (4.06 g, 84%):82 1H NMR (400 MHz, CDCl3) δ 
5.62 (br s, 1H), 4.78 (br s, 1H), 3.81–3.77 (m, 5H), 3.22 (s, 3H), 2.77 (br s, 1H) 1.44 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 171.2, 156.1, 80.3, 63.9, 61.8, 52.6, 52.6, 32.3, 28.5. 
(2S)-2-(N-tert-Butoxycarbonyl)amino-1-hydroxyoctadecan-3-one (49) 
 
(S)-[2-Hydroxy-1-(methoxymethylcarbamoyl)ethyl]-carbamic acid tert-butyl ester (48) (2.00 g, 
8.06 mmol) was dissolved in dry THF (16 mL) under N2. The resulting solution was cooled to –15 
°C via an ice/salt water bath. Next, s-BuMgCl (2.0 M in Et2O, 8.05 mL, 16.1 mmol) was added 
dropwise. After 5 min, pentadecylmagnesium bromide (48a) (0.42 M in THF, 24.9 mL, 10.5 mmol) 
was added dropwise at –15 °C. The resulting solution was allowed to warm to rt and stir overnight. 
The reaction was cooled to –15 °C and ice cold aqueous HCl (1.0 M, 20 mL) was added, followed 
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by EtOAc (20 mL). The two layers were separated, and the aqueous layer was extracted with 
DCM (3 × 35 mL). The combined organic extracts were washed with H2O (40 mL), dried (MgSO4), 
and concentrated. Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 
80:20) afforded (2S)-2-(N-tert-butoxycarbonyl)amino-1-hydroxyoctadecan-3-one (49) as a white 
solid (2.06 g, 64%):72 1H NMR (400 MHz, CDCl3) δ  5.63 (br s, 1H), 4.34 (s, 1H), 3.97–3.90 (m, 
2H), 2.63 (br s, 1H), 1.57 (m, 2H), 1.45 (s, 9H), 1.27–1.22 (m, 24H), 0.88 (t, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 208.1, 164.0, 80.3, 70.1, 68.9, 63.3, 61.6, 52.3, 49.8, 39.9, 31.9, 29.7, 
29.6, 29.4, 29.3, 29.2, 28.3, 23.5, 22.7, 14.1. 
 (2S)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldimethylsilanyloxyoctadecan-3-one (50) 
 
(2S)-2-(N-tert-Butoxycarbonyl)amino-1-hydroxyoctadecan-3-one (49) (1.22 g, 3.05 mmol) was 
dissolved in dry DMF (8 mL) under N2. Next, imidazole (0.63 g, 3.05 mmol) was added, followed 
by a catalytic amount of DMAP. After 20 min TBSCl (0.95 mL, 3.66 mmol) was added, and the 
reaction was stirred for 14 h. The reaction mixture was diluted with saturated aqueous NH4Cl (15 
mL), and the aqueous layer was extracted with DCM (3 × 20 mL). The combined organic extracts 
were washed with H2O (20 mL) and brine (20 mL), dried (MgSO4), and concentrated. Purification 
by flash chromatography on silica gel (petroleum ether/EtOAc, 99:1) afforded (2S)-2-(N-tert-
butoxycarbonyl)amino-1-tert-butyldimethylsilanyloxyoctadecan-3-one (50) as a colorless oil (1.73 
g, 89%):72 1H NMR (400 MHz, CDCl3) δ 5.49 (d, J = 7.0 Hz, 1H), 4.26 (t, J = 3.3 Hz, 1H), 4.05 (d, 
J = 10.3 Hz, 1H), 3.82 (dd, J = 10.2, 3.6 Hz, 1H), 2.62–2.43 (m, 2H), 1.58– (m, 2H), 1.45 (s, 9H), 
1.26 (m, 24H), 0.88 (t, J = 5.7 Hz, 3H), 0.86 (s, 9H), 0.03 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 
208.0, 155.5, 79.8, 63.6, 61.3, 40.3, 32.1, 29.8, 29.8, 29.8, 29.6, 29.6, 29.5, 29.4, 28.5, 25.9, 23.5, 
22.9, 18.3, 14.3, –5.4. 
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(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldimethylsilanyloxyoctadecan-3-ol 
(51a) 
 
Dry EtOH (28 mL) was cooled to –78 °C and stirred under N2 for 20 min. Then, LiAl(Ot-Bu)3H 
(5.13 g, 20.2 mmol) was added, and the mixtue was stirred for 20 min. Next, a solution of (2S)-2-
(N-tert-butoxycarbonyl)amino-1-tert-butyldimethylsilanyloxyoctadecan-3-one (50) (2.18 g, 3.4 
mmol) in dry EtOH (28 mL)  was added dropwise over 15 min to the stirred solution. The 
temperature was maintained –78 °C for 6 h. The reaction mixture was diluted with DCM (20 mL), 
and 10% aqueous citric acid solution (35 mL) was added. The mixture was stirred for 1.5 h at rt, 
and the aqueous layer was extracted with DCM (3 × 25 mL). The combined organic extracts were 
washed with H2O (25 mL) and brine (25 mL), dried (MgSO4), and concentrated. Purification by 
flash chromatography on silica gel (petroleum ether/EtOAc, 97:3) afforded (2S,3R)-2-(N-tert-
butoxycarbonyl)amino-1-tert-butyldimethylsilanyloxyoctadecan-3-ol (51a) as a colorless oil (2.07 
g, 95%):72 1H NMR (400 MHz, CDCl3) δ 5.32 (d, J = 6.6 Hz, 1H), 3.97 (dd, J = 10.6, 2.8 Hz, 1H), 
3.83 (d, J = 9.3 Hz, 1H), 3.65 (m, 1H), 3.51 (br s, 1H), 3.01 (br s, 1H), 1.53 (br s, 2H), 1.46 (s, 
9H), 1.26 (m, 24H), 0.92 (s, 9H), 0.89 (t, J = 7.7 Hz, 3H), 0.09 (s, 6H); 13C NMR (100 MHz, CDCl3) 
δ 155.9, 79.5, 74.5, 63.7, 54.1, 35.1, 32.1, 29.9, 29.8, 29.8, 29.6, 26.2, 26.0, 22.9, 18.3, 14.3, –
5.4, –5.4. 
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(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldimethylsilanyloxy-3-benzyloxyocta-
decane (51) 
 
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldimethylsilanyloxyoctadecan-3-ol (51a) (889 
mg, 1.39 mmol) was dissolved in dry DMF (10 mL), and the solution was cooled to 0 °C and stirred 
under N2. Then, tetrabutylammonium iodide (759 mg, 2.06 mmol) was added, followed by NaH 
(60% in mineral oil, 69 mg, 1.73 mmol). After 10 min benzylbromide (0.245 mL, 2.06 mmol) was 
added dropwise. After the addition the ice bath was removed, and the reaction mixture was stirred 
at rt for 4 h. The reaction was quenched with saturated aqueous NH4Cl (15 mL), and the mixture 
was extracted with Et2O (4 × 20 mL). The combined organic extracts were washed with H2O (25 
mL) and brine (25 mL), dried (MgSO4), and concentrated. Purification by flash chromatography 
on silica gel (petroleum ether/EtOAc, 99:1) afforded (2S,3R)-2-(N-tert-butoxycarbonyl)amino-1-
tert-butyldimethylsilanyloxy-3-benzyloxyoctadecane (51) as a clear oil (756 mg, 72%):72 1H NMR 
(400 MHz, CDCl3) δ 7.32 (m, 5H), 4.65 (br s, 1H), 4.49 (s, 2H), 3.79 (m, 2H), 3.58 (m, 1H), 3.47 
(br s, 1H), 1.49 (m, 2H), 1.39 (s, 9H), 1.21 (br s, 26H), 0.85 (s, 9H), 0.82 (t, J = 4.5 Hz, 3H), 0.00 
(s, 6H); 13C NMR (100 MHz, CDCl3) δ 155.8, 138.9, 128.8, 128.3, 127.8, 79.2, 78.6, 72.6, 62.2, 
53.8, 32.1, 30.7, 30.1, 29.9, 29.9, 29.8, 29.8, 29.6, 28.6, 25.5, 25.1, 22.9, 18.4, 18.3, 14.3, –4.3, 
–5.2. 
 (2S,3R)-2-Amino-3-benzyloxyoctadecan-1-ol (34a) 
 
Acetyl chloride (3.2 mL, 34.6 mmol) was added dropwise to MeOH (39.1 mL) at 0 °C. The solution 
was slowly warmed to rt under N2. (2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-
49 
 
butyldimethylsilanyloxy-3-benzyloxyoctadecane (51) (1.01 g, 13.2 mmol) dissolved in dry Et2O 
(39 mL) was slowly added, and the solution was stirred for 2 d at rt. The reaction mixture was 
concentrated then dissolved in DCM (10 mL). Saturated aqueous NaHCO3 (15 mL), followed by 
aqueous NaOH (1.0 M, 10 mL) was added. The mixture was stirred for 1 h, then diluted with DCM 
(75 mL). The aqueous layer was extracted with DCM (3 × 50 mL), and the combined organic 
extracts were dried (MgSO4) and concentrated. Purification by flash chromatography on silica gel 
(DCM/MeOH, 90:10) afforded (2S,3R)-2-amino-3-benzyloxyoctadecan-1-ol (34a) as a colorless 
oil (363 mg, 70%):72 1H NMR (400 MHz, CDCl3) δ 7.31 (m, 5H), 4.50 (m, 2H), 3.69 (m, 3H), 3.01 
(br s, 1H), 2.47 (br s, 3H), 1.35 (m, 2H), 1.20 (m, 26H), 0.82 (t, J = 5.9 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 138.6, 128.7, 128.0, 128.0, 82.5, 72.5, 63.7, 54.5, 32.1, 30.7, 30.1, 29.9, 29.9, 
29.8, 29.8, 29.6, 25.6, 22.9, 14.3. 
 (2S,3R)-3-Benzyloxy-2-(N-hexacosanoylamino)octadecan-1-ol (34) 
 
p-Nitrophenyl hexacosanoate (46) (132 mg, 0.254 mmol) was added to a stirred solution under 
N2 of (2S,3R)-2-amino-3-benzyloxyoctadecan-1-ol (34a) (83 mg, 0.212 mmol) in dry pyridine 
(4.15 mL). The reaction was stirred for 1 d at rt. The solution was concentrated, and the residue 
was purified by flash chromatography on silica gel (petroleum ether/EtOAc, 85:15) to afford 
(2S,3R)-3-benzyloxy-2-(N-hexacosanoylamino)octadecan-1-ol (34) as a white solid (84 mg, 
83%):72 1H NMR (400 MHz, CDCl3) δ 7.33 (m, 5H), 6.09 (d, J = 7.2 Hz, 1H), 4.62 (d, J = 11.6 Hz, 
1H), 4.36 (d, J = 11.6 Hz, 1H), 3.94 (m, 2H), 3.63 (br s, 1H), 3.55 (d, J = 9.1 Hz, 1H), 2.04 (m, 
2H), 1.68 (m, 1H), 1.53 (m, 3H), 1.22 (br s, 70H), 0.85 (t, J = 5.6 Hz, 6H); 13C NMR (100 MHz, 
CDCl3) δ 173.6, 138.2, 128.9, 128.3, 128.1, 82.2, 73.0, 62.4, 52.3, 36.9, 32.1, 31.6, 30.0, 29.9, 
29.8, 29.7, 29.6, 29.5, 25.9, 25.9, 22.9, 14.3.  
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p-Nitrophenyl hexacosanoic acid (46) 
 
Hexacosanoic acid (2.00 g, 5.04 mmol) was dissolved in dry DCM (285 mL) under N2. Then, p-
nitrophenol (637 mg, 4.58 mmol) was added, followed by DMAP (112 mg, 0.92 mmol) and DCC 
(1.00 g, 4.82 mmol). The reaction mixture was stirred at rt for 18 h. The solution was concentrated, 
and the residue was purified by flash chromatography on silica gel (petroleum ether/ EtOAc, 98:2 
to 95:5) to afford p-nitrophenyl hexacosanoic acid (46) as a white solid (2.14 g, 82%):83 1H NMR 
(400 MHz, CDCl3) δ 8.27 (d, J = 9.0 Hz, 2H), 7.28 (d, J = 9.1 Hz, 2H), 2.60 (t, J = 7.5 Hz, 2H), 
1.80-1.73 (m, 2H), 1.26 (s, 44H), 0.89 (t, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.5, 
155.8, 145.5, 125.4, 122.6, 34.6, 32.1, 29.9, 29.8, 29.7, 29.6, 29.4, 29.3, 25.0, 22.9, 14.3. 
n-Pentadecylmagnesium bromide (48a) 
 
Magnesium turnings (381 mg, 15.7 mmol) were placed in an oven-dried, three neck flask 
equipped with a condenser under N2, and anhydrous THF (2 mL) was added, followed by a crystal 
of iodine. The flask was heated in a preheated oil bath at 75 °C, until the pink solution turned 
colourless. Approximately 25% of a solution of 1-bromopentadecane (3.05 g, 10.5 mmol) in dry 
THF (8.5 mL) was added. After 10 min or until the brown color changed to gray, the rest of the 1-
bromopentadecane solution was added over 10 min, and the mixture was heated at reflux for 1.5 
h. The mixture was cooled to rt and the Grignard reagent was titrated with salicylaldehyde 
phenylhydrazone.84 The concentration of the generated n-pentadecylmagnesium bromide (48a)72 
solution was determined to be 0.44 M in THF. 
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(2S,3S,4R)-2-Azido-1,3,4-octadecanetriol (42) 
 
Sodium azide (5.00 g, 96.0 mmol) was dissolved in H2O (20 mL), followed by the addition of DCM 
(27 mL). The biphasic mixture was cooled to 0 °C and triflic anhydride (7.96 mL, 48.0 mmol) was 
added dropwise over 20 min, with vigorous stirring of the mixture. The flask was stoppered and 
stirred at 0 °C for 2.5 h. The mixture was slowly quenched with saturated aqueous NaHCO3 (15 
mL), while stirring was continued until gas evolution had ceased. The organic layer was 
separated, and the aqueous layer was extracted with DCM (2 × 25 mL). The combined organic 
extracts were washed with saturated aqueous NaHCO3 (15 mL). The resulting triflyl azide solution 
in DCM was used in the azidation step without further purification as follows; (2S,3S,4R)-2-amino-
1,3,4-octadecanetriol (5.00 g, 15.8 mmol), CuSO4·5H2O (16 mg, 0.065 mmol), and potassium 
carbonate (2.27 g, 16.5 mmol) were dissolved in the same volume of H2O as the volume of triflyl 
azide solution (42 mL). The DCM solution of TfN3 was then added with vigorous stirring, followed 
by the addition of MeOH (285 mL) over 5 min. After 20 h, the reaction mixture was diluted with 
H2O (130 mL) and extracted with EtOAc (4 × 100 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated. The residue was purified by flash chromatography on silica gel 
(EtOAc), to afford (2S,3S,4R)-2-azido-1,3,4-octadecanetriol (42) as a white solid (5.24 g, 97%):85 
mp = 92.0‒93.1 °C; [α]D
23 = +15.0 (c = 1.0, CHCl3); IR (neat) 3343, 2919, 2847, 2120, 1463 cm-1; 
1H NMR (400 MHz, CDCl3) δ 4.02 (dd, J = 11.4, 5.1 Hz, 1H), 3.88 (dd, J = 11.4, 4.4 Hz, 1H), 3.83‒
3.74 (m, 2H), 3.70‒3.66 (m, 1H), 1.61‒1.51 (m, 3H), 1.41‒1.26 (m, 23H), 0.88 (t, J = 6.8 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 74.8, 72.5, 63.0, 62.0, 31.9, 29.6, 29.5, 29.3, 25.7, 22.6, 14.1; 
HRMS (ESI) m/z calcd for C18H37N3NaO3 [M + Na]+ 366.2727, found 366.2722. 
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 (2S,3S,4R)-2-Azido-1-O-triphenylmethyl-1,3,4-octadecanetriol (43a) 
 
(2S,3S,4R)-2-Azido-1,3,4-octadecanetriol (42) (2.30 g, 6.5 mmol) was dissolved in dry pyridine 
(30 mL), followed by the addition of TrCl (7.30 g, 26.2 mmol) and DMAP (200 mg). The reaction 
mixture was stirred at 50 °C for 14 h. The solution was concentrated, and the residue was 
dissolved in EtOAc (50 mL) and washed with H2O (25 mL). The organic layer was dried (Na2SO4) 
and concentrated, and the residue was purified by flash chromatography on silica gel (petroleum 
ether/EtOAc, 90:10 to 85:15) to afford (2S,3S,4R)-2-azido-1-O-triphenylmethyl-1,3,4-octade-
canetriol (43a) as a colorless oil (2.30 g, 60%):86 [α]D
23 = +9.7 (c = 1.0, CHCl3); IR (neat) 3416, 
2907, 2849, 1449, 1215, 1070 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.48‒7.42 (m, 6H), 7.36‒7.23 
(m, 9H), 3.66‒3.61 (m, 2H), 3.56‒3.51 (m, 2H), 3.41 (dd, J = 10.5, 5.4 Hz, 1H), 2.35 (d, J = 5.4 
Hz, 1H), 1.81 (d, J = 5.4 Hz, 1H), 1.56‒1.24 (m, 26H), 0.88 (t, J = 6.4 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 143.3, 128.5, 127.9, 127.2, 87.4, 74.1, 72.0, 63.5, 62.1, 31.4, 29.6, 29.5, 29.3, 
25.6, 22.6, 14.0; HRMS (ESI) m/z calcd for C37H52N3O3 [M + H]+ 586.4015, found 586.4061. 
 (2S,3S,4R)- 2-Azido-3,4-di-O-benzyl-1-O-triphenylmethyl-1,3,4-octadecanetriol (43) 
 
(2S,3S,4R)-2-Azido-1-O-triphenylmethyl-3,4-octadecanetriol (43a) (2.74 g, 4.68 mmol) was 
dissolved in dry DMF (40 mL), followed by the addition of NaH (60% in mineral oil, 1.68 g, 14.0 
mmol). The mixture was stirred at rt for 1 h. Then, the mixture was cooled to 0 °C, and benzyl-
chloride (1.67 mL, 14.0 mmol) was added dropwise. The resulting mixture was allowed to warm 
to rt and stirred for 20 h. The excess NaH was quenched with ice-cooled water (100 mL), and the 
reaction mixture was extracted with EtOAc (3 × 100 mL). The combined organic extracts were 
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washed with brine (3 × 50 mL), dried (MgSO4) and concentrated. The residue was purified by 
flash chromatography on silica gel (petroleum ether/EtOAc, 99:1) to afford (2S,3S,4R)-2-azido-
3,4-di-O-benzyl-1-O-triphenylmethyl-1,3,4-octadecanetriol (43) as a colorless oil (3.17 g, 92%):86 
[α]D
23 = +9.9 (c = 1.0, CHCl3); IR (neat) 2914, 2849, 1450, 1086, 1028, 745 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.49‒7.07 (m, 25H), 4.60 (d, J = 11.1 Hz, 1H), 4.48 (d, J = 11.1 Hz, 1H), 4.45 (s, 
2H), 3.82‒3.77 (m, 1H), 3.60‒3.50 (m, 3H), 3.40 (dd, J = 10.1, 8.1 Hz, 1H), 1.68‒1.20 (m, 26H), 
0.91 (t, J = 6.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 144.0, 138.6, 138.2, 128.9, 128.5, 128.4, 
128.1, 128.0, 127.9, 127.7, 127.6, 127.2, 79.6, 79.4, 73.7, 72.3, 64.5, 63.5, 31.8, 30.0, 29.9, 29.6, 
29.3, 25.5, 22.9, 14.3; HRMS (ESI) m/z calcd for C51H63N3NaO3 [M + Na]+ 788.4767, found 
788.4780. 
(2S,3S,4R)-2-Azido-3,4-di-O-benzyl-1,3,4-octadecanetriol (44a) 
 
(2S,3S,4R)-2-Azido-3,4-di-O-benzyl-1-O-triphenylmethyl-1,3,4-octadecanetriol (43) (1.15 g, 1.56 
mmol) and 4-toluenesulfonic acid (131 mg, 0.76 mmol) were dissolved in dry DCM/MeOH  (12 
mL, 2:1) and stirred at rt. After 12 h the reaction mixture was washed with saturated aqueous 
NaHCO3 (15 mL) and extracted with EtOAc (2 × 15 mL). The combined organic extracts were 
dried (MgSO4) and concentrated. The residue was purified by flash chromatography on silica gel 
(petroleum ether/EtOAc, 90:10) to afford (2S,3S,4R)-1,3,4-di-O-benzyl-1-O-triphenylmethyl-2-
azido-3,4-octadecanetriol (44a) as a colorless oil which slowly solidified (740 mg, 96%):76 [α]D
23 = 
‒5.7 (c = 1.0, CHCl3); IR (neat) 3430, 2923, 2853, 2095, 1496, 1095, 1062, 734, 697 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.39‒7.29 (m, 10H), 4.73‒4.56 (m, 4H), 3.93‒3.88 (m, 1H), 3.83‒3.77 
(m, 1H), 3.73‒3.63 (m, 3H), 2.54 (t, J = 6.4 Hz, 1H), 1.74‒1.27 (m, 26 H), 0.90 (t, J = 6.4 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 138.2, 137.9, 128.7, 128.6, 128.3, 128.2, 128.0, 80.7, 79.3, 73.9, 
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72.8, 63.3, 62.5, 32.1, 30.4, 29.9, 29.9, 29.8, 29.7, 29.6, 25.7, 22.9, 14.3; HRMS (ESI) m/z calcd 
for C32H50N3O3 [M + H]+ 524.3852, found 524.3863. 
 (2S,3S,4R)-2-Amino-3,4-di-O-benzyl-1,3,4-octadecanetriol (44) 
 
(2S,3S,4R)-2-Azido-3,4-di-O-benzyl-1,3,4-octadecanetriol (44a) (627 mg, 1.27 mmol) and 
triphenylphosphine (682 mg, 2.60 mmol) were dissolved in stirring pyridine/water (36 mL, 9:1). 
After 12 h the solvent was removed under reduced pressure and co-distillation with toluene (2 × 
30 mL). The residue was purified by flash chromatography on silica gel (DCM/MeOH, 95:5 to 
80:20) to afford (2S,3S,4R)-2-amino-3,4-di-O-benzyl-1,3,4-octadecanetriol (44) as a colorless oil 
(531 mg, 84%):76 1H NMR (400 MHz, CDCl3) δ 7.34‒7.26 (m, 10H), 4.76‒4.55 (m, 4H), 3.76‒3.71 
(m, 2H), 3.59‒3.55 (m, 2H), 3.04‒3.00 (m, 1H), 2.32 (br s, 3H), 1.75–1.27 (m, 26H), 0.88 (t, J = 
6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 138.5, 138.4, 133.1, 132.2, 132.1, 132.1, 132.0, 83.2, 
73.6, 72.5, 64.7, 53.7, 32.0, 30.7, 29.9, 29.8, 29.7, 29.5, 26.0, 22.8, 14.2.  
 (2S,3S,4R)-3,4-Di-O-benzyl-2-hexacosanoylamino-1,3,4-octadecanetriol (35) 
 
(2S,3S,4R)-2-Azido-3,4-di-O-benzyl-1,3,4-octadecanetriol (44) (402 mg, 0.807 mmol) was 
dissolved in dry THF (25 mL), and NEt3 (0.41 mL, 2.90 mmol) and p-nitrophenyl hexacosanoic 
acid (46) (502 mg, 0.969 mmol) were added. The reaction mixture was stirred at 50 °C for 14 h. 
The solvent was removed under reduced pressure, and the residue was purified by flash 
chromatography on silica gel (petroleum ether/EtOAc, 99:1 to 95:5) to afford (2S,3S,4R)-3,4-di-
O-benzyl-2-hexacosanoylamino-1,3,4-octadecanetriol (35) as a white solid (604 mg, 85%):76 mp 
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= 75.1‒76.2 °C; [α]D
23 = +25.9 (c = 1.0, CHCl3); IR (neat) 2917, 2850, 1637, 1618, 1548, 1468, 
1102, 1053 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39‒7.28 (m, 10H), 4.72 (d, J = 11.7 Hz, 1H), 
4.67 (d, J = 11.4 Hz, 1H), 4.61 (d, J = 11.4 Hz, 1H), 4.46 (d, J = 11.7 Hz, 1H), 4.17‒4.12 (m, 1H), 
4.02‒3.98 (m, 1H), 3.72‒3.67 (m, 2H), 3.61 (ddd, J = 12.7, 8.5, 4.4 Hz, 1H), 3.05 (dd, J = 8.4, 4.4 
Hz, 1H), 2.06‒1.93 (m, 2H), 1.71‒1.26 (m, 72H), 0.90‒0.87 (m, 6H); 13C NMR (100 MHz, CDCl3) 
δ 173.0, 138.4, 138.0, 129.0, 128.7, 128.4, 128.3, 128.2, 128.0, 82.5, 79.3, 73.3, 73.1, 63.2, 50.8, 
37.0, 32.1, 31.1, 30.0, 29.8, 29.7, 29.6, 29.5, 26.3, 25.9, 22.9, 14.3; HRMS (ESI) m/z calcd for 
C58H102NO4 [M + H]+ 876.7809, found 876.7797. 
 (2S,3S,4R)-3,4-Di-O-benzyl-1-O-(6-azido-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranos-
yl)-2-hexacosylaminooctadecane-1,3,4-triol (52) 
 
6-Azido-2,3,4-tri-O-benzyl-6-deoxy--galactosyl fluoride (36) (352 mg, 0.736 mmol) and 
(2S,3S,4R)-3,4-di-O-benzyl-2-hexacosanoylamino-1,3,4-octadecanetriol (35) (461 mg, 0.526 
mmol) were azeotroped with toluene (3 × 15 mL), dissolved in dry THF and stirred with activated 
powdered 4 Å MS for 30 min. The reaction mixture was cooled to 0 °C; AgClO4 (349 mg, 1.68 
mmol) and SnCl2 (319 mg, 1.68 mmol) were introduced into the solution with protection from light. 
The mixture was allowed to warm to rt over 3 h under N2, then filtered through a pad celite. The 
filter cake was washed with Et2O (200 mL). The combined filtrate was concentrated and the 
resulting residue was purified by flash chromatography on silica gel (petroleum ether/EtOAc, 7:1) 
to afford (2S,3S,4R)-1-O-(6-azido-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3,4-di-O-
benzyl-2-hexacosylaminooctadecane-1,3,4-triol (52) as a white solid (365 mg, 52%): mp = 59.1‒
60.3 °C; [α]D
23 = +35.1 (c = 1.0, CHCl3); IR (neat) 2922, 2853, 2100, 1454, 1093, 1056, 1027, 732, 
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696 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.44‒7.28 (m, 25H), 5.91 (d, J = 8.7 Hz, 1H), 5.03 (d, J = 
11.4 Hz, 1H), 4.90‒4.78 (m, 5H), 4.69 (d, J = 11.8 Hz, 1H), 4.65 (m, 2H), 4.56 (d, J = 11.6 Hz, 
1H), 4.54 (d, J = 11.7 Hz, 1H), 4.37‒4.31 (m, 1H), 4.08 (dd, J = 10.0, 3.6 Hz, 1H), 3.95‒3.85 (m, 
3H), 3.83‒3.80 (m, 3H), 3.60‒3.56 (m, 1H), 3.55‒3.50 (m, 1H), 3.04 (dd, J = 12.4, 5.0 Hz, 1H), 
1.98–1.93 (m, 2H), 1.78‒1.63 (m, 2H), 1.59‒1.51 (m, 2H), 1.50‒1.42 (m, 1H), 1.41‒1.24 (m, 68H), 
0.93 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 172.9, 138.9, 138.8, 138.7, 138.6, 138.3, 128.6, 
128.6, 128.5, 128.1, 128.0, 127.9, 127.9, 127.8, 127.7, 127.7, 99.3, 80.1, 79.5, 79.0, 76.7, 75.1, 
74.8, 73.7, 73.5, 72.0, 70.2, 69.0, 51.6, 50.3, 36.9, 32.1, 30.3, 30.0, 29.9, 29.8, 29.7, 29.6, 26.1, 
25.9, 22.9, 14.3; HRMS (ESI) m/z calcd for C85H129N4O8 [M + H]+ 1333.9810, found 1333.9789. 
(2S,3S,4R)-1-O-(6-Amino-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3,4-di-O-
benzyl-2-hexacosylaminooctadecane-1,3,4-triol (53) 
 
(2S,3S,4R)1-O-(6-Azido-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3,4-di-O-benzyl-2-
hexacosylaminooctadecane-1,3,4-triol (52) (74 mg, 0.055 mmol) in THF (3 mL) was added H2O 
(0.7 mL) and triphenylphosphine (22 mg, 0.083 mmol). The reaction mixture was stirred at rt for 
18 h. The solution was concentrated under reduce pressure to afford (2S,3S,4R)-1-O-(6-amino-
2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3,4-di-O-benzyl-2-hexacosylaminooctade-
cane-1,3,4-triol (53) as a colorless oil (59 mg, 82%): IR (neat) 2922, 2852, 1665, 1545, 1454, 
1117, 744, 694 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37‒7.24 (m, 25H), 5.98 (d, J = 9.1 Hz, 1H), 
4.94 (d, J = 11.3 Hz, 1H), 4.82–4.70 (m, 5H), 4.62 (d, J = 11.8 Hz, 1H), 4.58 (d, J = 11.4 Hz, 1H), 
5.54 (d, J = 11.4 Hz, 1H), 5.49 (d, J = 11.5 Hz, 1H), 4.46 (d, J = 11.8 Hz, 1H), 4.26–4.19 (m, 1H), 
3.99 (dd, J = 10.1, 3.6 Hz, 1H), 3.93 (dd, J = 11.4, 7.6 Hz, 1H), 3.84–3.78 (m, 3H), 3.69–3.67 (m, 
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2H), 3.55–3.51 (m, 1H), 2.90 (dd, J = 12.9, 8.0 Hz, 1H), 2.64 (dd, J = 13.1, 3.4 Hz, 1H), 1.93–1.82 
(m, 2H), 1.68–1.58 (m 2H), 1.48–1.39 (m, 2H), 1.32–1.15 (m, 68H), 0.90–0.86 (m, 6H); 13C NMR 
(100 MHz, CDCl3) δ 173.3, 138.7, 138.6, 138.4, 133.2, 132.3, 132.2, 132.2, 132.1, 132.1, 128.1, 
128.7, 128.6, 128.6, 128.6, 128.1, 128.1, 128.0, 128.0, 127.9, 127.8, 127.8, 127.8, 127.6, 99.7, 
80.0, 79.9, 79.5, 76.8, 75.1, 74.7, 73.7, 73.4, 72.0, 70.7, 69.2, 50.8, 50.8, 42.1, 36.9, 32.1, 30.3, 
30.0, 29.9, 29.9, 29.7, 29.6, 29.6, 26.0, 25.9, 22.9, 14.3; HRMS (ESI) m/z calcd for C85H131N2O8 
[M + H]+ 1307.9905, found 1307.9968. 
(2S,3S,4R)-3,4-Di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-phenylacetamido--D-
galactopyranosyl)-2-hexacosylaminooctadecane-1,3,4-triol (54a) 
 
A mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (19 mg, 0.098 mmol) and 
phenylacetic acid (13 mg, 0.098 mmol) in dry DMF (3 mL) was stirred at rt for 1 h. Then, 
(2S,3S,4R)-1-O-(6-amino-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3,4-di-O-benzyl-2-
hexacosylaminooctadecane-1,3,4-triol (53) (130 mg, 0.098 mmol) was added, and the reaction 
mixture was allowed to stirred for an additional 3 h. DMF was removed, and the residue was 
purified by flash chromatography on silica gel (hexane/EtOAc, 90:10) to afford (2S,3S,4R)-3,4-di-
O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-phenylacetamido--D-galactopyranosyl)-2-hexacos-
ylaminooctadecane-1,3,4-triol (54a) as a white solid ( 59 mg, 42%): mp = 112.6‒115.0 °C; [α]D
23 = 
+29.4 (c = 1.0, CHCl3); IR (neat) 3290 (br), 2919, 2852, 1647, 1453, 1094, 731, 696 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.38‒7.14 (m, 30H), 5.92 (d, J = 8.6 Hz, 1H), 5.66 (dd, J = 7.0, 3.9 Hz, 1H), 
4.91 (d, J = 11.4 Hz, 1H), 4.81‒4.71 (m, 5H), 4.62 (d, J = 11.8 Hz, 1H), 4.59 (d, J = 11.6 Hz, 1H), 
4.57 (d, J = 11.3 Hz, 1H), 4.49‒4.46 (m, 2H), 4.23‒4.17 (m, 1H), 3.99 (dd, J = 10.0, 3.6 Hz, 1H), 
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3.85‒3.73 (m, 4H), 3.68 (dd, J = 6.3, 6.3 Hz, 1H), 3.58 (dd, J = 10.9, 3.8 Hz, 1H), 3.54‒3.44 (m, 
2H), 3.37 (s, 2H), 3.10 (ddd, J = 11.6, 7.2, 4.0 Hz, 1H), 2.05‒1.88 (m, 2H), 1.69‒1.40 (m, 7H), 
1.32‒1.21 (m, 65H), 0.88 (t, J = 6.6 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 173.1, 171.3, 138.9, 
138.7, 138.6, 138.5, 135.2, 129.5, 129.0, 128.8, 128.7, 128.6, 128.6, 128.2, 128.1, 128.0, 127.9, 
127.9, 127.8, 127.7, 127.4, 99.4, 80.1, 79.4, 79.4, 77.4, 76.6, 75.1, 74.8, 73.8, 73.7, 73.3, 72.0, 
69.3, 68.7, 50.5, 43.8, 40.5, 36.9, 32.2, 30.2, 30.1, 30.0, 29.7, 29.7, 29.6, 26.3, 26.0, 22.9, 14.3; 
HRMS (ESI) m/z calcd for C93H137N2O9 [M + H]+ 1426.0324, found 1426.0309. 
(2S,3S,4R)-1-O-(6-Deoxy-6-phenylacetamido--D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (15) 
 
Pd(OH)2/C (20 wt% Pd dry basis on carbon, 30 mg) was added to a solution of (2S,3S,4R)-3,4-
di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-phenylacetamido--D-galactopyranosyl)-2-hexa-
cosylaminooctadecane-1,3,4-triol (54a) (23 mg, 0.016 mmol) dissolved in in EtOH/CHCl3 (8 mL, 
3:1), and the mixture was hydrogenated under atmospheric pressure for 14 h. The mixture was 
purged for 10 min with N2 and filtered through a pad of celite. The filter cake was washed with 
EtOH/CHCl3 (25 mL, 3:1). The combined filtrate was concentrated, and the resulting solid was 
triturated with EtOAc (3 × 3 mL) to afford (2S,3S,4R)-1-O-(6-deoxy-6-phenylacetamido--D-
galactopyranosyl)-2-hexacosylaminooctadecane-1,3,4-triol (15) as a white solid (12 mg, 72%): 
mp = 179.4‒180.4 °C; [α]D
23 = +37.4 (c = 1.0, CHCl3/MeOH 1:1); IR (neat) 3273 (br), 2916, 2849, 
1640, 1550, 1467, 1136, 1077, 1031 cm-1; 1H NMR (400 MHz, pyridine-d5) δ 8.88 (dd, J = 5.4, 5.4 
Hz, 1H), 8.58 (d, J = 8.5 Hz, 1H), 7.38‒7.25 (m, 5H), 6.33 (br s, 5H), 5.51 (d, J = 3.6 Hz, 1H), 
5.28‒5.21 (m, 1H), 4.59‒4.55 (m, 2H), 4.47‒4.44 (m, 1H), 4.35‒4.29 (m, 5H), 4.21‒4.14 (m, 1H), 
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3.96‒3.88 (m, 3H), 2.56‒2.43 (m, 2H), 2.36‒2.26 (m, 1H), 1.99‒1.80 (m, 4H), 1.76‒1.64 (m, 1H), 
1.35‒1.20 (m, 66H), 0.88 (t, J = 6.2 Hz, 6H); 13C NMR (100 MHz, pyridine-d5) δ 173.8, 172.1, 
137.6, 130.3, 129.3, 127.4, 101.8, 77.2, 73.0, 71.6, 71.1, 70.5, 69.0, 51.9, 44.2, 41.9, 37.3, 34.9, 
32.6, 30.9, 30.7, 30.5, 30.3, 30.3, 30.1, 27.0, 26.9, 23.4, 14.8; HRMS (ESI) m/z calcd for 
C58H107N2O9 [M + H]+ 975.7977, found 975.8001. 
(2S,3S,4R)-3,4-Di-O-benzyl-1-O-[2,3,4-tri-O-benzyl-6-deoxy-6-(3-phenylpropylamido)--D-
galactopyranosyl]-2-hexacosylaminooctadecane-1,3,4-triol (54b) 
 
A mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (10.6 mg, .056 mmol) and 
phenylpropanoic acid (8.35 mg, 0.056 mmol) in dry DMF (1.7 mL)  was stirred at rt for 1 h. Then, 
(2S,3S,4R)-1-O-(6-amino-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3,4-di-O-benzyl-2-
hexacosylaminooctadecane-1,3,4-triol (53) (56 mg, 0.043 mmol) was added, and the reaction 
mixture was stirred for an additional 3 h. DMF was removed, and the residue was purified by flash 
chromatography on silica gel (hexane/EtOAc, 90:10) to afford (2S,3S,4R)-3,4-di-O-benzyl-1-O-
[2,3,4-tri-O-benzyl-6-deoxy-6-(3-phenylpropylamido)--D-galactopyranosyl]-2-hexacosylamino-
octadecane-1,3,4-triol (54b) as a white solid (44 mg, 72%): mp = 113.6‒115.0 °C; [α]D
23 = +30.4 
(c = 1.0, CHCl3); IR (neat) 3293 (br), 2921, 2851, 1644, 1534, 1454, 1261, 1093, 1049, 1027, 731, 
696 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39‒7.10 (m, 25H), 6.12 (d, J = 8.4 Hz, 1H), 5.35 (dd, J 
= 6.4, 6.4 Hz, 1H), 4.92 (d, J = 11.4 Hz, 1H), 4.85 (d, J = 11.8 Hz, 1H), 4.81‒4.72 (m, 4H), 4.64‒
4.60 (m, 3H), 4.51‒4.47 (m, 2H), 4.24‒4.16 (m, 1H), 4.02‒3.97 (m, 2H), 3.83 (dd, J = 10.0, 2.7 
Hz, 1H), 3.78‒3.64 (m, 4H), 3.53 (ddd, J = 7.2, 3.5, 3.5 Hz, 1H), 3.34 (ddd, J = 13.7, 6.9, 6.9 Hz, 
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1H), 3.14 (ddd, J = 13.7, 5.2, 5.2 Hz, 1H), 2.81 (t, J = 7.8 Hz, 2H), 2.30‒2.12 (m, 2H), 2.02‒1.89 
(m, 2H), 1.66‒1.40 (m, 8H), 1.34‒1.12 (m, 67H), 0.90‒0.86 (m, 6H); 13C NMR (100 MHz, CDCl3) 
δ 173.3, 172.4, 141.1, 138.8, 138.7, 129.2, 128.7, 128.6, 128.6, 128.6, 128.5,128.2, 128.1, 128.1, 
128.0, 127.9, 127.6, 126.4, 99.9, 79.9, 79.5, 77.4, 74.7, 74.5, 73.8, 73.8, 73.6, 72.1, 68.9, 51.0, 
40.1, 38.2, 36.9, 32.2, 31.7, 30.3, 30.0, 29.7, 29.7, 29.6, 26.1, 26.0, 22.9, 14.3; HRMS (ESI) m/z 
calcd for C94H139N2O9 [M + H]+ 1440.0481, found 1440.0443. 
(2S,3S,4R)-1-O-[6-Deoxy-6-(3-phenylpropylamido)--D-galactopyranosyl]-2-hexacosyl-
aminooctadecane-1,3,4-triol (16) 
 
(2S,3S,4R)-3,4-Di-O-benzyl-1-O-[2,3,4-tri-O-benzyl-6-deoxy-6-(3-phenylpropylamido)--D-gal-
actopyranosyl]-2-hexacosylaminooctadecane-1,3,4-triol (54b) (25 mg, 0.017 mmol) was 
dissolved in EtOH/CHCl3 (8 mL, 3:1), Pd(OH)2/C (20 wt% Pd dry basis on carbon, 30.4 mg) was 
added. The mixture was hydrogenated under atmospheric pressure for 14 h. The solution was 
filtered through a pad of celite, and the filter cake was washed with EtOH/CHCl3 (25 mL, 3:1). The 
filtrate was concentrated, and the resulting residue was purified by trituration with EtOAc (3 × 3 
mL) to afford (2S,3S,4R)-1-O-[6-deoxy-6-(3-phenylpropylamido)--D-galactopyranosyl]-2-hexa-
cosylaminooctadecane-1,3,4-triol (16) as a white solid (13 mg, 76%): mp = 184.8‒185.7 °C; 
[α]D
23 = +36.9 (c = 1.0, CHCl3/MeOH 1:1); IR (neat) 3295 (br), 2917, 2849, 1641, 1549, 1306, 1018 
cm-1; 1H NMR (400 MHz, pyridine-d5) δ 8.87 (dd, J = 5.4, 5.4 Hz, 1H), 8.58 (d, J = 8.4 Hz, 1H), 
7.35‒7.28 (m, 5H), 6.31 (br s, 5H), 5.49 (d, J = 3.4 Hz, 1H), 5.28‒5.20 (m, 1H), 4.63‒4.56 (m, 
2H), 4.47 (dd, J = 6.4, 6.4 Hz, 1H), 4.34‒4.27 (m, 5H), 4.20‒4.15 (m, 1H), 3.92‒3.86 (m, 1H), 
3.22‒3.18 (m, 2H), 2.88‒2.75 (m, 2H), 2.51‒2.46 (m, 2H), 2.35‒2.23 (m, 1H), 2.01‒1.77 (m, 4H), 
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1.76‒1.62 (m, 2H), 1.32‒1.26 (m, 66H), 0.89‒0.86 (m, 6H); 13C NMR (100 MHz, pyridine-d5) δ 
173.8, 173.5, 142.6, 129.4, 129.3, 126.9, 101.8, 77.2, 73.0, 71.7, 71.4, 71.0, 70.6, 68.9, 52.0, 
41.6, 38.9, 37.3, 34.9, 32.8, 32.6, 30.9, 30.7, 30.5, 30.4, 30.3, 30.3, 30.1, 27.0, 26.9, 23.4, 14.8; 
HRMS (ESI) m/z calcd for C59H109N2O9 [M + H]+ 989.8133, found 989.8123. 
(2S,3R)-1-O-(6-Azido-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3-benzyloxy-2-
hexacosylaminooctadecane-1,3-diol (55) 
 
6-Azido-2,3,4-tri-O-benzyl-6-deoxy--galactosyl fluoride (36) (152 mg, 0.318 mmol) and 
(2S,3R)-3-benzyloxy-2-(N-hexacosanoylamino)octadecan-1-ol (34) (245 mg, 0.318 mmol) were 
co-evaporated with toluene (3 × 15 mL), dissolved in dry THF (6 mL) and stirred with activated 
powdered 4 Å MS for 30 min. The reaction mixture was cooled to 0 °C, and AgClO4 (198 mg, 
0.954 mmol) and SnCl2 (181 mg, 0.954 mmol) were introduced into the solution with protection 
from light. The mixture was allowed to warm to rt over 3 h under N2, then filtered through a pad 
celite, and the filter cake was washed with Et2O. The combined filtrate was concentrated, and the 
resulting residue was purified by flash chromatography on silica gel (petroleum ether/EtOAc, 7:1) 
to afford (2S,3R)-1-O-(6-azido-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3-benzyloxy-2-
hexacosylaminooctadecane-1,3-diol (55) as a white solid (288 mg, 74%): mp = 57.9‒58.8 °C; 
[α]D
23 = +33.4 (c = 1.0, CHCl3); IR (neat) 3308, 2918, 2852, 2101, 1640, 1542, 1461, 1097, 1046 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.41‒7.26 (m, 20H), 5.83 (d, J = 8.8 Hz, 1H), 4.99 (d, J = 11.5 
Hz, 1H), 4.87‒4.84 (m, 2H), 4.80 (d, J = 11.8 Hz, 1H), 4.76 (d, J = 11.8 Hz, 1H), 4.66 (d, J = 11.8 
Hz, 1H), 4.60 (d, J = 11.4 Hz, 1H), 4.59 (d, J = 11.6 Hz, 1H), 4.44 (d, J = 11.6 Hz, 1H), 4.28 (m, 
1H), 4.04 (dd, J = 10.0, 3.5 Hz, 1H), 3.89 (dd, J = 10.1, 2.6 Hz, 1H), 3.85‒3.75 (m, 4H), 3.60‒3.56 
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(m, 1H), 3.54‒3.49 (m, 1H), 2.97 (dd, J = 12.5, 4.6 Hz, 1H), 2.02 (m, 2H), 1.62‒1.51 (m, 4H), 
1.43‒1.16 (m, 70H), 0.90 (t, J = 6.5 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 173.0, 138.8, 138.7, 
138.6, 138.3, 128.6, 128.6, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7, 99.0, 79.2, 78.9, 76.7, 75.2, 
74.8, 73.6, 72.3, 70.4, 68.0, 51.7, 51.4, 37.0, 32.1, 31.0, 30.1, 29.9, 29.8, 29.6, 29.6, 25,9, 25.6, 
22.9, 14.3; HRMS (ESI) m/z calcd for C78H123N4O7 [M + H]+ 1227.9392, found 1227.9417. 
(2S,3R)-1-O-(6-Amino-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3-benzyloxy-2-
hexacosylaminooctadecane-1,3-diol (56) 
 
 (2S,3R)-1-O-(6-Azido-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3-benzyloxy-2-hexa-
cosylaminooctadecane-1,3-diol (55) (78 mg, 0.064 mmol) was dissolved in THF (3 mL) and H2O 
(0.7 mL), and triphenylphosphine (25 mg, 0.095 mmol) was added. The reaction mixture was 
stirred at rt for 18 h. The solution was concentrated, and the residue was purified by flash 
chromatography on silica gel (DCM/MeOH, 80:20) to afford (2S,3R)-1-O-(6-amino-2,3,4-tri-O-
benzyl-6-deoxy--D-galactopyranosyl)-3-benzyloxy-2-hexacosylaminooctadecane-1,3-diol (56) 
as a colorless oil (64 mg, 82%): mp = 71.8‒74.0 °C; [α]D
23 = +26.8 (c = 1.0, CHCl3); IR (neat) 3294 
(br), 2921, 2851, 1640, 1454, 1094, 1045, 1027, 731, 696 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.39‒7.22 (m, 20H), 6.02 (d, J = 8.6 Hz, 1H), 4.95 (d, J = 11.4 Hz, 1H), 4.89 (d, J = 3.2 Hz, 1H), 
4.83 (d, J = 11.7 Hz, 1H), 4.77 (d, J = 11.9 Hz, 1H), 4.73 (d, J = 11.8 Hz, 1H), 4.64 (d, J = 11.9 
Hz, 1H), 4.60 (d, J = 11.4 Hz, 1H), 4.55 (d, J = 11.6 Hz, 1H), 4.43 (d, J = 11.5 Hz, 1H), 4.25‒4.19 
(m, 1H), 4.25‒4.19 (m, 1H), 4.01 (dd, J = 9.3, 3.0 Hz, 1H), 3.87‒3.74 (m, 4H), 3.65 (s, 1H), 3.55 
(dd, J = 11.8, 6.0 Hz, 1H), 2.99‒2.94 (m, 1H), 2.74‒2.69 (m, 1H), 2.10‒1.95 (m, 2H), 1.60‒1.46 
(m, 8H), 1.45‒1.10 (m, 66H), 0.90‒0.86 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 173.4, 138.5, 
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138.5, 138.4, 138.0, 128.5, 128.5, 128.4, 128.4, 128.0, 127.9, 127.8, 127.8, 127.7, 127.5, 99.3, 
79.6, 78.9, 76.3, 75.0, 74.5, 73.4, 73.4, 72.4, 70.6, 68.5, 51.8, 41.6, 36.9, 31.9, 31.1, 29.9, 29.7, 
29.5, 29.4, 25.7, 25.5, 22.7, 14.3; HRMS (ESI) m/z calcd for C78H125N4O7 [M + H]+ 1201.9487, 
found 1201.9442. 
(2S,3R)-3-Benzyloxy-1-O-[2,3,4-tri-O-benzyl-6-deoxy-6-phenylacetamido--D-galacto-
pyranosyl]-2-hexacosylaminooctadecane-1,3-diol (57a) 
 
A mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (7.8 mg, 0.041 mmol) and 
phenylacetic acid (5.5 mg, 0.041 mmol) in dry DMF (2 mL) was stirred at rt for 1 h. Then, (2S,3R)-
1-O-(6-amino-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3-benzyloxy-2-hexacosylamino-
octadecane-1,3-diol (56) (33 mg, 0.027 mmol) was added, and the reaction mixture stirred for an 
additional 3 h. DMF was removed, and the residue was purified by flash chromatography on silica 
gel (hexane/EtOAc, 90:10) to afford (2S,3R)-3-benzyloxy-1-O-[2,3,4-tri-O-benzyl-6-deoxy-6-
phenylacetamido--D-galactopyranosyl]-2-hexacosylaminooctadecane-1,3-diol (57a) as a white 
solid (21 mg, 60%): mp = 112.6‒115.0 °C; [α]D
23 = +35.1 (c = 1.0, CHCl3); IR (neat) 3317 (br), 
2920, 2851, 1648, 1638, 1545, 1467, 1454, 1050 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37‒7.18 
(m, 25H), 5.78‒5.72 (m, 2H), 4.91 (d, J = 11.3 Hz, 1H), 4.81‒4.75 (m, 3H), 4.71 (d, J = 11.8 Hz, 
1H), 4.62 (d, J = 11.7 Hz, 1H), 4.56 (d, J = 11.4 Hz, 1H), 4.54 (d, J = 11.5 Hz, 1H), 4.41 (d, J = 
11.6 Hz, 1H), 4.23‒4.19 (m, 1H), 3.98 (dd, J = 10.0, 3.6 Hz, 1H), 3.81 (dd, J = 9.9, 2.5 Hz, 1H), 
3.74‒3.73 (m, 1H), 3.69‒3.66 (m, 2H), 3.56‒3.46 (m, 3H), 3.43 (s, 2H), 3.16‒3.10 (m, 1H), 2.10‒
1.94 (m, 2H), 1.59‒1.49 (m, 6H), 1.32‒1.25 (m, 74H), 0.88 (t, J = 6.6 Hz, 6H); 13C NMR (100 MHz, 
CDCl3) δ 173.1, 171.2, 138.9, 138.8, 138.7, 138.6, 138.5, 129.5, 129.1, 128.7, 128.7, 128.6, 
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128.1, 127.9, 127.9, 127.7, 127.4, 99.3, 79.3, 79.0, 76.6, 75.3, 74.8, 73.7, 73.4, 72.2, 69.3, 68.0, 
51.6, 43.9, 40.5, 37.0, 32.2, 31.0, 30.2, 30.0, 29.7, 29.6, 26.0, 25.5, 22.9, 14.3; HRMS (ESI) m/z 
calcd for C86H131N2O8 [M + H]+ 1319.9905, found 1319.9865. 
(2S,3R)-1-O-[6-Deoxy-6-phenylacetamido--D-galactopyranosyl]-2-hexacosylamino-
octadecane-1,3-diol (17) 
 
(2S,3R)-3-Benzyloxy-1-O-[2,3,4-tri-O-benzyl-6-deoxy-6-phenylacetamido--D-galactopyranos-
yl]-2-hexacosylaminooctadecane-1,3-diol (57a) (7.0 mg, 0.0050 mmol) was dissolved in dry 
EtOH/CHCl3 (8 mL, 3:1) was added Pd(OH)2/C (20 wt% Pd dry basis on carbon, 30 mg), and the 
mixture was hydrogenated under atmospheric pressure for 14 h. The solution was filtered through 
a pad of celite, and the filter cake was washed with EtOH/CHCl3 (3:1). The combined filtrate was 
concentrated, and the resulting residue was purified by trituration with EtOAc (3 × 3 mL) to afford 
(2S,3R)-1-O-[6-deoxy-6-phenylacetamido--D-galactopyranosyl]-2-hexacosylaminooctadecane-
1,3-diol (17) as a white solid (4.9 mg, 96%): mp = 168.3‒170.0 °C; [α]D
23 = +36.4 (c = 1.0, 
CHCl3/MeOH 1:1); IR (neat) 3418 (br), 3289 (br), 2918, 2850, 1641, 1551, 1466, 1076, 1033 cm-1; 
1H NMR (400 MHz, pyridine-d5) δ 8.82 (dd, J = 5.4, 5.4 Hz, 1H), 8.61 (d, J = 8.6 Hz, 1H), 7.63‒
7.59 (m, 1H), 7.38‒7.34 (m, 2H), 7.28‒7.24 (m, 1H), 5.68 (br s, 4H), 5.40 (d, J = 3.5 Hz, 1H), 
4.77‒4.68 (m, 1H), 4.58 (dd, J = 9.6, 3.6 Hz, 1H), 4.49‒4.46 (m, 1H), 4.42‒4.38 (m, 1H), 4.35‒
4.25 (m, 3H), 4.21‒4.15 (m, 1H), 4.00‒3.86 (m, 3H), 2.59‒2.43 (m, 2H), 1.91‒1.85 (m, 5H), 1.61‒
1.28 (m, 69H), 0.89‒0.86 (m, 6H); 13C NMR (100 MHz, pyridine-d5) δ 173.6. 171.6, 137.1, 129.9, 
128.9, 127.0, 102.0, 72.0, 71.3, 70.7, 70.3, 69.6, 54.9, 43.8, 41.6, 36.8, 35.3, 32.2, 30.2, 30.1, 
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30.1, 29.9, 29.8, 29.6, 26.6, 26.5, 23.0, 14.3; HRMS (ESI) m/z calcd for C58H86N2NaO8 [M + Na]+ 
981.7847, found 981.7848. 
(2S,3R)-3-Benzyloxy-1-O-[2,3,4-tri-O-benzyl-6-deoxy-6-(3-phenylpropylamido)--D-gal-
actopyranosyl]-2-hexacosylaminooctadecane-1,3-diol (57b) 
 
A mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (9.4 mg, 0.049 mmol) and phenyl-
propanoic acid (7.4 mg, .049 mmol) in dry DMF (1 mL) was stirred at rt for 1 h. Then (2S,3R)-1-
O-(6-amino-2,3,4-tri-O-benzyl-6-deoxy--D-galactopyranosyl)-3-benzyloxy-2-hexacosylamino-
octadecane-1,3-diol (56) (40 mg, 0.033 mmol) was added, and the reaction mixture was allowed 
to stir for an additional 3 h. DMF was removed, and the residue was purified by flash 
chromatography on silica gel (hexane/EtOAc, 90:10) to afford (2S,3R)-3-benzyloxy-1-O-[2,3,4-tri-
O-benzyl-6-deoxy-6-(3-phenylpropylamido)--D-galactopyranosyl]-2-hexacosylaminooctade-
cane-1,3-diol (57b) as a white solid (31 mg, 71%): mp = 113.8‒114.7 °C; [α]D
23 = +38.0 (c = 1.0, 
CHCl3); IR (neat) 3318 (br), 2921, 2853, 1642, 1545, 1459, 1148, 1100, 1052 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.40‒7.14 (m, 25H), 5.91 (d, J = 8.6 Hz, 1H), 5.51 (t, J = 5.6 Hz, 1H), 4.93 (d, J = 
11.4 Hz, 1H), 4.85 (d, J = 11.7 Hz, 1H), 4.82 (d, J = 3.7 Hz, 1H), 4.78 (d, J = 11.7 Hz, 1H), 4.73 
(d, J = 11.7 Hz, 1H), 4.64 (d, J = 11.8 Hz, 1H), 4.62 (d, J = 11.4 Hz, 1H), 4.57 (d, J = 11.6 Hz, 
1H), 4.43 (d, J = 11.5 Hz, 1H), 4.22‒4.16 (m, 1H), 4.01 (dd, J = 10.0, 3.6 Hz, 1H), 3.89‒3.80 (m, 
2H), 3.70‒3.63 (m, 3H), 3.55 (dd, J = 11.5, 5.8 Hz, 1H), 3.36 (ddd, J = 13.6, 6.6, 6.6 Hz, 1H), 3.20 
(ddd, J = 13.5, 5.5, 5.5 Hz, 1H), 2.87 (t, J = 7.7 Hz, 2H), 2.37‒2.19 (m, 2H), 1.64‒1.24 (m, 4H), 
1.64‒1.24 (m, 73 H), 0.90‒0.87 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 173.3, 172.3, 141.1, 138.7, 
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138.6, 138.6, 129.1, 128.8, 128.8, 128.7, 128.7, 128.6, 128.5, 128.1, 127.9, 127.9, 127.8, 127.6, 
126.4, 99.8, 79.4, 79.3, 74.6, 73.7, 73.6, 72.4, 69.0, 68.8, 52.0, 40.1, 38.3, 37.0, 32.1, 31.8, 31.2, 
30.1, 29.9, 29.8, 29.7, 29.6, 26.0, 25.5, 22.9, 14.3; HRMS (ESI) m/z calcd for C87H133N2O8 [M + 
H]+ 1334.0062, found 1333.9927. 
(2S,3R)-1-O-[6-Deoxy-6-(3-phenylpropylamido)--D-galactopyranosyl]-2-hexacosylamino-
octadecane-1,3-diol (18) 
 
(2S,3R)-3-Benzyloxy-1-O-[2,3,4-tri-O-benzyl-6-deoxy-6-(3-phenylpropylamido)--D-galactopy-
ranosyl]-2-hexacosylaminooctadecane-1,3-diol (57b) (7.4 mg, 0.0050 mmol) was dissolved in dry 
EtOH/CHCl3 (8 mL, 3:1). Then, Pd(OH)2/C (20 wt% Pd dry basis on carbon, 30 mg) was added, 
and the mixture was hydrogenated under atmospheric pressure for 14 h. The solution was filtered 
through a pad of celite, and the filter cake was washed with EtOH/CHCl3 (25 mL, 3:1). The filtrate 
was concentrated, and the resulting residue was purified by trituration with EtOAc (3 × 3 mL) to 
afford (2S,3R)-1-O-[6-deoxy-6-(3-phenylpropylamido)--D-galactopyranosyl]-2-hexacosylamino-
octadecane-1,3-diol (18) as a white solid (5.7 mg, 97%): mp = 174.2‒175.5 °C; [α]D
23 = +35.2 (c 
= 1.0, CHCl3/MeOH 1:1); IR (neat) 3417 (br), 3292 (br), 2919, 2850, 1640, 1557, 1468, 1138, 
1082, 1042 cm-1; 1H NMR (400 MHz, pyridine-d5) δ 8.85 (t, J = 5.3 Hz, 1H), 8.62 (d, J = 8.4 Hz, 
1H), 7.38‒7.36 (m, 2H), 7.33‒7.29 (m, 2H), 5.45 (br s, 4H), 4.72 (m, 1H), 4.60 (dd, J = 9.8, 3.6 
Hz, 1H), 4.51‒4.44 (m, 2H), 4.38 (dd, J = 10.0, 3.1 Hz, 1H), 4.30‒4.27 (m, 3H), 4.19 (ddd, J = 
13.4, 6.6, 6.6 Hz, 1H), 3.95 (ddd, J = 13.2, 6.8, 6.8 Hz, 1H), 3.23 (t, J = 7.4 Hz, 2H), 2.92‒2.77 
(m, 2H), 2.60‒2.47 (m, 2H), 1.90‒1.85 (m, 5H), 1.58‒1.53 (m, 1H), 1.48‒1.18 (m, 69H), 0.89‒
0.86 (m, 6H); 13C NMR (100 MHz, pyridine-d5) δ 173.6, 173.0, 142.2, 128.9, 128.8, 126.4, 102.0, 
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72.0, 71.3, 71.0, 70.6, 70.3, 69.5, 55.0, 41.2, 38.4, 36.8, 35.3, 32.3, 32.2, 30.2, 30.1, 30.1, 29.9, 
29.8, 29.6, 26.7, 26.5, 23.0, 14.3; HRMS (ESI) m/z calcd for C59H109N2O8 [M + H]+ 973.8184, 
found 973.8209. 
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Chapter 2 New reactions of 2-methyleneoxetanes 
2.1 Introduction 
As a class of structurally unique organic compounds, oxetanes have been the focus of 
much attention in organic synthesis. Such interest in this structural motif stems from its 
applications in material and polymer science; cationic ring-opening polymerization;1 and as 
crosslinkers.2 Strategies employing oxetanes as synthetic intermediates include: (a) ring opening 
with nucleophiles; (b) ring expansions; and (c) rearrangements.3,4 The oxetane moiety is found in 
natural products, biologically active compounds, and agrochemicals.4 Oxetanes have also 
emerged as important structures in medicinal chemistry due to their physicochemical properties.5 
2.1.1 Oxetanes in natural products 
One of the most well-known oxetane-containing natural products is paclitaxel, also known 
by its brand name, Taxol (Figure 29). Taxol is an anti-cancer chemotherapy drug that was first 
isolated in 1971 from the bark of the pacific yew tree, Taxus brevifolia.6 Between 1992 and 1994, 
Taxol was approved by the FDA for the treatment of both ovarian and breast cancer.7 Taxol, along 
with a structurally related compound called docetaxel which is sold under the brand name 
Taxotere, are presently used in chemotherapy (Figure 29).8 
 
Figure 29. Structures of paclitaxel (Taxol) and docetaxel (Taxotere). 
Only a few natural products contain oxetane rings, but when present, this scaffold is often 
important for biological activity (Figure 30). Oxetanocin A is a nucleoside analogue that was 
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isolated from the fermentation broth of bacteria, Bacillus megaterium,9,10 and showed potent 
inhibition against HIV,11 hepatitis B virus,12 herpes simplex virus,9 and human cytomegalovirus.13 
Oxetin was isolated from the soil bacterium, Streptomyces sp. OM-2317, and exhibited herbicidal 
and antibacterial activity.14 Thromboxane A2 is produced by activated platelets to promote 
vasoconstriction and platelet aggregation.15 Ramariolide B was isolated from the mushroom, 
Ramaria cystidiophora, and contains an unusual spiro oxetane moiety; it showed in vitro 
antimicrobial activity against Mycobacterium tuberculosis and Mycobacterium smegmatis.16 
Maoyecrystal I and Mitrephorone A are both polycyclic diterpenoids shown to be cytotoxic.17,18 
Laureatin is a major metabolite of the red marine algae genus, Laurencia nipponica, and has 
shown potent insecticidal activity against mosquitos.19 Dictyoxetane is a marine diterpene isolated 
from a sample of the brown algae, Dictyota dichotoma; its biological activity is currently 
unknown.20 Merrilactone A was isolated from Illicium merrillianum and has shown neurotropic 
activity in cultures of fetal rat cortical neurons.21 Bradyoxetin is produced by the soil bacterium, 
Bradyrhizobium japonicum, and is involved in gene regulation in the soybean plant.22 Finally, 
Pennigritrem is a tremorgenic mycotoxin isolated from the fungus, Penicillium nigricans.23 
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Figure 30. Oxetane-containing natural products. 
2.1.2 Oxetanes as replacement groups 
In recent years, incorporation of the oxetane moiety has surged, mainly due to its ability 
to influence solubility, lipophilicity, metabolic stability, basicity, and other physicochemical 
properties of drugs and drug candidates. In 2006, Carreira and co-workers demonstrated the 
remarkable abilities of the 3,3-disubstituted oxetane motif as a replacement group (isostere) for 
gem-dimethyl groups in medicinal chemistry (Figure 31A).24 In drug discovery, a gem-dimethyl 
group is commonly used to block metabolically unstable methylene groups. However, the 
replacement of methylene hydrogens with methyl groups can result in increased lipophilicity, 
which may have adverse effects on the physicochemical and pharmacokinetic properties of 
compounds. Results showed substituting a gem-dimethyl group with an oxetane group increased 
the polar surface area without changing the overall conformation or molecular size; this decreased 
lipophilicity and increased metabolic stability.  
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Figure 31. Oxetanes as surrogates for (A) gem-dimethyl, (B) carbonyl groups, (C) aminoacids, and (D) morpholines. 
Carreira and co-workers later investigated using oxetane as carbonyl surrogates (Figure 
31B).25 The lone pair of electrons on the oxygen of oxetane and on the carbonyl group share 
similar spatial orientation, dipoles, and H-bonding properties. Replacement of the carbonyl group 
with an oxetane could be beneficial due to the susceptibility of carbonyl compounds (aldehydes, 
ketones, and esters) to undergo enzymatic modification and -deprotonation/epimerization of 
stereogenic centers. This methodology was later utilized in the synthesis of oxetanyl peptides, 
where the amide bond is replaced by a non-hydrolyzable aminooxetane fragment (Figure 31C).26 
Carreira and co-workers also demonstrated that a spirocyclic oxetane could serve as a 
surrogate for morpholine, a common motif in pharmaceutical drugs (Figure 31D).25,27 Morpholine 
is often incorporated into drug scaffolds to increase solubility, however it can be susceptible to 
oxidative metabolism.  Many drug candidates fail to reach clinical trials due to poor solubility, poor 
lipophilicity, or metabolic instability; thus, incorporation of the oxetane motif into small molecules 
can enhance physicochemical expand the pool of potential drug candidates. 
2.1.3 Introduction to 2-methyleneoxetanes 
2-Methyleneoxetanes, oxetanes that bear an exocyclic double bond at the C2 position, 
are a largely unexplored class of strained heterocycles. The unique combination of functionalities 
and reactivities contained in oxetanes and an exocyclic double bond offers intriguing possibilities 
for further manipulation. 
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2.1.3 Synthesis of 2-methyleneoxetanes 
The synthesis of 2-alkylideneoxetanes was first reported in the 1960s utilizing a Paternò-
Büchi reaction.  Arnold and Glick showed that benzophenone could be added to tetramethylallene 
under a high-pressure mercury arc lamp to give photochemical cycloaddition products (Scheme 
14A),28 although yields were low, and the major products tended to be the bis-addition of the 
carbonyl compounds to give dioxaspiroheptanes. Concurrently, Hammond and co-workers 
extended the substrate scope of the Paternò-Büchi reaction with various allene and carbonyl 
compounds.29 The yields for the formation 2-alkylideneoxetanes were higher than that of 
benzophenone, likely due to the stability of the oxetanes formed.  
 
Scheme 14. (A) Synthesis of 2-alkylideneoxetanes by the Paternò-Büchi reaction. (B) Synthesis of 2-
methyleneoxetanes by the Paternò-Büchi reaction. 
In 1996, Howell and co-workers utilized the Paternò-Büchi reaction with aliphatic 
aldehydes and a range of allenes (Scheme 14B).30 Reaction of 3-methyl-1,2-butadiene 
(dimethylallene) with various aldehydes gave 2-methyleneoxetanes and 2-alkylideneoxetanes as 
the major products.  However, these reactions had significant disadvantages in poor selectivity 
and generally low yields. In addition, require a large excess of allene was required, and slow 
reacting aldehydes exhibited more side-products. 
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In the 1970s, Hudrlik and Mohtady demonstrated that 2-alkylideneoxetanes could be 
synthesized through intramolecular O-alkylation of ketone enolates (Scheme 15).31 Treatment of 
ketone 58 with potassium hydride afforded the O-alkylation product, 2-benzylideneoxetane (59), 
along with the C-alkylation product, cyclobutanone (60), in estimated yields of 36% and 25%, 
respectively. 
 
Scheme 15. Synthesis of 2-alkylideneoxetanes through intramolecular O-alkylation. 
In 1996, Howell and co-workers reported the first general protocol for the synthesis of 2-
methyleneoxetanes (Scheme 16).32 It was found that 2-methyleneoxetanes could be obtained 
through the methylenation of -lactones using a Petasis reagent, dimethyltitanocene. This 
approach proved to be a useful way to generate various substituted 2-methyleneoxetanes in good 
isolated yields. This protocol was also used for the synthesis of a 2-methyleneoxetane analogue 
of orlistat, an anti-obesity drug (Scheme 16).33 In comparing the IC50 values of orlistat and 
analogue 61 in an assay against porcine pancreatic lipase (PPL), lower activity was found for the 
methyleneoxetane analogue 61. The lower activity of 61 is significant considering the carbonyl 
group of orlistat is believed to be integral for its biological activity. 
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Scheme 16. Synthesis of 2-methyleneoxetanes via methylenation of -lactones. 
2.1.4 The reactivity of 2-methyleneoxetanes 
Over the last two decades, the Howell group has extensively investigated the reactivity of 
2-methyleneoxetanes (Figure 32). The reactivity of 2-methyleneoxetanes can be separated into 
two types of transformations; 1) ring opening of the oxetane; and 2) oxetane-intact 
functionalization of the exocyclic double bond. For instance, treatment of 2-methyleneoxetanes 
62 with lithium diisopropylamide (LDA) and an electrophile resulted in the efficient formation of 
homopropargylic alcohols 63.34 Reductive ring opening of 2-methyleneoxetanes 62 with lithium 
di-tert-butyldiphenyl (LDBB), followed by addition of an electrophile, gave functionalized ketones 
64.35 Nucleophilic ring opening of 62 with strong nucleophiles, such as carbanion or heteroatom 
nucleophiles, afforded -substituted ketones 65.36,37 Additionally, 2-methyleneoxetanes 62 have 
been reported to undergo rearrangement to ,-unsaturated methylketones 66 at high 
temperatures.38 
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Figure 32. Reactivity of 2-methyleneoxetanes. 
In addition to ring opening reactions, 2-methyleneoxetanes can be converted to a variety 
of oxetane-intact species. For instance, treatment 2-methyleneoxetanes 62 with anhydrous 
dimethyldioxirane (DMDO) afforded a very reactive species, 1,5-dioxaspiro[3.2]hexanes 67, in 
excellent yields.39,40 Cyclopropanation of the exocyclic double bond on 2-methyleneoxetanes 62 
via modified Simmons-Smith conditions provided 4-oxaspiro[2.3]hexanes 68.41 Intramolecular 
iodetherification of 2-methyleneoxetanes 62 with potassium tert-butoxide (KOtBu) and I2 provided 
the first example of a [2.2.0]-fused ketal 69.42 2-Methyleneoxetanes 62 were also used to access 
oxetanocin-type analogues 70 by electrophilic addition of F+ followed by nucleophilic attack of the 
nucleobase.43 
2.1.4.1 Generation and transformations of oxetane oxocarbenium ions 
 In exploring the reactivity of 2-methyleneoxetanes 62 and 1,5-dioxaspiro[3.2]hexanes 67, 
similar reactivity was observed in the generation of oxetane oxocarbenium ions using suitable 
electrophiles or Lewis acids (Scheme 17). Subsequent addition of various nucleophiles gave two 
distinct reaction pathways, ring opening or 1,2-addition. In this section, our work on the generation 
of oxetane oxocarbenium ions from 2-methyleneoxetanes and 1,5-dioxaspiro[3.2]hexanes, and 
their reactivity with various nucleophiles, will be discussed. 
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Scheme 17. Generation of oxetane oxocarbenium ion from 2-methyleneoxetane or 1,5-dioxaspiro[3.2]hexane, and 
reaction with nucleophiles, to obtain ring open or oxetane intact products. 
The reactivity of 1,5-dioxaspiro[3.2]hexanes 67a was first investigated with a variety of 
heteroatom nucleophiles, hydride donors, and organoaluminum reagents (Scheme 18).40 It was 
found that some nucleophiles, such as water, tetrabutylammonium acetate, sodium thiolate, and 
imidazole, gave the corresponding hydroxyl ketones 71a-71d. Lithium aluminum hydride also 
gave ring opening followed by reduction to give 1,3-diol 71e. Interestingly, treatment of 1,5-
dioxaspiro[3.2]hexanes 67a with diisobutylaluminum hydride (DIBAL-H) gave nucleophilic attack 
at the internal position of the ring to give oxetane-intact product 72f. Ring opening of just the 
epoxide also occurred when TMSN3 and AlMe3 were used as nucleophiles, giving oxetane-intact 
products 72g and 72h, respectively. In these reactions, coordination of the epoxide oxygen to the 
Lewis acid was proposed with generation of an oxetane oxocarbenium ion (see Scheme 17). 
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Scheme 18. Reactions of 1,5-dioxaspiro[3.2]hexanes with various nucleophiles. 
In 2003, Howell and co-workers reported the reaction of 1,5-dioxaspiro[3.2]hexanes 67 
with heteroaromatic nucleophiles. The pKa of the nucleophile was correlated to the reaction 
outcome (Table 1).44  It was shown that more acidic nucleophiles (pKa < 10) led to oxetane-intact 
products 72 via 1,2-addition, while more basic nucleophiles (pKa > 10) gave ring-opened products 
71. 
 
Table 1.  Reactions of dioxaspirohexanes with nucleophiles and the effects of pKa. 
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Formation of the oxetane oxocarbenium ion from dioxaspirohexanes has been utilized in 
the syntheses of C-2 functionalized oxetanes (Scheme 19).45 epi-Oxetin 74 was synthesized from 
an L-serine derived 1,5-dioxaspiro[3.2]hexane 67b, which underwent DIBAL-H epoxide ring 
opening to provide 2-hydroxymethyloxetane 73 as a key intermediate. 
 
Scheme 19. 1,5-Dioxaspiro[3.2]hexane 67b utilized in the synthesis of epi-oxetin 74. 
In 2012, epoxide ring opening of 1,5-dioxaspiro[3.2]hexane 67c with DIBAL-H was used 
to generate hydroxymethyloxetane 75 as a possible key intermediate in the synthesis of laureatin 
(Scheme 20).46 However, attempted N-bromosuccinimide (NBS)-mediated cyclization of oxetane 
alcohol 76, provided an unexpected rearrangement, yielding epoxytetrahydrofuran 77, rather than 
the expected laureatin core 78. 
 
Scheme 20. Unexpected rearrangement of oxetane alcohol 76 afforded epoxytetrahydrofuran 77. 
Similarly, 2-methyleneoxetanes, the precursors of 1,5-dioxaspiro[3.2]hexanes, have been 
utilized in the generation of oxetane oxocarbenium ions with suitable electrophiles. In particular, 
we reported an intramolecular iodoetherification of 2-methyleneoxetane 79 to provide an 
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intermediate oxetane oxocarbenium ion 80 (Scheme 21).42 Subsequent trapping of 80 with the 
pendant alcohol provided the first synthesis of a [2.2.0]-fused ketal, 81, in 40% yield. 
 
Scheme 21. Synthesis of [2.2.0]-fused ketal 81 via oxocarbenium ion with O-nucleophile. 
A similar strategy was used in the first psico-oxetanocin analogue of the potent antiviral 
natural product, oxetanocin A.43 This was achieved through F+-mediated oxetane oxocarbenium 
ion formation followed by 1,2-additon of the nucleobase (Scheme 22). 
 
Scheme 22. Utility of oxetane oxocarbenium ion in the synthesis of psico-oxetanocin analogue. 
2.1.5 Exocyclic enol ethers as nucleophiles in carbon-carbon bond formation 
Exocyclic enol ethers are useful in many reaction for introducing diverse functionality to 
the exocyclic double bond. Exocyclic enol ethers have been used as substrates in pericyclic 
reactions, radical reactions, rearrangements, hydrogenation, oxidative additions, hydroboration, 
and as both electrophiles and nucleophiles. However, exocyclic enol ethers as nucleophiles in 
carbon-carbon bond forming reactions has received limited attention. Carbon-carbon bond 
formation is widely regarded by synthetic organic chemistry for applications in natural product 
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synthesis and medicinal chemistry. This section will demonstrate the utility of exocyclic enol 
ethers as nucleophiles in carbon-carbon bond formation reactions. 
In 1992, Nicotra and co-workers synthesized C-disaccharides by a Lewis acid catalyzed 
dimerization of exo-glycals (Scheme 23).47 This reaction was proposed to proceed via the 
nucleophilic attack of the exocyclic enol ether 82 to the oxonium ion 82a formed in-situ from 
another molecule of the 82. Subsequent addition of water provided bis-tetrahydropyran 83 in 66% 
yield with excellent stereoselectivity. 
 
Scheme 23. Synthesis of C-disaccharides through dimerization of exo-glycals. 
Smoliakova and co-workers demonstrated the nucleophilic properties of exo-glucal for a 
one-pot synthesis of -C-glucopyranosides (Scheme 24).48 This was achieved through the 
nucleophilic addition of exo-glycal 82 to episulfonium ion 84, followed by trapping of the oxonium 
ion intermediate with water to provide -C-glucopyranoside 85. The observed stereoselectivity of 
the addition of water from the opposite face of the C-6 substituent to afford the -anomer is based 
upon steric and electronic factors.49 
 
Scheme 24. Synthesis of -C-glucopyranosides from exo-glycal. 
Totah and co-workers demonstrated the feasibility of using exocyclic enol ethers in 
nucleophilic addition processes for the synthesis of tetrahydropyranyl ketides (Scheme 25).50 In 
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a three component coupling reaction, 2-methylenetetrahydropyrans 86 underwent nucleophilic 
addition to an activated aldehyde or ketone with trapping of the oxonium ion intermediate 87 by a 
secondary nucleophile providing -hydroxy-tetrahydropyrans 88. This protocol used equimolar 
amounts of the aldehyde and Lewis acid to facilitate rapid addition of the exocyclic enol ether prior 
to competing double bond isomerization 86a. This transformation was highlighted in the synthesis 
of a C31-C47 fragment of spirastrelloide A (89), a potent and selective inhibitor of protein 
phosphatase 2A.51 
 
Scheme 25. Three component coupling reaction of 2-methylenetetrahydropyrans and application in the synthesis of 
the C31-C47 fragment of spirastrelloide A. 
2.1.6 Carbonyl-ene reactions of exocyclic enol ethers 
 Carbonyl-ene reactions of acyclic enol ethers in the presence of Lewis acid catalysts have 
been extensively studied.52 However, exocyclic enol ethers are rarely used in carbonyl-ene 
reactions. To date, only one general methodology for exocyclic enol ether carbonyl-ene reactions 
has been published. Furthermore, syntheses which utilize this chemistry include only two 
examples:  product formation driven by aromatization53,54 and a Diels-Alder reaction gave some 
byproduct formation.56 Thus, exocyclic enol ethers have been under-utilized in carbonyl-ene 
reactions. 
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 In 2005, Miles and co-workers demonstrated that -hydroxyfurans 91 could be obtained 
via the carbonyl-ene reaction of 2-methylene-2,5-dihydrofuran 90 with various enophiles (Table 
2).53 Reaction of 90 with the highly activated enophile, ethyl glyoxylate, provided -hydroxyfuran 
91a in 89% yield, without the presence of a catalyst (Entry 1). Non-activated enophiles in the 
presence of Lewis acid catalysts, zinc(II) chloride and Yb(fod)3, gave -hydroxyfurans 91b and 
91c, respectively (Entries 2 and 4) in good to excellent yields. Interestingly, the carbonyl-ene 
reaction of 90 with decanal using titanium(IV)/(S)-BINOL catalyst provided (S)-91b with good 
enantioselectivity (Entry 3). An important driving factor in this carbonyl-ene methodology is the 
development of the furan aromaticity. 
 
Table 2.  Carbonyl-ene reaction of 90 with various enophiles to provide -hydroxy furans. 
Similarly, Feng and coworkers demonstrated a catalytic asymmetric carbonyl-ene reaction 
of ,-unsaturated -ketoesters with 5-methyleneoxazolines in the presence of a chiral N,N’-
dioxide-MgII complex (Scheme 26).54 A series of chiral -hydroxyesters with a quaternary center 
were obtained with excellent enantioselectivites. The utility of this methodology is highlighted by 
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the unsaturated bonds (alkene or alkyne) in the desired products, which allows further 
derivatization, and the resulting oxazole units are found in various natural products and 
biologically active compounds.55 
 
Scheme 26. Catalytic asymmetric carbonyl-ene reaction of ,-unsaturated -ketoesters with 5-methyleneoxazolines. 
Rizzacasa and co-workers observed the formation of carbonyl-ene adduct 95 as a 
byproduct in the Lewis acid catalyzed hetero-Diels-Alder reaction of a 2-
methylenetetrahydropyran 92 (Table 3).56 Reaction of exocyclic enol ether 92 with enone 93 at 
high temperatures gave the desired Diel-Alder product (3), in low yields (Entries 1 and 2). Addition 
of the Lewis acid catalyst, Eu(fod)3, improved the yield of the spiroketal 94; however, the formation 
of a carbonyl-ene byproduct (95) also resulted (Entries 3 and 4). 
 
Table 3.  Reaction of 2-methylenepyran 92 with enone 93. 
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In 2013, Totah and co-workers reported an interesting result upon further evaluation of the 
reaction conditions associated with the three component coupling reaction (Scheme 27).57 
Reaction of exocyclic enol ether 86 with ethyl glyoxylate 96 in the presence of 1 equiv zinc chloride 
at room temperature gave the carbonyl-ene product 97, instead of the anticipated aldol-type 
product (88). Similar results were obtained when the reaction was conducted at concentrations of 
0.5 M using only 5 mol % of ZnCl2. Support for the carbonyl-ene type mechanism comes from the 
formation of the carbonyl-ene product 98 in the presence of 3 equiv triethylsilane (Et3SiH) 
(Scheme 27C). However, treatment of product 98 with BF3·OEt2 and triethylsilane provided the 
tetrahydropyran product 99 in 93% yield.  
 
Scheme 27. Lewis acid and temperature dependent transformations of 2-methylenetetrahydropyrans. 
 The scope of this transformation was further evaluated by varying the enophile component 
(Table 4). Good to excellent yields were obtained when the reaction was carried out in THF at 
room temperature with catalytic ZnCl2. As shown, the reaction was successful with activated 
aldehydes and ketones (Entries 1 and 2), aromatic aldehydes bearing either an electron 
withdrawing or an electron donating group (Entries 3 and 4), and ,-unsaturated (Entry 6), 
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aliphatic (Entry 7), or sterically hindered (Entry 8) substrates. Higher yields were obtained for less 
activated aldehydes (Entry 5) by increasing the amount of ZnCl2 to 20 mol %. 
 
Table 4.  Reaction of 2-methylenetetrahydropyran with various enophiles. 
This methodology was further explored by reacting various exocyclic enol ethers with ethyl 
glyoxylate (Table 5). Under the optimized conditions, 2-methylenetetrahydropyrans with 
substitution at C-3 (Entries 1 and 2) or C-6 (Entries 3 and 4) and the electron-deficient 
dihydrocumarin enol ether (Entry 5) underwent reaction with ethylglyoxylate to provide the 
carbonyl-ene adducts in excellent yields. Interestingly, reaction of a seven-membered enol ether 
(Entry 6) with ethyl glyoxylate afforded the hydrolyzed carbonyl-ene adduct in moderate yield. 
91 
 
 
Table 5.  Carbonyl-ene reaction with various exocyclic enol ethers. 
2.1.7 Endocyclic enol ethers as nucleophiles in carbon-carbon bond formation 
Exocyclic enol ethers have only been utilized sporadically as nucleophiles in carbon-
carbon bond forming reactions, likely due to the susceptibility of these systems to undergo ring 
opening, isomerization, and hydrolysis. Nonetheless, chemical transformations have been 
successfully applied to the double bond of exocyclic enol ether systems (vide infra). On the other 
hand, endocyclic enol ethers have been more extensively utilized as nucleophiles in carbon-
carbon bond forming reactions and provide insight on the reactivity of these structurally similar 
motifs. This section will review the use of endocyclic enol ethers as nucleophiles in coupling 
reactions. 
In 1988, Mukiyama and co-workers reported the utility of endocyclic enol ethers as 
nucleophiles for a carbon-carbon bond-forming transformation.58 This methodology employed the 
nucleophilic addition of olefin substrates such as styrene, endocyclic ethers, and vinyl ethers, to 
acetals under mild conditions (Table 6). The reaction of endocyclic enol ethers with acetal 100 in 
the presence of tin(II) chloride and trimethylsilyl chloride (Entry 1) or tin(II) trifilate and trityl 
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chloride (Entry 2) afforded the corresponding methoxy adduct 101a and 101b. When styrene was 
employed as an olefin with an equimolar amount of tin(II) chloride and trimethylsilyl chloride, the 
result was the exclusive formation of the corresponding chloride adduct 102 in 80% yield (Entry 
3). 
 
Table 6.  Mukaiyama electrophilic addition of acetals to activated olefins under mild conditions. 
These result suggest the formation of a chloride species as a key intermediate in the 
reaction pathway (Scheme 28). The proposed reaction mechanism starts with the activation of 
acetal 100, using a tin catalyst, resulting in formation of oxocarbenium ion 104. Nucleophilic 
addition of dihydropyran 103a to intermediate 104 and subsequent chlorine addition provides the 
intermediate chloride 105. Lastly, replacement of the intermediate chloride 105 with a methoxide 
furnishes tetrahydropyran 101a. 
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Scheme 28. Proposed mechanism for the addition reaction of acetal 100 with olefin 103a. 
Similarly, Sugimura and co-workers developed a methodology for the synthesis of chiral 
oxetanes by an intramolecular Prins reaction with enol ethers and aldehydes (Scheme 29).59 It 
was proposed that reaction of dihydropyran 103a with the boron trifluoride etherate activated 
aldehyde 106 formed the zwitterion 107 at –78 °C. Intramolecular cyclization by oxocarbenium 
ion provided fused oxetane 108. 
 
Scheme 29. Formation of oxetane 108 from dihydrofuran 103a. 
In 1999, Ghosh and co-workers reported a titanium(IV) chloride mediated three 
component coupling reaction for the synthesis of 2,3-disubstituted tetrahydropyrans.60 
Presumably, reaction of dihydropyran 103a and ethyl glyoxylate 96 in the presence of titanium(IV) 
chloride at –78 °C led to the formation of oxocarbenium ion intermediate 109, which was trapped 
with a secondary nucleophile to give 2,3-disubstituted tetrahydropyrans 110 (Scheme 30A, Path 
1).  
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Scheme 30. (A) Temperature dependent formation of tetrahydropyran 110 and tetrahydropyrilidene acetate 112. (B) 
Probed reaction conditions for the attempted elimination of the hydroxyl group from 110.  
Ghosh and co-workers found that, when the coupling reaction was carried out at 0 °C, the 
eliminated product, substituted tetrahydropyrilidene acetate 112, was isolated as the major 
product (Scheme 30A, Path 2).61 Interestingly, the hydroxyl group from tetrahydropyran 6 was 
found not to be prone to elimination (Scheme 30B). Subjection of tetrahydropyran 110 to p-
toluenesulfonic acid or camphorsulphonic acid in refluxing benzene, as well as treatment of 110 
with excess TiCl4 at –78 °C to 23 °C, provided only recovered starting material and no eliminated 
product 112. Furthermore, treatment of the mesylate analogue of 110 with trimethylamine or DBU 
in refluxing benzene for several hours did not yield eliminated product 112. The stability of the 
hydroxyl group in 110 suggests that the elimination occurs from titanium complex 109 upon 
warming to 23 °C, forming a new oxocarbenium ion intermediate 111 which then yields eliminated 
product 112 upon addition of a secondary nucleophile. 
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This three-component coupling methodology developed by Ghosh and co-workers, has 
been applied to a number of systems, including pyruvates,62 functionalized -amino acids,63 
benzo-fused oxabicyclooctanes,64 flavone analogues,65 substituted pyrrolidines and prolines,66 
cyclopentenoids,67 modified nucleosides,68 and the natural product eburnamonine.69 
2.2 Research design and mechanistic hypothesis  
Strained heterocycles possessing unique structural features display interesting reactivity 
and have been shown to be valuable in organic syntheses.70 Over the past two decades, we have 
pioneered research on one member of this important class of heterocycles, 2-methyleneoxetanes 
(62), for the preparation of bioactive natural products and synthetic analogues.71 Our group has 
demonstrated that 2-methyleneoxetanes can be converted to oxetane oxocarbenium ions when 
treated with a suitable electrophiles (Figure 33). This oxocarbenium ion can react with a 
nucleophile in one of two distinct reaction pathways, ring opening or 1,2 addition.  
 
Figure 33. Generation and reactivity of oxetane oxocarbenium ions. 
2.2.1 Mechanistic hypothesis 
Our interest in utilizing 2-methyleneoxetanes as synthetic scaffolds led us to examine the 
electron rich exocyclic double bond for the development of nucleophilic transformations. We 
anticipated that nucleophilic addition of 62 to an aldehyde or ketone would generate an oxetane 
oxocarbenium ion and a nucleophilic species (Figure 34). Our previous work58b,58c led us to 
anticipate two reaction outcomes: intramolecular ring opening at C-4 or 1,2-addition. Reaction at 
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C-4 would provide tetrahydropyran-4-ones (THPOs),72 and 1,2-addition would give 
dioxaspiroheptanes73; either reaction would lead to synthetically useful products. 
 
Figure 34. Generation and proposed reaction pathways of oxetane oxocarbenium ions from 2-methyleneoxetanes. 
2.3 Results 
2.3.1 Initial studies 
 In order to evaluate the feasibility of using 2-methyleneoxetanes in nucleophilic addition 
processes, we examined the reaction of 3-phenyl-2-methyleneoxetane (62a) with ethyl glyoxylate 
(96). The initial reaction was carried out by adding zinc(II) chloride (1.0 equiv) and DIPEA (1.0 
equiv) to DCM at –78 °C (Scheme 31). A premixed solution of methyleneoxetane 62a (1.0 equiv) 
with ethyl glyoxylate (96) (1.5 equiv) in dry DCM was then added dropwise. The reaction was 
slowly warmed to room temperature over 12 h by allowing the dry ice to sublime. To our delight, 
formation of the dioxaspiroheptane 113a was observed in 10% yield without the formation of 
tetrahydropyranone 114a. Encouraged by these results, we decided to optimize the reaction and 
explore the scope of this transformation. Preliminary studies included screening of Lewis acids, 
variation of the reaction stoichiometry, temperature, and concentration, and evaluation of reagent 
addition order/time. 
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Scheme 31. Initial reaction of methyleneoxetane 62a with ethyl glyoxylate 96 to give dioxaspiroheptane 113a. 
Initial efforts in optimizing the formation of dioxaspiroheptane 113a focused on screening 
various Lewis acids (Table 7). Reactions conducted with Lewis acids EtAlCl2, Et2AlCl, BF3·OEt2, 
MgCl2, or Mg(OTf)2 (Entries 4-7) gave decomposition of the starting material, no reaction, or 
undesired byproducts. ZnCl2 and Zn(OTf)2 gave formation of the desired product 113a, albeit in 
very low yields (Entries 1 and 2). The best results were obtained using stronger Lewis acids such 
as TiCl4 or SnCl4 (Entries 8 and 9). These results suggested the need for a strong Lewis acid to 
efficiently promote the addition of the 2-methyleneoxetane. 
 
Table 7.  Effect of Lewis acids on the reaction of 3-phenyl-2-methyleneoxetane (62a) with ethyl glyoxylate (96). 
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Further optimization in the formation of dioxaspiroheptane 113a from 2-methyleneoxetane 
62a included changing the reaction concentration and the reaction stoichiometry, whereby relative 
amounts of Lewis acid, electrophile, and base were varied to increase the yield (Table 8). 
Evaluation of the quantity of tin(II) chloride revealed that using one equivalent with respect to the 
methyleneoxetane gave the best yield (Entry 4). Decreasing the amount of tin(II) chloride showed 
a direct correlation with a decrease in yield (Entries 1-3). Additionally, increasing the amount of 
tin(II) chloride to two molar equivalents gave a decreased yield (Entry 5). 
Examination of the reaction stoichiometry, where ethyl glyoxylate (96) and 2-
methyleneoxetane (113a) were varied, showed an insignificant effect on the reaction yield (Entries 
4, 6, and 7). Nonetheless, excess ethyl glyoxylate was used due to ethyl glyoxylate existing in a 
partly polymerized form, which is problematic for accurately measuring exact amounts. 
Surprisingly, when the reaction was conducted without DIPEA, no product formation was 
observed (Entry 8). The effect of increasing the amount of DIPEA to 1.5 equivalents was 
insignificant on the reaction yield (Entry 9). Furthermore, the best yields for the formation of 
dioxaspirohexane 113a were obtained at concentrations of 0.25 M with respect to 62a (Entries 4, 
10, 11, and 12).  
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Table 8.  Optimization of conditions for formation of dioxaspiroheptane 113a. 
2.3.2 Preparation of -lactones and 2-methyleneoxetane substrates 
 A variety of 2-methyleneoxetanes was prepared to explore the scope of dioxaspiroheptane 
ring formation. The starting -lactones were prepared from previously reported lactonization 
procedures or using modified procedures. The formation of -lactones can be classified into three 
types of transformations: (1) lactonization by oxygen-acyl bond formation; (2) lactonization by 
oxygen-alkyl bond formation; and (3) [2+2] cycloaddition of ketenes (or ketene equivalents) and 
carbonyl compounds (Figure 35). Methylenations of various -lactones were conducted using our 
previously reported protocol by reacting the -lactones with the Petasis reagent.34,37 
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Figure 35. General methods for the formation of -lactones. 
 The syntheses of C-3 monosubstituted -lactones 115a and 115b was achieved by the 
lactonization of tropic acid 116 and N-tert-butyloxycarbonyl substituted L-serine 117, respectively, 
using modified Mitsunobu conditions (Scheme 32).74,75 -Lactone 115a was then utilized for the 
synthesis of 3,3-disubstituted -lactones. Formation of the -lactone enolate of 115a with LDA at 
– 78 °C, followed by treatment with an electrophile, provided 115c and 115d in good yields.32 
 
Scheme 32. Synthesis of -lactones using modified Mitsunobu conditions and formation of 3,3-disubstituted -
lactones. 
 The synthesis of -lactone 62e was accomplished by employing the coupling reagent, 
(benzotriazol-1-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate (PyBOP), with N-
trityl-protected L-serine 118 (Scheme 33).76,77 Other coupling agents, such as N,N-
diisopropylcarbodiimide (DIC)78 and N,N-dicyclohexylcarbodiimide (DCC),79 have also been 
reported for the synthesis of 115e, but in much lower yields. 
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Scheme 33. Synthesis of -lactone 115e using the PyBOP coupling reagent. 
The syntheses of gem-dimethyl substitiuted -lactones 115f-115i were accomplished by 
utilizing a methodology developed by Adam and co-workers (Scheme 34).80 This method 
commenced with formation of -hydroxy acid 119 via the condensation of -lithio carboxylate 
salts with various ketones or aldehydes. Subsequent lactonization of the -hydroxy acids (119) 
with benzenesulfonyl chloride in pyridine at low temperatures (0-5 °C) afforded tri- and tetra-
substituted -lactones 115f-115i.  
 
Scheme 34. Synthesis of gem-dimethyl substituted -lactones. 
Additional tri- and tetra-substituted -lactones 115j and 115k were synthesized using an 
aldol-lactonization methodology developed by Schick and co-workers (Scheme 35).81 
Deprotonation of phenyl isobutyrate (120) with lithium diisopropylamide (LDA) and aldolization of 
heptanal, pivaldehyde or cyclohexanone afforded -lactones 115r, 115k and 115j, respectively. 
The activation of the carbonyl group with a phenoxy group assisted in the in situ intramolecular 
102 
 
cyclization of O-lithiated phenyl -hydroxyalkanoates 121 intermediates to a -lactone by 
elimination of lithium phenoxide. 
 
Scheme 35. Synthesis of -lactones via a tandem aldol-lactonization reaction. 
trans-Disubstituted -lactone 115l was made using a ZnCl2-mediated tandem Mukaiyama 
aldol-lactonization reaction developed by Romo and co-workers (Scheme 36).82  Reaction of 
hydrocinnamaldehyde 122 and TBS thiopyridyl ketene acetal 123 (E/Z, 19:1) with ZnCl2 delivered 
-lactone 115l in 79% yield and with excellent diastereoselectivity (>18:1) favoring the trans--
lactone. 
 
Scheme 36. Synthesis of -lactone 115l via tandem Mukaiyama aldol-lactonization. 
The syntheses of C-4 monosubstituted -lactones 115m, 115n, and 115o were 
accomplished with a catalyzed acyl halide-aldehyde cyclocondensation (AAC) reaction developed 
by Nelson and co-workers (Scheme 37).83 This reaction proceeds by in situ ketene 124a formation 
via N,N-diisopropylethylamine (DIPEA) mediated dehydrohalogenation of acyl halide 124. Next, 
[2+2] cycloaddition of the ketene with aldehyde 125, activated by the Lewis acid catalyst 
Al(SbF6)3, delivered the desired -lactones 115m, 115n, and 115o. 
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Scheme 37. Synthesis of -lactone using Lewis acid-catalzed acyl halide aldehyde cyclocondensation. 
Similarly, -silyl--lactone 127 was prepared from a [2+2]-cycloaddition of silyketene 128 
and diphenylacetaldehyde 129 in the presence of catalytic BF3∙OEt2 (Scheme 38).84 Treatment of 
-silyl--lactone 130 with TBAF at –78 °C provided C-Si bond cleavage to afford C-4 
monosubstituted -lactone 115p in good yield (Scheme 38).85 
 
Scheme 38. Synthesis of -lactone 115p by [2+2]-cycloaddition and subsequent C-Si bond cleavage with TBAF.  
Methylenation of the -lactones using the Petasis reagent provided a library of 2-
methyleneoxetanes in fair to good yields (Table 9). One exception was the methylenation of tetra-
substituted -lactone 115i which gave only the ring-opened methylene product. It should also be 
noted that 2-methyleneoxetanes are prone to ring-opening with silica gel chromatography. To 
minimize their propensity for ring-opening during column chromatography, the silica gel was 
deactivated with triethylamine. 
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Table 9. Preparation of 2-methyleneoxetanes from methylenation of -lactones. 
2.3.3 Scope of the reaction  
The preliminary experiments demonstrated the feasibility of 2-methyleneoxetanes 62a to 
act as neutral nucleophiles in carbon-carbon bond-forming reactions with ethyl glyoxylate 96 
(Table 10, Entry 1). The optimized conditions using one equivalent of tin(IV) chloride were applied 
to a variety of mono-, di-, tri-, and tetrasubstituted 2-methyleneoxetanes.  
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We first explored mono-substituted 2-methyleneoxetanes 62o and 62p, with substituents 
at the C-4 position of the oxetane ring. When 62o or 62p were treated with tin(IV) chloride, no 
dioxaspirohexane resulted; instead, ring opened diol products 131o and 131p were isolated 
(Table 10, Entries 2 and 3) as a 1:1 mixture of diastereomers after column chromatography. The 
same reaction outcome was also observed when the Lewis acid was changed to titanium(IV) 
chloride. Hydrolyzed ring opened products were observed possibly, due to instability of the 
spiroketal moiety. It must be noted that diastereomeric ratios are typically determined from crude 
1H NMR spectra; however, impurities present in the reaction mixtures made these measurements 
difficult for many reactions. Even though a majority of the column fractions were analyzed, in most 
reactions, it is possible that other diastereomers and products formed. Additionally, the 
diastereomeric ratio could be affected by the purification process. 
 
Table 10. Reaction of mono-substituted 2-methyleneoxetanes with ethyl glyoxylate. 
The reaction of di- and tri-substituted 2-methyleneoxetanes (62) with ethyl glyoxylate (96) 
also provided ring-opening products under optimized conditions (Table 11). When disubstituted 
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2-methyleneoxetane 62c was used, the unexpected ring-opened chloride product 132c was 
isolated as one diastereoisomer in 66% yield (Entry 1). Reaction outcomes with 62c were the 
same with and without aqueous workups. Reactions conducted with trans-substituted 2-
methyleneoxetanes 62j and 62l provided the ring-opened diol products as a mixture of 
diastereoisomers in 45% and 49% yields, respectively (Entries 2 and 3).  
Reactions with trisubstituted 2-methyleneoxetanes 62g and 62f provided ring-opened 
products in good yields (Entries 4–6). Reaction with 62g provided diol 131g as mixture of 
diastereomers (3:2 ratio) that were inseparable by column chromatography (Entry 4). 
Diastereomeric ratios were determined by 1H NMR intergrations of purified product, and the 
relative stereochemistry of the products was not determined. Additionally, reaction of 62g in the 
presence of TiCl4 gave the ring-opened chloride product 132g as a mixture of diastereomers 
(Entry 5). The reaction of 2-methyleneoxetane 62f in the presence of SnCl4 gave a mixture of 
alcohol and chloride substituted ring-opened products 133f and 133f’ (Entry 6) that were 
separated by column chromatography. Surprisingly, the crude reaction mixture only showed the 
formation of the chloride compound. Thus, substitution most likely occurred during the purification 
process. 
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Table 11. Reaction of di- and trisubstituted 2-methyleneoxetanes with ethyl glyoxylate. 
The reaction of ethyl glyoxylate with tetrasubstituted 2-methyleneoxetanes was also 
examined (Table 12). Reaction with 2-methyleneoxetane 62h in the presence of SnCl4 or TiCl4 
suggested a cycloreversion to form benzophenone (134) in quantitative yield had occurred (Entry 
1). However, reaction of 62h in the presence of ZnCl2 resulted in the formation of 
tetrahydropyranone 114h (Entry 2). 
Similarly, reaction of 2-methyleneoxetane 62j in the presence of SnCl4 or ZnCl2 provided 
different reaction outcomes (Entries 3 and 4). Reaction of 62j using the stronger Lewis acid, 
SnCl4, led to the ring-opened alkene product 135 in 58% yield (Entry 3). On the other hand, 
reaction of 62j in the presence of a weaker Lewis acid, ZnCl2, led to the formation of 
tetrahydropyranone 114j (Entry 4). 
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Table 12. Reaction of tetrasubstituted 2-methyleneoxetanes with ethyl glyoxylate. 
Up until this point, reactions conducted under optimized or slightly modified conditions did 
not lead to formation of the desired dioxaspiroheptanes in a significant amount. However, the 
formation of dioxaspiroheptanes was achieved using certain 2-methyleneoxetanes under the 
standard reaction conditions or with slight modifications (Table 13). Reaction of N-trityl-protected 
2-methyleneoxetane 62e with ethyl glyoxylate 96 and the titanium BINOL catalyst provided 
dioxaspiroheptane 113e as a diastereomic mixture (Entry 2). As previously discussed, purification 
of the crude mixture was required in order to determine the diastereomer ratio, which could be 
altered during purification. The relative stereochemistry for the mixture of 113e was not 
determined.  
Reaction of C-3 disubstituted 2-methyleneoxetane 62d in the presence of ZnCl2 gave 
dioxaspiroheptane 113d as a mixture of diastereomers (Entry 3). Additionally, trisubstituted 2-
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methyleneoxetane 62k also provided dioxaspiroheptane 113k in low yields (Entry 4). Surprisingly, 
reactions with 2-methyleneoxetanes 62g and 62f in the presence of SnCl4 gave 
diaoxspiroheptanes 113g and 113f in moderate yields (Entries 5 and 6). Previous reactions of 
62g and 62f using the same electrophile and Lewis acid led to the formation of ring-opened 
products (see Table 11). It is possible the formation of the dioxaspiroheptanes could be related 
to the reaction temperature. Formation of dioxaspirohetanes 113g and 113f was observed when 
the reactions were slowly warmed from –78 °C to room temperature by allowing the dry ice to 
sublime.  
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Table 13. Formation of dioxaspiroheptanes from 2-methyleneoxetanes. 
2.3.4 Reaction with different electrophiles 
After examining a variety of 2-methyleneoxetanes, we sought to evaluate the scope of 
electrophiles that could be used in this aldol-type addition. At the outset of this study, 3-phenyl-2-
methyleneoxetane 62a was used as a substrate model and reacted with various electrophiles 
(Table 14). Reactions of 2-methyleneoxetane 62a with p-nitrobenzaldehyde, a relatively activated 
aldehyde, using SnCl4, resulted in messy reactions and low conversions to coupled products 
(Entry 1). Changing the Lewis acid to ZnCl2 or TiCl4 also resulted in very messy reactions with 
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significant formation of coupled product(s) (Entries 2 and 3). Along these lines, reaction of 2-
methyleneoxetanes with moderately or non-activated electrophiles did not provide coupled 
product(s) in appreciable yields (Entries 4-8). These results suggest a need for activated 
electrophiles and/or 2-methyleneoxetanes that have a greater level of stability.  
 
Table 14. Reaction of 2-methyleneoxetane 62a with various electrophiles. 
Further exploration using 2-methyleneoxetane 62f with p-nitrobenzaldehyde and TiCl4 
gave enone 136f in 96% yield (Scheme 39). A single X-ray crystal structure was obtained for 
enone 136f. The incorporation of chloride can occur via intramolecular attack by a chloride from 
the titanium or by loss of the Cl– followed by attack. 
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Scheme 39. Reaction of 2-methyleneoxetane 62f with p-nitrobenzaldehyde. 
This transformation was further explored with enophiles of different reactivities in the 
presence of TiCl4 (Table 15). Reaction of 2-methyleneoxetanes 62f or 62g with moderately 
activated aldehydes, such as p-nitrobenzaldehyde, o-nitrobenzaldehyde, and p-
bromobenzaldehyde, gave similar ring-opened enone products (Entries 1-6) in good to excellent 
yields. 2-Methyleneoxetane 62g also reacted with aromatic aldehydes bearing slight activating 
groups (Entry 8), non-activated (Entry 7), and somewhat deactivating groups (Entries 9 and 10), 
albeit in lower yields. The reaction with conjugated aldehydes and 62g also provided aldol-type, 
ring-opened products (Entries 11 and 12). Low conversion or no product formation was observed 
with heptanal and tert-butylsulfinamide (Entries 13 and 14).  
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Table 15. Reaction of tri-substituted 2-methyleneoxetanes with various electrophiles. 
2.3.5 5-Membered rings 
In light of the results obtained with four-membered exocyclic enol ethers, we wondered 
what effect ring size would have on the reaction outcome. Previous research has shown that 
under similar reaction conditions 2-methylenetetrahydropyrans gave either the carbonyl-ene 
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adduct or the aldol-type adduct (see Scheme 27). However, reaction of five-membered exocyclic 
enol ether 146 with ethyl glyoxyate 96 in the presence of a Lewis acid has not been reported 
(Figure 36).  
 
Figure 36. Probing of five-membered exocyclic enol ethers 146 with ethyl glyoxylate 96 and various Lewis acids. 
We decided to synthesize benzyl substituted 2-methylenetetrahydrofuran 146a as a model 
substrate due to the low boiling point of the unsubstituted 2-methylenetetrahydrofuran (Scheme 
40). Benzyl substituted -lactone 148 was prepared by alkylation of -butryolactone (147) using 
LDA and benzyl bromide.86 Methylenation of -lactone 148 using the Petasis reagent provided 2-
methylenetetrahydrofuran 146a in 64% yield. 
 
Scheme 40. Synthesis of 2-methylenetetrahydrofuran 146a. 
We first examined the reaction of 2-methylenetetrahydrofuran 146a and ethyl glyoxylate 
(1.2 equiv) with stoichiometric ZnCl2 at –78 °C (Scheme 41). After the addition of ZnCl2, the 
reaction was allowed to slowly warm to room temperature over 12 hours. Not unexpectedly, 
formation of the -hydroxydihydrofuran 149 was observed in 72% yield. Based on literature 
related to cyclic enol ether reactions with Lewis acid catalysts, we hypothesized two potential 
pathways for the formation of 149 (Scheme 41). This Lewis acid catalyzed reaction can proceed 
via a concerted mechanism with a polar transition state, 150, or a stepwise mechanism, forming 
an oxocarbenium ion intermediate, 151. Similar transformations are often classified as falling 
somewhere in between a concerted and stepwise mechanism. 
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Scheme 41. Reaction of 2-methylenetetrahydrofuran with ethyl glyoxylate in the presence of ZnCl2 and the possible 
mechanism. 
Reaction of 2-methylenetetrahydrofuran 146a with ethyl glyoxylate (96) and stoichiometric 
SnCl4 or TiCl4 provides a different reaction outcome, the formation of diene 152 (Scheme 42). The 
formation of the elimination product 152, rather than hydroxide 149, is likely due to the use of 
stronger Lewis acids. Based on literature related to endocyclic enol ethers reactions (vide infra), 
we hypothesize that the reaction goes via a stepwise mechanism (Scheme 42). The first step in 
the reaction mechanism is the activation of ethyl glyoxylate (96) by the Lewis acid, followed by 
nucleophilic addition of 2-methylenetetrahydrofuran 146a to give oxonium intermediate 153. 
Elimination of the oxonium ion-titanium complex would give oxonium ion intermediate 154. 
Deprotonation of 154 would provide diene 152.  
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Scheme 42. Reaction of 2-methylenetetrahydrofuran with ethyl glyoxylate in the presence of SnCl4 or TiCl4 and the 
possible mechanism. 
2.4 Conclusion 
 2-Methyleneoxetanes were utilized for the first time as nucleophiles in carbon-carbon 
bond-forming reactions. Notably, a number of 2-methyleneoxetanes were shown to react with 
ethyl glyoxylate to provide dioxaspiroheptanes in the presence of a Lewis acid. Reaction of 
tetrasubstituted 2-methyleneoxetanes provided a different reaction outcome in that 
tetrahydropyranones were formed. Furthermore, certain 2-methyleneoxetanes reacted with ethyl 
glyoxylate to provide ring-opened products. These reaction conditions were also applied to 2-
methylenetetrahydrofuran for the formation of -hydroxydihydrofuran or its eliminated equivalent. 
In exploring aldehydes other than ethyl glyoxylate, it was found that only activated aldehydes, 
such as p-nitrobenzaldehyde reacted productively under typical conditions. 
2.5 Experimental 
2.5.1 General Information 
 All moisture sensitive reactions were run in a flame-dried flask under and atmosphere of 
nitrogen. Methylene chloride (DCM), dimethylforamide (DMF), toluene, and pyridine were dried 
over CaH2 of over 4 Å molecular sieves. Tetrahydrofuran (THF) was dried using J. C. Meyer 
Solvent Dispensing System (SDS) under nitrogen. Deuterated chloroform was dried over 4 Å 
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molecular sieves. Zinc(II) chloride was freshly fused prior to use. Commercially available reagents 
were purchased from Acros, Aldrich, Alfa Aesar, or TCI America and were purified as necessary. 
 Flash column chromatography was performed using silica gel, 40 microns flash silica. 
Silica gel was deactivated with triethylamine when necessary. Thin layer chromatography was 
carried out with silica gel (Silica Gel 60 F254) glass plates, and the compounds were visualized by 
UV (254 nm), 0.5% KMnO4 in 0.1 M aqueous NaOH solution, 5% phosphomolybdic acid in EtOH, 
or a 2.5% solution of p-anisaldehyde in 95% EtOH. 1H NMR spectra were recorded on a Bruker 
AVANCE 300, 400, or 500 MHz spectrometer. 13C NMR spectra were recorded on a Bruker 
AVANCE 75, 100, or 125 MHz spectrometer. 1H NMR chemical shifts are reported as  values in 
ppm calibrated to residual CHCl3 (7.26 ppm). 1H NMR coupling constants (J) are reported in Hertz 
(Hz). 13C NMR chemical shifts are calibrated to the CDCl3 peak at 77.23 ppm. Infrared spectra 
were obtained on a FTIR spectrometer. High-resolution mass spectra (HRMS) were obtained 
using DART AccuTOF or JEOL JMS-AX505HA mass spectometers.  
General procedure for the preparation of 3,3-dimethyl--lactones 
 
n-Butyllithium (2.5 M in hexanes, 2.0 equiv) was added dropwise to a stirred solution of 
diisopropylamine (2.0 equiv) in dry THF (0.15 M) at 0 °C under N2. The solution was maintained 
at 0 °C for 15 min, and then isobutyric acid (1.0 equiv, 1.0 M solution in dry THF) was added 
dropwise at 0 °C. The ice bath was removed and reaction was stirred for 1 h at rt. Then, the 
aldehyde (1.0 equiv, 2.5 M solution in dry THF) was added dropwise at rt, and the solution was 
stirred for 48 h at rt. The reaction mixture was poured onto ice (equal to the total volume of the 
solution) and acidified with HCl (6 N) to pH 2. The mixture was extracted with Et2O (3 × equal 
volumes), and the combined organic extracts were washed with brine (2 × 1/3 total volume), dried 
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(MgSO4), and concentrated in vacuo. The residue was purified by flash chromatography on silica 
gel.  
Benzenesulfonyl chloride (3.0 equiv) was added drop-wise to a solution of -hydroxyacid 
(1.0 equiv) in dry pyridine (0.15 M) at 0 °C under N2. The resulting solution was stirred at 0 °C for 
48 h. Then, it was poured onto crushed ice (10 mL per 1.0 mmol) and stirred for 15 min. Et2O (5  
mL per 1.0 mmol) was added, and the layers were separated. The aqueous layer was extracted 
with Et2O (3 × 7 mL per 1.0 mmol). The combined organic extracts were washed with saturated 
aqueous NaHCO3 (2 × 5 mL per 1.0 mmol), 10% aqueous CuSO4 (4 × 10 mL per 1.0 mmol) and 
H2O (1 × 5 mL per 1.0 mmol), dried (MgSO4) and concentrated. The residue was purified by flash 
chromatography on silica gel. 
3-Hydroxy-2,2-dimethyl-3-phenylpropanoic acid (119g) 
 
3-Hydroxy-2,2-dimethyl-3-phenylpropanoic acid (119g) was prepared from benzaldehyde (5.50 
g, 53.5 mmol) using the general procedure. Purification by flash chromatography on silica gel 
(DCM/MeOH, 95:5) afforded 3-hydroxy-2,2-dimethyl-3-phenylpropanoic acid (119g) as a white 
solid (7.89 g, 70%):87 1H NMR (500 MHz, CDCl3) δ 7.35–7.31 (m, 5H), 4.95 (s, 1H), 1.17 (s, 6H); 
13C NMR (125 MHz, CDCl3) δ 182.9, 139.8, 128.2, 128.2, 127.9, 78.8, 47.8, 23.6, 18.9. 
3-Hydroxy-2,2-dimethyl-3-(naphthalene-1-yl)propanoic acid (119f) 
 
3-Hydroxy-2,2-dimethyl-3-(naphthalene-1-yl)propanoic acid (119f) was prepared from 1-
naphthaldehyde (8.36 g, 53.5 mmol) using the general procedure. Purification by flash 
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chromatography on silica gel (DCM/MeOH, 95:5) afforded 3-hydroxy-2,2-dimethyl-3-
(naphthalene-1-yl)propanoic acid (119f) as a white solid (9.94 g, 76%): IR (neat) 3571, 3467, 
1707, 1050, 806, 785 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.31–8.29 (m, 1H), 7.89–7.87 (m, 1H), 
7.83–7.81 (m, 1H), 7.76–7.74 (m, 1H), 7.53–7.44 (m, 3H), 6.03 (s, 1H), 4.92 (br s, 1H), 1.23 (s, 
3H), 1.03 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 179.8, 137.2, 133.6, 132.0, 128.4, 127.7, 125.9, 
125.3, 124.9, 124.5, 123.6, 72.2, 48.3, 23.0, 18.1; HRMS (ESI) m/z calcd for C15H15O3 [M – H]+ 
243.1021, found 243.1019. 
3-Hydroxy-2,2-dimethyl-3,3-diphenylpropanoic acid (119h) 
 
3-Hydroxy-2,2-dimethyl-3,3-diphenylpropanoic acid (119h) was prepared from benzophenone 
(10.0 g, 54.8 mmol) using the general procedure. Purification by flash chromatography on silica 
gel (DCM/MeOH, 95:5) afforded 3-Hydroxy-2,2-dimethyl-3,3-diphenylpropanoic acid (119h) as a 
white solid (7.6 g, 51%):88 1H NMR (300 MHz, CDCl3) δ 7.49–7.14 (m, 10H), 1.34 (s, 6H); 13C 
NMR (75 MHz, CDCl3) δ 185.7, 145.1, 128.9, 127.8, 127.5, 82.7, 49.1, 24.1; 
3,3-Dimethyl-4-phenyloxetan-2-one (115g) 
 
3,3-Dimethyl-4-phenyloxetan-2-one (115g) was prepared from 3-hydroxy-2,2-dimethyl-3-
phenylpropanoic acid (119g) (5.70 g, 29.3 mmol) using the general procedure. Purification by 
flash chromatography on silica gel (petroleum ether/EtOAc, 90:10) afforded 3,3-dimethyl-4-
phenyloxetan-2-one (115g) as a white solid (4.45 g, 86%): 1H NMR (400 MHz, CDCl3) δ 7.41–
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7.24 (m, 5H), 5.31 (s, 1H), 1.55 (s, 3H), 0.87 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 175.0, 135.4, 
128.7, 128.5, 125.3, 82.8, 56.7, 22.5, 18.0. 
3,3-Dimethyl-4-(naphthalene-1-yl)oxetan-2-one (115f) 
 
3,3-Dimethyl-4-(naphthalene-1-yl)oxetan-2-one (115f) was prepared from 3-hydroxy-2,2-
dimethyl-3-(naphthalene-1-yl)propanoic acid (119f) (3.00 g, 12.5 mmol) using the general 
procedure. Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 90:10), 
afforded 3,3-dimethyl-4-(naphthalene-1-yl)oxetan-2-one (115f) as a white solid (1.73 g, 76%): IR 
(neat) 1812, 1085, 921, 866, 789, 773 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.94–7.91 (m, 1H), 
7.85–7.83 (m, 1H), 7.69–7.67 (m, 1H), 7.62–7.49 (m, 4H), 5.99 (s, 1H), 1.81 (s, 3H), 0.83 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 174.5, 133.2, 131.6, 129.7, 129.0, 128.4, 126.6, 126.0, 125.3, 
122.5, 121.9, 81.3, 56.8, 22.0, 16.9; HRMS (ESI) m/z calcd for C15H15O2 [M + H]+ 227.1072, found 
227.1086. 
3,3-Dimethyl-4,4-diphenyloxetan-2-one (115h) 
 
3,3-Dimethyl-4,4-diphenyloxetan-2-one (115h) was prepared from 3-hydroxy-2,2-dimethyl-3,3-
diphenylpropanoic acid (119h) (7.55 g, 27.9 mmol) using the general procedure. Purification by 
flash chromatography on silica gel (petroleum ether/EtOAc, 90:10), afforded 3,3-dimethyl-4,4-
diphenyloxetan-2-one (115h) as a white solid (4.02 g, 57%):89 1H NMR (400 MHz, CDCl3) δ 7.51–
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7.27 (m, 10H), 1.25 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 175.0, 139.9, 128.6, 127.9, 125.8, 88.7, 
60.0, 21.7. 
3-Phenyloxetan-2-one (115s) 
 
Triphenylphosphine (3.18 g, 12.0 mmol) was dissolved in dry THF (40 mL) under N2, and the 
solution was cooled to –78 °C. Then diethyl azodicarboxylate (2.10 g, 12.0 mmol) was added to 
the solution dropwise and the solution stirred for 20 min. A solution of tropic acid (2.00 g, 12.0 
mmol) in dry THF (40 mL) was added dropwise, and the reaction mixture was stirred at –78 °C. 
After 30 min the mixture was slowly warmed to 0 °C in an ice bath over 2 h. The mixture was 
preloaded on silica gel and purified by flash chromatography on silica gel (petroleum ether/EtOAc, 
90:10), yielding 3-phenyloxetan-2-one (115a) as a colorless syrup (1.78 g, 70%):74 IR (neat) 1814, 
1104, 880, 698 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.42–7.29 (m, 5H) 4.94 (dd, J = 6.6, 4.9 Hz, 
1H), 4.67 (dd, J = 6.8, 5.2 Hz, 1H), 4.36 (dd, J = 5.0, 5.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
169.7, 132.8, 129.4, 128.5, 127.3, 66.6, 57.1; HRMS (ESI) m/z calcd for C9H9O2 [M + H]+ 
149.0603, found 149.0603. 
3-Allyl-3-phenyloxetan-2-one (115d) 
 
n-Butyllithium (2.5 M in hexanes, 3.05 mL, 7.63 mmol) was added dropwise to a stirred solution 
of diisopropylamine (1.07 mL, 7.63 mmol) in dry THF (44 mL) at 0 °C under N2. The solution was 
maintained at 0 °C for 15 min, then cooled to –78 °C. A solution of 3-phenyloxetan-2-one (115a) 
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(1.13 g, 7.63 mmol) in dry THF (22 mL) was added dropwise, and the solution was stirred for 30 
min more. Allyl iodide (3.52 g, 21.0 mmol) in dry THF (16.5 mL) was added dropwise over 15 min, 
and the solution was maintained at –78 °C for 2 h. The reaction was quenched with saturated 
aqueous NH4Cl (40 mL). The organic layer was separated, and the aqueous layer was extracted 
with Et2O (3 × 50 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated. The residue was purified by flash chromatography on silica gel (petroleum 
ether/EtOAc, 95:5) to afford 3-allyl-3-phenyloxetan-2-one (115d) as a yellow oil (0.91 g, 64%):32 
1H NMR (400 MHz, CDCl3) δ 7.37–7.25 (m, 5H), 5.78–5.67 (m, 1H), 5.18–5.13 (m, 2H), 4.48 (d, 
J = 5.3 Hz, 1H), 4.46 (d, J = 5.2 Hz, 1H), 2.76 (dd, J = 14.1, 7.0 Hz, 1H), 2.68 (dd, J = 14.1, 7.5 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 171.8, 137.2, 131.3, 128.8, 127.8, 126.1, 120.3, 69.6, 
65.0, 41.6. 
3-Methyl-3-phenyloxetan-2-one (115c) 
 
n-Butyllithium (2.5 M in hexanes, 5.40 mL, 13.5 mmol) was added dropwise to a stirred solution 
of diisopropylamine (1.50 g, 14.8 mmol) in dry THF (78 mL) at 0 °C under N2. The solution was 
maintained at 0 °C for 15 min, then cooled to –78 °C. A solution of 3-phenyloxetan-2-one (115a) 
(2.00 g, 13.5 mmol) in dry THF (39 mL) was added dropwise, and the solution was stirred for 30 
min more. Methyl iodide (5.80 g, 40.8 mmol) in dry THF (29 mL) was added dropwise over 20 
min, and the solution was maintained at –78 °C for 2 h. The reaction was quenched with saturated 
aqueous NH4Cl (70 mL). The organic layer was separated, and the aqueous layer was extracted 
with Et2O (3 × 90 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated. The residue was purified by flash chromatography on silica gel (petroleum 
ether/EtOAc, 95:5) to afford 3-methyl-3-phenyloxetan-2-one (115c) as a yellow oil (1.45 g, 66%):32 
123 
 
1H NMR (400 MHz, CDCl3) δ 7.41–7.29 (m, 5H), 4.52 (d, J = 4.7 Hz, 1H), 4.39 (d, J = 4.7 Hz, 1H), 
1.77 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 173.1, 138.6, 129.0, 127.8, 125.5, 73.1, 61.2, 23.6. 
4-Cyclohexyloxetan-2-one (115o) 
 
A solution of Ag(SbF6)3 (3.03 g, 8.87 mmol) in dry DCM (20 mL) was added to a solution of AlCl3 
(0.39 g, 2.96 mmol) and i-Pr2NEt (1.53 mL, 8.87 mmol) in DCM (20 mL) at –25 °C. Then i-Pr2NEt 
(2.57 mL, 14.8 mmol), acetyl chloride (1.57 mL, 22.2 mmol), and a solution of cyclohexylcarbox-
aldehyde (1.67 g, 14.8 mmol) in DCM (5 mL) were added. The reaction mixture was stirred at –
25 °C for 4 h. The reaction mixture was filtered through a pad of Celite, and the pad was washed 
with DCM (15 mL). The filtrate was then concentrated to give a yellow oil. The residue was purified 
by flash chromatography on silica gel (petroleum ether/EtOAc, 90:10) to afford 4-
cyclohexyloxetan-2-one (115o) as a colorless oil (1.60 g, 71%):82 1H NMR (400 MHz, CDCl3) δ 
4.21–4.16 (m, 1H), 3.41 (dd, J = 16.3, 5.8 Hz, 1H), 3.10 (dd, J = 16.3, 4.4 Hz, 1), 1.97–1.55 (m, 
6H), 1.33–0.93 (m, 5H); 13C NMR (100 MHz, CDCl3) δ 168.8, 75.0, 42.1, 41.2, 28.3, 27.3, 26.1, 
25.6, 25.3. 
4-(2-Diphenylmethyl)oxetan-2-one (115p) 
 
4-(2-Diphenylmethyl)-3-trimethylsilyloxetane-2-one84 (2.36 g, 7.60 mmol) was dissolved in dry 
THF (50 mL) under nitrogen and cooled to –78 °C. A solution of TBAF (1.0 M in THF, 8.0 mL, 8.0 
mmol) was added to the flask dropwise and the solution stirred at –78 °C. After stirring for 30 min, 
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the reaction was quenched with pH 7 buffer (30 mL), and the solution was extracted with Et2O (3 
× 50 mL). The combined organic extracts were then dried (MgSO4), filtered and concentrated, 
yielding a yellow oil. The crude oil was purified by flash chromatography on silica gel (petroleum 
ether/EtOAc, 90:10), to afford 4-(2-diphenylmethyl)oxetan-2-one (115p) as a colorless oil  (1.35 
g, 72%): IR (neat) 1825, 1118, 740, 697 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36–7.22 (m, 10H), 
5.15 (ddd, J = 8.3, 5.6, 4.4 Hz, 1H), 4.26 (d, J = 8.3 Hz, 1H), 3.51 (dd, J = 16.5, 5.7 Hz, 1H), 3.15 
(dd, J = 16.5, 4.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 167.7, 139.6, 139.5, 129.2, 128.9, 128.7, 
128.6, 127.7, 127.5, 72.3, 55.2, 42.7; HRMS (ESI) m/z calcd for C16H15O2 [M + H]+ 239.1072, 
found 239.1090. 
(S)-3-(Tritylamino)oxetan-2-one (115e) 
 
N-Tritylserine (2.00 g, 5.76 mmol) was suspended in dry DCM (30 mL) under N2 at rt. Then 
triethylamine (2.29 mL, 16 mmol) was added, and the mixture became homogeneous. 
Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (3.57 g, 8.07 mmol) 
was added in three portions over 15 min, and the solution stirred for 1 h. The reaction was then 
diluted with H2O (30 mL) and stirred for an additional 20 min. The organic layer was separated, 
and the aqueous layer was extracted with DCM (3 × 30 mL). The combined organic layers were 
dried (MgSO4), filtered and concentrated, yielding a yellow solid. The crude solid was purified by 
flash chromatography on silica gel (petroleum ether/EtOAc, 85:15) to afford (S)-3-(tritylamino)-
oxetan-2-one (115e) as a white solid  (1.35 g, 72%):45 1H NMR (400 MHz, CDCl3) δ 7.42–7.29 (m, 
5H), 4.94 (dd, J = 6.6, 4.9 Hz, 1H), 4.67 (dd, J = 6.8, 5.2 Hz, 1H), 4.36 (dd, J = 5.0, 5.0 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 172.3, 145.4, 128.7, 128.6, 128.2, 128.0, 127.5, 127.2, 71.0, 70.8, 
64.7. 
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3,3-Dimethyloxetan-2-one-4-spirocyclohexane (115j) 
 
n-Butyllithium (2.5 M in hexanes, 5.85 mL, 14.7 mmol) was added dropwise to a stirred solution 
of diisopropylamine (2.30 mL, 16.5 mmol) in dry THF (25 mL) at 0 °C under N2. The solution was 
maintained at 0 °C for 15 min, then cooled to –78 °C. A solution of phenyl isobutyrate (2.00 g, 
12.5 mmol) in dry THF (5 mL) was added dropwise, and the solution was left to stir to 30 min. 
Cyclohexanone (1.25 mL, 12.3 mmol) in dry THF (5 mL) was added dropwise, and the solution 
was maintained at –78 °C for 30 min. The reaction was slowly warmed to 0 °C over 2.5 h and 
stirred for an additional 1 h at 0 °C. The reaction was quenched with saturated aqueous NH4Cl 
(10 mL), and the reaction mixture was diluted with Et2O (10 mL). The organic layer was separated, 
and the aqueous layer was extracted with Et2O (3 × 15 mL). The combined organic extracts were 
dried (MgSO4), filtered and concentrated to give a yellow oil. The residue was purified by flash 
chromatography on silica gel (petroleum ether/EtOAc, 95:5) to afford 3,3-dimethyloxetan-2-one-
4-spirocyclohexane (115j) as a white solid (1.22 g, 58%):90 1H NMR (400 MHz, CDCl3) δ 2.00–
1.92 (m, 2H), 1.68–1.61 (m, 7H), 1.30 (br s, 7H); 13C NMR (100 MHz, CDCl3) δ 176.3, 85.3, 54.6, 
32.5, 25.0, 22.9, 18.3. 
trans-4-(2-Phenylethyl)-3-methyloxetan-2-one (115l) 
 
Anhydrous ZnCl2 (5.04 g, 37.0 mmol) was freshly fused (under vacuum at 0.5 mmHg) and after 
cooling to rt was broken into small pieces with a spatula. Then dry DCM (190 mL) was added, 
followed by the addition of hydrocinnamaldehyde (3.46 g, 25.8 mmol) dissolved in dry DCM (12 
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mL). After stirring for 20 min, TBS-thiopyridylketene acetal (123)82 (8.00 g, 28.4 mmol) in dry DCM 
(12 mL) was added, and the reaction mixture was stirred for 24 h at rt. Freshly made phosphate 
buffer (pH = 7, 30 mL) was added, and the resulting mixture was stirred vigorously for 20 min. 
The mixture was filtered through a pad of Celite, and the Celite was washed with DCM (3 × 15 
mL). The organic layer was separated, and the aqueous layer was extracted with DCM (3 × 30 
mL). The combined organic extracts were dried (MgSO4), and CuBr2 (7.52 g, 33.6 mmol) was 
added and stirred for 1.5 h at rt. The mixture was filtered through a pad of Celite, and the Celite 
was washed with DCM (3 × 15 mL). The filtrate was washed with saturated aqueous K2CO3 (40 
mL) and brine (40 mL). The organic layer was dried (MgSO4), filtered and concentrated to give a 
sticky oil. Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 95:5) 
afforded trans-4-(2-phenylethyl)-3-methyloxetan-2-one (115l) as a colorless oil (3.76 g, 79%):91 
1H NMR (400 MHz, CDCl3) δ 7.36–7.22 (m, 5H), 4.20 (ddd, J = 7.4, 6.0, 4.1 Hz, 1H), 3.23 (dq, J 
= 7.6, 4.0 Hz, 1H), 2.89–2.70 (m, 2H), 2.26–2.07 (m, 2H), 1.34 (d, J = 7.6 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 172.0, 140.3, 128.8, 128.5, 126.6, 78.8, 51.0, 36.0, 31.5, 12.6. 
 3-Benzyltetrahydrofuran-2-one (148)  
 
n-Butyllithium (2.5 M in hexanes, 10.4 mL, 26.0 mmol) was added to diisopropylamine (2.67 g, 
26.0 mmol) in dry THF (30 mL) under N2 at –78 °C. The resulting solution was stirred 20 min. -
Butyrolactone (2.59 g, 26.0 mmol) was added neat over 20 min; then benzyl bromide (4.90 g, 
28.6 mmol) in THF (15 mL) was added dropwise over 20 min. The resulting reaction mixture was 
stirred for 1.5 h at –78 °C. The reaction was quenched with saturated aqueous NH4Cl (30 mL) 
and extracted with diethyl ether (50 mL × 3). The combined organic extracts were dried (MgSO4), 
filtered and concentrated. The residue was purified by flash chromatography on silica gel 
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(petroleum ether/EtOAc, 85:15) to afford 3-benzyltetrahydrofuran-2-one (148) as a colorless oil 
(3.52 g, 77%):86 IR (neat) 1762, 1144, 1019, 699 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.32–7.19 
(m, 5H), 4.20 (ddd, J = 8.8, 8.8, 3.0 Hz, 1H), 4.12 (ddd, J = 9.2, 9.2, 6.7 Hz, 1H), 3.23 (dd, J = 
13.5, 3.9 Hz, 1H), 2.84 (ddd, J = 13.4, 9.2, 4.2 Hz, 1H), 2.74 (dd, J = 13.5, 9.3 Hz, 1H), 2.26–2.19 
(m, 1H), 2.02-1.92 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 178.8, 138.5, 128.9, 128.6, 126.8, 66.6, 
41.1, 36.2, 28.1; HRMS (ESI) m/z calcd for C11H13O2 [M + H]+ 177.0916, found 177.0916. 
Preparation of dimethyltitanocene 
 
Methyllithium (1.60 M in Et2O, 116 mL, 185 mmol) was added dropwise under N2 to a stirred slurry 
of bis(cyclopentadienyl)titanocene dichloride (20.0 g, 80.3 mmol) in dry toluene (160 mL) at 0 °C. 
The mixture was stirred at 0 °C for 1 h and allowed to warm to rt over 1 h. Then the mixture was 
cooled to 0 °C and quenched carefully with ice-cold aqueous NH4Cl (6%, 70 mL). The organic 
layer was separated and washed with H2O (2 × 50 mL) and brine (2 × 50 mL), dried MgSO4, and 
filtered to provide an orange solution. The solution was concentrated to one-third the volume and 
stored as a 0.50 M solution in toluene in the freezer.32 1H NMR (400 MHz, CDCl3) δ 6.27–6.24 
(m, 10H), 0.19–0.17 (m, 6H). 
General procedure for the preparation of 2-methyleneoxetanes 
A solution of dimethyltitanocene (0.50 M in toluene, 1.5–2.5 equiv) and -lactone (1.0 equiv) was 
stirred in the dark at 75 °C in a pressure tube. The reaction was monitored over a period of 4–12 
h by TLC until the disappearance of the starting material. The reaction mixture was cooled to rt 
and poured into petroleum ether (10 volumes) and stirred overnight. The orange precipitate was 
filtered through a pad of Celite, and the filter cake was washed with petroleum ether until the 
filtrate was colorless. The filtrate was concentrated to one-tenth the volume, and the residue was 
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purified by flash column chromatography on silica gel (deactivated by 5% NEt3 in petroleum 
ether).  
3,3-Dimethyl-4-phenyl-2-methyleneoxetane (62g) 
 
3,3-Dimethyl-4-phenyl-2-methyleneoxetane (62g) was prepared from 3,3-dimethyl-4-
phenyloxetan-2-one (115g) (234 mg, 1.33 mmol) using the general procedure (2.0 eq of 
dimethyltitanocene). Purification by flash chromatography on silica gel (petroleum ether/NEt3 
99:1) afforded 3,3-dimethyl-4-phenyl-2-methyleneoxetane (62g) as a yellow oil (162 mg, 70%): 
1H NMR (400 MHz, CDCl3) δ 7.45–7.34 (m, 5H), 5.56 (s, 1H), 4.23 (d, J = 3.7 Hz, 1H), 3.84 (d, J 
= 3.7 Hz, 1H), 1.55 (s, 3H), 0.87 (3, 3H); 13C NMR (100 MHz, CDCl3) δ 173.2, 138.8, 128.2, 127.8, 
125.2, 90.3, 76.1, 46.9, 26.5, 21.7. 
3,3-Dimethyl-4-(naphthalene-1-yl)-2-methyleneoxetane (62f) 
 
3,3-Dimethyl-4-(naphthalen-1-yl)-2-methyleneoxetane (62f) was prepared from 3,3-dimethyl-4-
(naphthalen-1-yl)oxetan-2-one (115f) (310 mg, 1.37 mmol) using the general procedure (2.0 eq 
of dimethyltitanocene). Purification by flash chromatography on silica gel (petroleum ether/ NEt3 
99:1) afforded 3,3-dimethyl-4-(naphthalen-1-yl)-2-methyleneoxetane (62f) as a yellow oil (221 
mg, 72%): IR (neat) 3061, 3026, 2978, 2896, 1683, 959, 769, 697 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.97–7.86 (m, 3H), 7.73–7.70 (m, 1H), 7.64–7.55 (m, 3H), 6.34 (s, 1H), 4.38 (d, J = 3.8 Hz, 1H), 
3.95 (d, J = 3.7 Hz, 1H), 1.82 (s, 3H), 0.87 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 173.2, 134.3, 
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133.4, 130.2, 129.1, 128.0, 126.3, 125.8, 125.7, 123.1, 122.5, 88.6, 76.5, 47.4, 26.4, 21.2; HRMS 
(ESI) m/z calcd for C16H15O [M + H]+ 223.1123, found 223.1144. 
3,3-Dimethyl-4,4-diphenyl-2-methyleneoxetane (62h) 
 
3,3-Dimethyl-4,4-diphenyl-2-methyleneoxetane (62h) was prepared from 3,3-dimethyl-4,4-
diphenyloxetan-2-one (115h) (0.90 g, 3.6 mmol) using the general procedure (1.5 eq of 
dimethyltitanocene). Purification by flash chromatography on silica gel (petroleum ether/NEt3 
99:1) afforded 3,3-dimethyl-4,4-diphenyl-2-methyleneoxetane (62h) as a white solid (0.65 g, 
72%): 1H NMR (400 MHz, CDCl3) δ 7.55–7.25 (m, 10H), 4.30 (d, J = 3.7 Hz, 1H), 3.83 (d, J = 3.7 
Hz, 1H), 1.20 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 171.8, 142.4, 128.4, 127.2, 125.7, 93.8, 76.2, 
51.2, 25.6. 
3-Phenyl-2-methyleneoxetane (62a) 
 
3-Phenyl-2-methyleneoxetane (62a) was prepared from 3-phenyloxetan-2-one (115a) (0.50 g, 3.4 
mmol) using the general procedure (1.5 eq of dimethyltitanocene). Purification by flash 
chromatography on silica gel (petroleum ether/NEt3 99:1) afforded 3-phenyl-2-methyleneoxetane 
(62a) as a colorless oil (0.31 g, 63%):32 1H NMR (400 MHz, CDCl3) δ 7.48–7.35 (m, 5H), 5.02 (dd, 
J = 7.6, 5.1 Hz, 1H), 4.75–4.72 (m, 1H), 4.64 (dd, J = 5.1, 5.1 Hz, 1H), 4.37–4.36 (m, 1H), 3.91–
3.90 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 168.5, 138.7, 128.9, 127.5, 127.5, 80.4, 76.0, 47.3. 
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3-Allyl-3-phenyl-2-methyleneoxetane (62d) 
 
3-Allyl-3-phenyl-2-methyleneoxetane (62d) was prepared from 3-allyl-3-phenyloxetan-2-one 
(115d) (365 mg, 1.94 mmol) using the general procedure (1.8 eq of dimethyltitanocene). 
Purification by flash chromatography on silica gel (petroleum ether/NEt3/EtOAc, 97.5:0.5:2) 
afforded 3-allyl-3-phenyl-2-methyleneoxetane (62d) as a yellow oil (254 mg, 70%):32 IR (neat) 
3061, 3026, 2978, 2896, 1683, 959, 769, 697 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.43–7.29 (m, 
5H), 5.87–5.76 (m, 1H), 5.20–5.16 (m, 2H), 4.80 (d, J = 5.0 Hz, 1H), 4.76 (d, J = 5.0 Hz, 1H), 4.38 
(d, J = 4.0 Hz, 1H), 4.08 (d, J = 4.0 Hz, 1H), 2.84–2.75 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 
170.5, 142.0, 133.3, 128.6, 127.0, 126.3, 118.9, 80.5, 79.2, 54.1, 44.1; HRMS (ESI) m/z calcd for 
C13H15O [M + H]+ 187.1123, found 187.1123. 
3-Methyl-3-phenyl-2-methyleneoxetane (62c) 
 
3-Methyl-3-phenyl-2-methyleneoxetane (62c) was prepared from 3-methyl-3-phenyloxetan-2-one 
(115c) (540 mg, 3.33 mmol) using the general procedure (1.8 eq of dimethyltitanocene). 
Purification by flash chromatography on silica gel (petroleum ether/NEt3/EtOAc, 97.5:0.5:2) 
afforded 3-methyl-3-phenyl-2-methyleneoxetane (62c) as a yellow oil (332 mg, 62%):32 1H NMR 
(400 MHz, CDCl3) δ 7.53–7.33 (m, 5H), 4.77 (d, J = 4.9 Hz, 1H), 4.73 (d, J = 4.9 Hz, 1H), 4.36 (d, 
J = 4.0 Hz, 1H), 4.03 (d, J = 4.0 Hz, 1H), 1.82 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.9, 143.3, 
128.6, 126.9, 125.7, 112.1, 82.3, 78.8, 50.5, 26.3.  
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4-Cyclohexyl-2-methyleneoxetane (62o) 
 
4-Cyclohexyl-2-methyleneoxetane (62o) was prepared from 4-cyclohexyloxetan-2-one (115o) 
(0.50 g, 3.3 mmol) using the general procedure (1.8 eq of dimethyltitanocene). Purification by 
flash chromatography on silica gel (petroleum ether/NEt3 99:1) afforded 4-cyclohexyl-2-
methyleneoxetane (62o) as a colorless oil (0.26 mg, 52%):71c 1H NMR (400 MHz, CDCl3) δ 4.40 
(ddd, J = 7.9, 6.7, 5.3 Hz, 1H), 4.09–4.07 (m, 1H), 3.72–3.70 (m, 1H), 3.17–3.10 (m, 1H), 2.88–
2.82 (m, 1H), 1.94–1.88 (m, 1H), 1.78–1.58 (m, 5H), 1.31–1.10 (m, 3H), 0.99–0.83 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 163.0, 83.0, 79.6, 43.3, 32.4, 27.9, 26.6, 26.5, 25.7, 25.5. 
4-(2-Diphenylmethyl)-2-methyleneoxetane (62p) 
 
4-(2-Diphenylmethyl)-2-methyleneoxetane (62p) was prepared from 4-(2-diphenylmethyl)oxetan-
2-one (115p) (0.33 g,  1.4 mmol) using the general procedure (1.8 eq of dimethyltitanocene). 
Purification by flash chromatography on silica gel (petroleum ether/NEt3 99:1) afforded 4-(2-
diphenylmethyl)-2-methyleneoxetane (62p) as a yellow oil (0.25 g, 76%): IR (neat) 3061, 1689, 
951, 697 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39–7.24 (m, 10H), 5.45 (ddd, J = 9.2, 6.5, 5.2 Hz, 
1H), 4.36 (d, J = 9.2 Hz, 1H), 4.24 (ddd, J = 3.4, 2.4, 2.4 Hz, 1H), 3.83 (ddd, J = 3.5, 1.8, 1.8 Hz, 
1H), 3.25 (dddd, J = 15.1, 4.0, 1.9, 1.9 Hz, 1H), 2.97 (dddd, J = 7.2 4.5, 2.1, 2.1 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 161.7, 140.7, 140.0, 128.9, 128.7, 128.6, 128.5, 127.2, 127.0, 80.5, 80.1, 
56.5, 33.7; HRMS (ESI) m/z calcd for C17H17O [M + H]+ 237.1279, found 237.1290. 
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 (S)-3-Tritylamino-2-methyleneoxetane (62e) 
 
(S)-3-Tritylamino-2-methyleneoxetane (62e) was prepared from (S)-3-tritylaminooxetan-2-one 
(115e) (280 mg, 0.855 mmol) using the general procedure (1.8 eq of dimethyltitanocene). 
Purification by flash chromatography on silica gel (petroleum ether/NEt3 99:1) afforded (S)-3-
tritylamino-2-methyleneoxetane (62e) as a white solid (174 mg, 62%):32 1H NMR (400 MHz, 
CDCl3) δ 7.65 (d, J = 7.5 Hz, 6H), 7.42–7.30 (m, 9H), 4.61–4.55 (m, 1H), 4.29 (dd, J = 3.4, 2.5 
Hz, 1H), 4.14 (dd, J = 3.4, 1.8 Hz, 1H), 4.02 (dd, J = 6.0, 6.0 Hz, 1H), 3.64 (dd, J = 5.5, 5.5 Hz, 
1H), 2.69 (d, J = 11.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 171.0, 146.1, 129.0, 128.6, 127.0, 
80.3, 79.6, 70.4, 55.4. 
3,3-Dimethyl-2-methyleneoxetane-4-spirocyclohexane (62j) 
 
3,3-Dimethyl-2-methyleneoxetane-4-spirocyclohexane (62j) was prepared from 3,3-
dimethyloxetan-2-one-4-spirocyclohexane (115j) (500 mg, 2.96 mmol) using the general 
procedure (1.5 eq of dimethyltitanocene). Purification by flash chromatography on silica gel 
(petroleum ether/NEt3 99:1) afforded 3,3-dimethyl-2-methyleneoxetane-4-spirocyclohexane (62j) 
as a yellow oil (335 mg, 67%): 1H NMR (300 MHz, CDCl3) δ 3.93 (d, J = 3.4 Hz, 1H), 3.61 (d, J = 
3.4 Hz, 1H), 1.97–1.92 (m, 2H), 1.63–1.52 (m, 8H), 1.22 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 
173.2, 90.1, 75.2, 46.4, 33.0, 25.3, 22.7, 22.1. 
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trans-3-Methyl-4-(2-phenylethyl)-2-methyleneoxetane (62l) 
 
trans-3-Methyl-4-(phenylethyl)-2-methyleneoxetane (62l) was prepared from trans-4-
(phenylethyl)-3-methyloxetan-2-one (115l) (0.50 g, 2.7 mmol) using the general procedure (2.0 
eq of dimethyltitanocene). Purification by flash chromatography on silica gel (petroleum 
ether/NEt3/EtOAc, 98.5:0.5:1) afforded trans-3-methyl-4-(phenylethyl)-2-methyleneoxetane (62l) 
as a yellow oil (0.36 mg, 72%):37 1H NMR (400 MHz, CDCl3) δ 7.34–7.22 (m, 5H), 4.42 (ddd, J = 
7.5, 5.3, 5.3 Hz, 1H), 4.13 (dd, J = 3.4, 2.3 Hz, 1H), 3.78 (dd, J = 3.5, 1.8 Hz, 1H), 3.11–3.03 (m, 
1H), 2.79 (ddd, J = 14.2, 9.5, 5.6 Hz, 1H), 2.67 (ddd, J = 14.2, 9.1, 7.0 Hz, 1H), 2.23–2.14 (m, 
1H), 2.09–2.00 (m, 1H), 1.27 (d, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 168.6, 141.2, 
128.6, 128.6, 126.2, 86.6, 78.0, 42.1, 37.3, 30.9, 16.8. 
3-Benzyl-2-methylenetetrahydrofuran (146a) 
 
3-Benzyl-2-methylenetetrahydrofuran (146a) was prepared from 3-benzyltetrahydrofuran-2-one 
(148) (305 mg, 1.73 mmol) using the general procedure (1.5 eq of dimethyltitanocene). 
Purification by flash chromatography on silica gel (petroleum ether/NEt3, 99:1) afforded 3-benzyl-
2-methylenetetrahydrofuran (146a) as a white solid (193 mg, 64%): IR (neat) 1708, 1085, 1019, 
732, 698 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.34–7.22 (m, 5H), 4.30 (dd, J = 1.6, 1.6 Hz, 1H), 
4.09 (ddd, J = 7.9, 7.9, 4.2 Hz, 1H), 3.96 (ddd, J = 8.4, 8.4, 6.5 Hz, 1H), 3.86 (dd, J = 1.6, 1.6 Hz, 
1H), 3.06 (dd, J = 13.3, 5.2 Hz, 1H), 3.02–2.94 (m, 1H), 2.62 (dd, J = 13.4, 9.6 Hz, 1H), 2.03–1.95 
(m, 1H), 1.78–1.69 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 166.3, 140.1, 129.0, 128.6, 126.5, 
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112.2, 79.0, 68.9, 42.7, 39.7, 31.2; HRMS (ESI) m/z calcd for C12H15O [M + H]+ 175.1123, found 
175.1112. 
General procedure for the preparation of aldol type reaction 
Anhydrous DCM (0.25 M) was added to a reaction tube containing 4 Å MS (50 mg / 1 mL DCM) 
under N2. The mixture was cooled to –78 °C and the enol ether (1.0 mmol, 1 eq.) and the carbonyl 
derivative (1.4 mmol, 1.4 eq.) was added. Then N,N-diisopropylethylamine (1.0 mmol, 1 eq.) and 
the Lewis acid (1.0 mmol, 1 eq.) were added dropwise respectively. The solution was slowly 
warmed to rt over 2 h and stirred at rt for 12-24 h. The reaction mixture was concentrated in vacuo 
and the residue was purified directly by flash column chromatography on silica gel (petroleum 
ether/EtOAc). 
Ethyl 7-phenyl-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113a) 
 
Ethyl 7-phenyl-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113a) was prepared from 3-phenyl-2-
methyleneoxetane (62a) (146 mg, 1.0 mmol) using the general procedure. Purification by flash 
chromatography on silica gel (petroleum ether/EtOAc, 90:10) afforded ethyl 7-phenyl-1,5-
dioxaspiro[3.3]heptane-2-carboxylate (113a) as a colorless oil (184 mg, 74%): IR (neat) 1730, 
1205, 1029, 940, 700 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.42–7.26 (m, 5H), 4.80 (dd, J = 8.0, 5.9 
Hz, 1H), 4.57 (dd, J = 7.9, 6.0 Hz, 1H), 4.41 (dd, J = 5.8, 5.8 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 
4.15 (dd, J = 7.7, 6.4 Hz, 1H), 2.79 (dd, J = 13.1, 8.1 Hz, 1H), 2.58 (dd, J = 13.1, 5.7 Hz, 1H), 
1.28 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.1, 136.5, 129.3, 128.0, 127.8, 117.0, 
69.6, 68.9, 61.6, 52.5, 36.4, 14.3; HRMS (ESI) m/z calcd for C14H17O4 [M + H]+ 249.1127, found 
249.1123. 
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Ethyl 6-cyclohexyl-2,6-dihydroxy-4-oxohexanoate (131o) 
 
Ethyl 6-cyclohexyl-2,6-dihydroxy-4-oxohexanoate (131o) was prepared from 4-cyclohexyl-2-
methyleneoxetane (62o) (129 mg, 0.847 mmol) using the general procedure. Purification by flash 
chromatography on silica gel (petroleum ether/EtOAc, 70:30) afforded ethyl 6-cyclohexyl-2,6-
dihydroxy-4-oxohexanoate (131o) as a colorless oil (230 mg, 78%, dr 1:1): IR (neat) 3459 (br), 
2921, 1712, 1203, 1095, 1027 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.50–4.44 (m, 1H), 4.28–4.17 
(m, 2H), 3.85–3.78 (m, 1H), 3.00–2.82 (m, 3H), 2.59–2.57 (m, 2H), 1.82–1.60 (m, 6H), 1.37–0.92 
(m, 10H); 13C NMR (100 MHz, CDCl3) δ 209.7, 209.6, 173.8, 71.9, 71.8, 67.1, 67.1, 62.1, 47.5, 
47.4, 47.0, 43.3, 29.0, 28.4, 26.6, 26.3, 26.2, 14.3; HRMS (ESI) m/z calcd for C14H25O5 [M + H]+ 
273.1702, found 273.1702. 
Ethyl 2,6-dihydroxy-4-oxo-7,7-diphenylheptanoate (131p) 
 
Ethyl 2,6-dihydroxy-4-oxo-7,7-diphenylheptanoate (131p) was prepared from 4-(2-diphenyl-
methyl)-2-methyleneoxetane (62p) (156 mg, 0.660 mmol) using the general procedure. 
Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 70:30) afforded ethyl 
2,6-dihydroxy-4-oxo-7,7-diphenylheptanoate (131p) as a colorless oil (210 mg, 83%, dr 1:1): IR 
(neat) 3442 (br), 1720, 1095, 1031, 746, 704 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.40–7.17 (m, 
10H), 4.88 (dd, J = 8.7, 8.7 Hz, 1H), 4.48–4.41 (m, 1H), 4.23 (q, J = 7.2 Hz, 1H), 3.92 (d, J = 9.0 
Hz, 1H), 3.17 (dd, J = 4.9, 3.4 Hz, 1H), 2.94–2.78 (m, 2H), 2.66–2.51 (m, 3H), 1.28–1.24 (m, 3H); 
13C NMR (100 MHz, CDCl3) δ 208.6, 173.8, 141.9, 141.3, 129.1, 129.0, 128.9, 128.5, 127.1, 70.2, 
136 
 
70.2, 67.1, 67.0, 62.2, 58.0, 48.7, 48.6, 47.2, 47.1, 14.3; HRMS (ESI) m/z calcd for C21H25O5 [M 
+ H]+ 357.1702, found 357.1689. 
Ethyl 6-chloro-2-hydroxy-5-methyl-4-oxo-5-phenylhexanoate (132c) 
 
Ethyl 2,6-dihydroxy-5-methyl-4-chloro-5-phenylhexanoate (132c) was prepared from 3-methyl-3-
phenyl-2-methyleneoxetane (62c) (110 mg, 0.686 mmol) using the general procedure. 
Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 90:10) afforded ethyl 
2,6-dihydroxy-5-methyl-4-oxo-5-phenylhexanoate (132c) as a colorless oil (135 mg, 66%): IR 
(neat) 3507 (br), 1734, 1707, 1207, 1097, 1025, 699 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.40–
7.23 (m, 5H), 4.41–4.38 (m, 1H), 4.28–4.12 (m, 2H), 4.06 (d, J = 11.3 Hz, 1H), 3.82 (dd, J = 11.3, 
2.2 Hz, 1H), 3.08 (dd, J = 15.2, 5.2 Hz, 1H), 2.93–2.80 (m, 1H), 2.73–2.65 (m, 1H), 1.71 (s, 3H), 
1.26–1.23 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 208.0, 207.8, 173.9, 138.8, 129.2, 128.2, 126.8, 
67.0, 66.8, 62.1, 56.9, 51.3, 42.1, 42.0, 19.7, 14.3; HRMS (ESI) m/z calcd for C15H20ClO4 [M + H]+ 
299.1050, found 299.1045. 
Ethyl 2,6-dihydroxy-5,5-dimethyl-4-oxo-6-phenylhexanoate (131g) 
 
Ethyl 2,6-dihydroxy-5,5-dimethyl-4-oxo-6-phenylhexanoate (131g) was prepared from 3,3-
dimethyl-4-phenyl-2-methyleneoxetane (62g) (174 mg, 1.00 mmol) using the general procedure. 
Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 90:10 to 70:30) 
afforded ethyl 2,6-dihydroxy-5,5-dimethyl-4-oxo-6-phenylhexanoate (131g) as a colorless oil (244 
mg, 83%, dr 3:2). The diastereomers were inseparable during column chromatography: IR (neat) 
137 
 
3480 (br), 1733, 1710, 1200, 1096, 1054, 1028, 702 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35–7.32 
(m, 5H), 5.32 (s, 0.6H), 5.31 (s, 0.4 H), 4.51–4.46 (m, 1H), 4.28–4.23 (m, 2H), 3.18–3.02 (m, 2H), 
1.30–1.25 (m, 6H), 1.01 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 211.1, 211.0, 173.9, 137.1, 129.3, 
128.6, 128.1, 68.0, 67.9, 67.1, 67.0, 62.0, 53.7, 53.6, 42.6, 42.5, 23.8, 23.7, 18.7, 18.6, 14.3; 
HRMS (ESI) m/z calcd for C16H22O5 [M]+ 294.1467, found 294.1730. 
Ethyl 6-chloro-5,5-dimethyl-2-hydroxy-4-oxo-6-phenylhexanoate (132g) 
 
Ethyl 6-chloro-5,5-dimethyl-2-hydroxy-4-oxo-6-phenylhexanoate (132g) was prepared from 3,3-
dimethyl-4-phenyl-2-methyleneoxetane (62g) (174 mg, 1.00 mmol) using the general procedure 
with TiCl4 as the Lewis acid. Purification by flash chromatography on silica gel (petroleum 
ether/EtOAc, 90:10 to 80:20) afforded ethyl 6-chloro-5,5-dimethyl-2-hydroxy-4-oxo-6-
phenylhexanoate (132g) as a colorless oil (163 mg, 52%, dr 2:1). The diastereomers were 
inseparable during column chromatography: 1H NMR (400 MHz, CDCl3) δ 7.38–7.29 (m, 7.5H), 
4.92 (s, 1H), 4.86 (dd, J = 8.0, 3.6 Hz, 1H), 4.41 (s, 0.5H), 4.38 (dd, J = 12.4, 3.2 Hz, 0.5H), 4.29–
4.17 (m, 3H), 3.08 (dd, J = 15.4, 8.0 Hz, 1H), 3.04 (dd, J = 14.6, 12.4 Hz, 0.5H), 2.84 (dd, J = 
15.3, 3.6 Hz, 1H), 2.65 (dd, J = 14.6, 3.2 Hz, 0.5H), 1.31 (t, J = 9.2 Hz, 1.5H), 1.26 (t, J = 7.2 Hz, 
3H), 1.08 (s, 1.5H), 1.06 (s, 3H), 1.03 (s, 3H), 0.97 (s, 1.5H); 13C NMR (100 MHz, CDCl3) δ 210.0, 
209.7, 170.8, 169.4, 136.6, 136.3, 128.4, 128.3, 128.1, 128.1, 128.0, 86.4, 83.2, 76.9, 76.0, 72.9, 
61.8, 61.8, 50.8, 50.3, 40.8, 38.7, 29.9, 20.9, 19.9, 19.9, 19.5, 14.4; HRMS (ESI) m/z calcd for 
C16H25ClNO4 [M + NH4]+ 330.1472, found 330.1471. 
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Ethyl 2,6-dihydroxy-5,5-dimethyl-6-(naphthalene-1-yl)-4-oxohexanoate (133f) 
 
Ethyl 2,6-dihydroxy-5,5-dimethyl-6-(naphthalene-1-yl)-4-oxohexanoate (133f) was prepared from 
3,3-dimethyl-4-(naphthalen-1-yl)-2-methyleneoxetane (62f) (224 mg, 1.00 mmol) using the 
general procedure. Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 
90:10) afforded ethyl 2,6-dihydroxy-5,5-dimethyl-6-(naphthalene-1-yl)-4-oxohexanoate (133f) as 
a colorless oil (185 mg, 59%): IR (neat) 2975, 1746, 1718, 1135, 1023, 792 cm-1; 1H NMR (400 
MHz, CDCl3) δ 8.01 (d, J = 7.6 Hz, 1H), 7.89–7.82 (m, 3H), 7.57–7.44 (m, 3H), 5.38 (s, 1H), 4.51 
(dd, J = 12.4, 3.3 Hz, 1H), 4.29–4.24 (m, 2H), 3.14 (dd, J = 14.6, 12.4 Hz, 1H), 2.73 (dd, J = 14.6, 
3.3 Hz, 1H), 1.31 (t, J = 7.2 Hz, 3H), 1.22 (s, 3H), 0.89 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
210.1, 169.5, 133.8, 132.4, 131.5, 129.2, 129.0, 127.5, 126.2, 125.5, 125.2, 123.8, 76.3, 61.9, 
52.1, 40.8, 20.5, 20.3, 14.3; HRMS (ESI) m/z calcd for C20H24O5 [M]+ 344.1624, found 344.1837. 
Ethyl 6-chloro-5,5-dimethyl-2-hydroxy-6-(naphthalene-1-yl)-4-oxohexanoate (133f’) 
 
Ethyl 6-chloro-5,5-dimethyl-2-hydroxy-6-(naphthalene-1-yl)-4-oxohexanoate (133f’) was 
obtained as the minor product from the above reaction. Compound 133f’ was obtained as a 
colorless oil (54 mg, 15%): IR (neat) 2924, 1713, 1127, 906, 727 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 8.13 (d, J = 8.3 Hz, 1H), 7.88–7.84 (m, 2H), 7.57–7.46 (m, 4H), 5.92 (s, 1H), 4.72 (dd, J = 7.0, 
5.6 Hz, 1H), 4.24–4.13 (m, 2H), 3.56 (dd, J = 15.6, 7.2 Hz, 1H), 1.22–1.20 (m, 6H), 1.15 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 210.5, 170.8, 134.1, 132.1, 131.9, 129.3, 129.1, 126.9, 126.6, 
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125.8, 124.8, 123.9, 78.3, 72.2, 61.8, 50.8, 39.1, 23.3, 20.5, 14.3; HRMS (ESI) m/z calcd for 
C20H23ClO4 [M]+ 362.1285, found 362.2022. 
Ethyl 5,5-dimethyl-4-oxo-6,6-diphenyloxane-2-carboxylate (114h) 
 
Ethyl 5,5-dimethyl-4-oxo-6,6-diphenyloxane-2-carboxylate (114h) was prepared from 3,3-
dimethyl-4,4-diphenyl-2-methyleneoxetane (62h) (137 mg, 0.548 mmol) using the general 
procedure with ZnCl2 as the Lewis acid. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc, 90:10) afforded ethyl 5,5-dimethyl-4-oxo-6,6-diphenyloxane-2-
carboxylate (114h) as a colorless oil (56 mg, 29%): IR (neat) 2920, 1738, 1709, 1657, 1446, 1275, 
698 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36–7.23 (m, 10H), 4.31–4.12 (m, 2H), 3.87 (dd, J = 11.8, 
4.4 Hz, 1H), 2.99 (dd, J = 16.0, 11.8 Hz, 1H), 2.58 (dd, J = 16.0, 4.3 Hz, 1H), 1.40 (s, 3H), 1.28 
(t, J = 7.1 Hz, 3H), 1.13 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 211.2, 170.5, 142.3, 141.3, 132.6, 
130.8, 130.3, 129.3, 128.5, 128.4, 127.4, 127.0, 87.8, 68.9, 61.5, 52.8, 39.3, 24.3, 19.7, 14.3; 
HRMS (ESI) m/z calcd for C22H25O4 [M + H]+ 353.1752, found 353.1747. 
Ethyl 5-(cyclohex-1-en-1-yl)-2-hydroxy-5-methyl-4-oxohexanoate (135) 
 
Ethyl 5-(cyclohex-1-en-1-yl)-2-hydroxy-5-methyl-4-oxohexanoate (135) was prepared from 3,3-
dimethyl-4-phenyl-2-methyleneoxetane (62j) (174 mg, 1.00 mmol) using the general procedure. 
Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 95:5) afforded ethyl 5-
(cyclohex-1-en-1-yl)-2-hydroxy-5-methyl-4-oxohexanoate (135) as colorless oil (281 mg, 58%): 
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IR (neat) cm-1; 1H NMR (400 MHz, CDCl3) δ 5.72–5.65 (m, 1H), 4.40 (ddd, J = 7.3, 7.3, 7.3 Hz, 
1H), 4.23 (q, J = 9.5 Hz, 2H), 3.16 (d, J = 7.6 Hz, 1H), 2.93 (dd, J = 23.8, 5.5 Hz, 1H), 2.86 (dd, J 
= 23.8, 7.4 Hz, 1H), 2.13–2.05 (m, 2H), 1.84–1.74 (m, 2H), 1.62–1.50 (m, 4H), 1.28 (t, J = 9.5 Hz, 
3H), 1.18 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 212.3, 174.3, 139.7, 123.1, 67.4, 61.9, 53.6, 40.6, 
26.0, 25.8, 23.3, 23.1, 23.0, 22.4, 14.3; HRMS (ESI) m/z calcd for C15H25O4 [M + H]+ 269.1753, 
found 269.1760. 
Ethyl 7-tritylamino-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113e) 
 
Ethyl 7-tritylamino-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113e) was prepared from (S)-3-
tritylamino-2-methyleneoxetane (62e) (220 mg, 0.67 mmol) using the general procedure. 
Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 90:10) afforded ethyl 
7-tritylamino-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113e) as a colorless oil (114 mg, 40%): 
IR (neat) 1732, 1447, 1260, 1031, 700 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.50–7.46 (m, 6H), 
7.29–7.17 (m, 9H), 4.93 (dd, J = 8.6, 6.0 Hz, 1H), 4.39–4.25 (m, 2H), 3.88–3.82 (m, 2H), 3.78–
3.73 (m, 1H), 3.20–3.10 (m, 1H), 2.91 (dd, J = 13.1, 8.6 Hz, 1H), 2.42 (dd, J = 13.2, 6.0 Hz, 1H), 
1.33 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.1, 146.0, 128.6, 128.4, 126.9, 119.1, 
73.4, 70.8, 70.4, 61.7, 58.9, 34.0, 14.6; HRMS (ESI) m/z calcd for C27H28NO4 [M + H]+ 430.2018, 
found 430.1991. 
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Ethyl 7-tritylamino-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113e’) 
 
Ethyl 7-tritylamino-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113e’) was obtained as the minor 
isomer from the above reaction. Compound 113e’ was obtained as a colorless oil (76 mg, 26%):  
IR (neat) 1730, 1205, 1029, 940, 700 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.54–7.52 (m, 6H), 7.34–
7.21 (m, 9H), 5.05 (dd, J = 8.3, 6.1 Hz, 1H), 3.91 (ddd, J = 12.7, 6.4, 6.4 Hz, 1H), 3.62 (dd, J = 
12.5, 6.1 Hz, 1H), 3.45 (dd, J = 6.4, 6.4 Hz, 1H), 2.93–2.88 (m, 2H), 2.18 (d, J = 12.3 Hz, 1H) , 
1.34 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.1, 146.0, 128.6, 128.4, 126.9, 119.1, 
73.4, 70.8, 70.4, 61.7, 58.9, 34.0, 14.6; HRMS (ESI) m/z calcd for C27H28NO4 [M + H]+ 430.2018, 
found 430.2020. 
Ethyl 7-phenyl-7-(prop-2-en-1-yl)-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113d) 
 
Ethyl 7-phenyl-7-(prop-2-en-1-yl)-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113d) was prepared 
from 3-allyl-3-phenyl-2-methyleneoxetane (62d) (310 mg, 1.66 mmol) using the general 
procedure with ZnCl2 as the Lewis acid. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc, 90:10) afforded ethyl 7-phenyl-7-(prop-2-en-1-yl)-1,5-
dioxaspiro[3.3]heptane-2-carboxylate (113d) as a colorless oil (186 mg, 39%): IR (neat) 2920, 
1742, 1203, 1032, 949 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.41–7.28 (m, 5H), 5.54–5.43 (m, 1H), 
5.06 (dd, J = 17.1, 1.4 Hz, 1H), 4.98 (d, J = 10.1 Hz, 1H), 4.90 (dd, J = 8.5, 5.8 Hz, 1H), 4.70 (d, 
J = 5.6 Hz, 1H), 4.38 (d, J = 5.7 Hz, 1H), 4.30–4.21 (m, 2H), 3.07–2.96 (m, 2H), 2.73 (dd, J = 
13.2, 8.6 Hz, 1H), 2.53 (dd, J = 13.2, 5.8 Hz, 1H), 1.31 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, 
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CDCl3) δ 172.0, 139.3, 133.5, 128.9, 127.2, 127.2, 118.5, 118.0, 71.7, 69.8, 61.6, 55.9, 39.0, 36.8, 
14.4; HRMS (ESI) m/z calcd for C17H21O4 [M + H]+ 289.1440, found 289.1416. 
Ethyl 7-phenyl-7-(prop-2-en-1-yl)-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113d’) 
 
Ethyl 7-phenyl-7-(prop-2-en-1-yl)-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113d’) was obtained 
as the minor isomer from the above reaction. Compound 113d’ was obtained as a colorless oil 
(125 mg, 26%):  IR (neat) 1731, 1206, 1029, 944, 914, 700 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.44–7.23 (m, 5H), 5.51–5.41 (m, 1H), 5.06 (dd, J = 17.1, 1.3 Hz, 1H), 5.01–4.98 (m, 1H), 4.68 
(dd, J = 7.9, 6.2 Hz, 1H), 4.64 (dd, J = 5.6, 1.4 Hz, 1H), 4.38 (d, J = 5.6 Hz, 1H), 4.26 (q, J = 7.2 
Hz, 2H), 3.10 (dd, J = 14.5, 8.3 Hz, 1H), 2.87–2.80 (m, 2H), 2.53 (dd, J = 13.2, 6.2 Hz, 1H), 1.29 
(t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.1, 139.7, 133.3, 129.1, 127.4, 126.7, 118.8, 
116.4, 71.6, 68.9, 61.8, 55.6, 38.8, 37.0, 14.4; HRMS (ESI) m/z calcd for C17H21O4 [M + H]+ 
289.1440, found 289.1418. 
Ethyl 7,7-dimethyl-6-(naphthalene-1-yl)-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113f) 
 
Ethyl 7,7-dimethyl-6-(naphthalene-1-yl)-1,5-dioxaspiro[3.3]heptane-2-carboxylate (113f) was 
prepared from 3,3-dimethyl-4-(naphthalen-1-yl)-2-methyleneoxetane (62f) (224 mg, 1.00 mmol) 
using the general procedure. Purification by flash chromatography on silica gel (petroleum 
ether/EtOAc, 90:10) afforded ethyl 7,7-dimethyl-6-(naphthalene-1-yl)-1,5-dioxaspiro[3.3]heptane-
2-carboxylate (3c) as a colorless oil (189 mg, 58%, dr 4:1). The diastereomers were inseparable 
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during column chromatography: IR (neat) 2966, 1736, 1015, 948, 733 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.90–7.86 (m, 1.2H), 7.79–7.77 (m, 1H), 7.72–7.70 (m, 0.8H), 7.62–7.60 (m, 1H), 7.56–
7.46 (m, 3H), 6.07 (s, 0.8H), 5.86 (s, 0.2H), 5.01–4.97 (m, 1H), 4.32–4.17 (m, 2H), 3.16–3.06 (m, 
0.4H), 3.08 (dd, J = 12.8, 8.5 Hz, 0.8H), 2.87 (dd, J = 13.0, 5.4 Hz, 0.8H), 1.74 (s, 2.4H), 1.64 (s, 
0.6H), 1.31 (t, J = 7.2 Hz, 2.4H), 1.29 (t, J = 7.2 Hz, 0.6H), 0.75 (s, 0.6H), 0.66 (s, 2.4H); 13C NMR 
(100 MHz, CDCl3) δ 172.2, 172.1, 137.6, 135.6, 135.2, 133.5, 133.4, 133.3, 130.3, 129.1, 129.0, 
127.9, 127.8, 126.3, 126.1, 125.9, 125.7, 123.7, 122.8, 122.6, 122.5, 117.3, 117.0, 85.2, 84.5, 
69.6, 61.5, 47.9, 47.5, 35.8, 35.6, 24.0, 22.1, 18.8, 16.7, 14.3; HRMS (ESI) m/z calcd for C20H23O4 
[M + H]+ 327.1596, found 327.1603. 
Ethyl 3-(3-benzyl-4,5-dihydrofuran-2-yl)-2-hydroxypropanoate (149) 
 
Ethyl 3-(3-benzyl-4,5-dihydrofuran-2-yl)-2-hydroxypropanoate (149) was prepared from 3-benzyl-
2-methylenetetrahydrofuran (146a) (115 mg, 0.660 mmol) using the general procedure with ZnCl2 
as the Lewis acid. Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 
90:10) afforded ethyl 3-(3-benzyl-4,5-dihydrofuran-2-yl)-2-hydroxypropanoate (149) as a 
colorless oil (182 mg, 83%): IR (neat) 3454, 2899, 1731, 1196, 1149, 1091 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.31–7.17 (m, 5H), 4.40 (dd, J = 11.2, 6.4 Hz, 1H), 4.29–4.11 (m, 4H), 3.37 (s, 
2H), 3.13 (d, J = 7.1 Hz, 1H), 2.78–2.66 (m, 2H), 2.49–2.44 (m, 2H), 1.28 (t, J = 7.1 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 174.2, 147.3, 140.0, 128.6, 128.6, 126.3, 109.9, 69.2, 68.4, 61.8, 33.1, 
32.8, 31.2, 14.4; HRMS (ESI) m/z calcd for C16H21O4 [M + H]+ 277.1440, found 277.1422. 
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Ethyl (2E)-3-(3-benzyl-4,5-dihydrofuran-2-yl)prop-2-enoate (152) 
 
Ethyl (2E)-3-(3-benzyl-4,5-dihydrofuran-2-yl)prop-2-enoate (152) was prepared from 3-benzyl-2-
methylenetetrahydrofuran (146a) (115 mg, 0.660 mmol) using the general procedure with SnCl4 
(or TiCl4) as the Lewis acid. Purification by flash chromatography on silica gel (petroleum 
ether/EtOAc, 90:10) afforded ethyl (2E)-3-(3-benzyl-4,5-dihydrofuran-2-yl)prop-2-enoate (152) as 
a colorless oil (133 mg, 78%): IR (neat) 1717, 1299, 1275, 1178, 1027, 983, 700 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.40 (d, J = 15.4 Hz, 1H), 7.31–7.15 (m, 5H), 6.16 (d, J = 15.4 Hz, 1H), 4.31 
(t, J = 9.4 Hz, 2H), 4.23 (q, J = 7.1 Hz, 2H), 3.58 (s, 2H), 2.62 (t, J = 9.4 Hz, 2H), 1.31 (t, J = 7.1 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 167.6, 148.4, 138.8, 129.7, 128.8, 128.7, 126.7, 122.1, 
118.9, 68.3, 60.6, 34.3, 33.2, 14.5; HRMS (ESI) m/z calcd for C16H19O3 [M + H]+ 259.1334, found 
259.1329. 
(1E)-5-Chloro-4,4-dimethyl-5-(naphthalene-1-yl)-1-(4-nitrophenyl)pent-1-en-3-one (136f) 
 
(1E)-5-Chloro-4,4-dimethyl-5-(naphthalene-1-yl)-1-(4-nitrophenyl)pent-1-en-3-one (136f) was 
prepared from 3,3-dimethyl-4-(naphthalen-1-yl)-2-methyleneoxetane (62f) (224 mg, 1.00 mmol) 
using the general procedure with TiCl4 as the Lewis acid. Purification by flash chromatography on 
silica gel (petroleum ether/EtOAc, 96:4) afforded (1E)-5-chloro-4,4-dimethyl-5-(naphthalene-1-
yl)-1-(4-nitrophenyl)pent-1-en-3-one (136f) as colorless needles (378 mg, 96%): IR (neat) 1601, 
1515, 1337, 1053, 786 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.25–8.16 (m, 3H), 7.87–7.83 (m, 3H), 
7.65–7.47 (m, 6H), 7.18 (d, J = 15.6 Hz, 1H), 6.45 (br s, 1H), 1.57 (br s, 3H), 1.13 (br s, 3H); 13C 
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NMR (100 MHz, CDCl3) δ 201.5, 148.8, 141.1, 141.1, 133.9, 133.6, 131.7, 129.4, 129.3, 129.1, 
128.8, 126.8, 125.9, 125.2, 124.9, 124.3, 123.1, 62.2, 54.0, 24.2, 20.0; HRMS (ESI) m/z calcd for 
C23H20ClNO3 [M]+ 393.1132, found 393.1132. 
(1E)-5-Chloro-4,4-dimethyl-1-(4-nitrophenyl)-5-phenylpent-1-en-3-one (136g) 
 
(1E)-5-Chloro-4,4-dimethyl-1-(4-nitrophenyl)-5-phenylpent-1-en-3-one (136g) was prepared from 
3,3-dimethyl-4-phenyl-2-methyleneoxetane (62g) (174 mg, 1.00 mmol) using the general 
procedure with TiCl4 as the Lewis acid. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc, 95:5) afforded (1E)-5-chloro-4,4-dimethyl-1-(4-nitrophenyl)-5-
phenylpent-1-en-3-one (136g) as colorless oil (316 mg, 92%): IR (neat) 1684, 1602, 1516, 1338, 
1052 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.25–8.23 (m, 2H), 7.71–7.68 (m, 3H), 7.41–7.30 (m, 
5H), 7.22 (d, J = 15.6 Hz, 1H), 5.38 (br s, 1H), 1.40 (br s, 3H), 1.16 (br s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 200.9, 148.7, 141.2, 141.1, 137.3, 129.2, 128.7, 128.1, 124.6, 124.3, 68.2, 53.1, 23.4, 
19.6; HRMS (ESI) m/z calcd for C19H22ClN2O3 [M + NH4]+ 361.1319, found 361.1335. 
(1E)-1-(4-Bromophenyl)-5-chloro-4,4-dimethyl-5-phenylpent-1-en-3-one (138g) 
 
(1E)-1-(4-Bromophenyl)-5-chloro-4,4-dimethyl-5-phenylpent-1-en-3-one (138g) was prepared 
from 3,3-dimethyl-4-phenyl-2-methyleneoxetane (62g) (174 mg, 1.00 mmol) using the general 
procedure with TiCl4 as the Lewis acid. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc, 96:4) afforded (1E)-1-(4-bromophenyl)-5-chloro-4,4-dimethyl-5-
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phenylpent-1-en-3-one (138g) as colorless oil (347 mg, 94%): IR (neat) 1681, 1601, 1482, 1054, 
996, 818, 754, 701 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 15.5 Hz, 1H), 7.54–7.51 (m, 
2H), 7.44–7.38 (m, 4H), 7.35–7.30 (m, 3H), 7.10 (d, J = 15.5 Hz, 1H), 5.39 (s, 1H), 1.40 (s, 3H), 
1.14 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 201.2, 143.0, 137.6, 133.9, 132.4, 130.0, 129.2, 128.6, 
128.1, 125.0, 121.4, 68.4, 53.0, 23.4, 19.9; HRMS (ESI) m/z calcd for C19H19BrClO [M + H]+ 
377.0308, found 377.0330. 
(4E,6E)-1-Chloro-2,2-dimethyl-1,7-diphenylhepta-4,6-dien-3-one (143g) 
 
(4E,6E)-1-Chloro-2,2-dimethyl-1,7-diphenylhepta-4,6-dien-3-one (143g) was prepared from 3,3-
dimethyl-4-phenyl-2-methyleneoxetane (62g) (174 mg, 1.00 mmol) using the general procedure 
with TiCl4 as the Lewis acid. Purification by flash chromatography on silica gel (petroleum 
ether/EtOAc, 95:5) afforded (4E,6E)-1-chloro-2,2-dimethyl-1,7-diphenylhepta-4,6-dien-3-one 
(143g) as colorless oil (282 mg, 87%): IR (neat) 1680, 1581, 1052, 1000, 749, 700 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.54–7.48 (m, 3H), 7.40–7.30 (m, 8H), 7.02–6.93 (m, 2H), 6.71 (d, J = 14.8 
Hz, 1H), 5.39 (s, 1H), 1.37 (s, 3H), 1.10 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 201.5, 144.5, 142.3, 
137.8, 136.3, 129.4, 129.2, 129.1, 128.5, 128.0, 127.5, 127.0, 124.2, 68.5, 52.7, 23.4, 19.9; 
HRMS (ESI) m/z calcd for C21H22ClO [M + H]+ 325.1359, found 325.1375. 
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(1E)-5-Chloro-4,4-dimethyl-1-(2-nitrophenyl)-5-phenylpent-1-en-3-one (137g) 
 
(1E)-5-Chloro-4,4-dimethyl-1-(2-nitrophenyl)-5-phenylpent-1-en-3-one (137g) was prepared from 
3,3-dimethyl-4-phenyl-2-methyleneoxetane (62g) (174 mg, 1.00 mmol) using the general 
procedure with TiCl4 as the Lewis acid. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc, 90:10) afforded (1E)-5-chloro-4,4-dimethyl-1-(2-nitrophenyl)-5-
phenylpent-1-en-3-one (137g) as colorless oil (281 mg, 82%): IR (neat) 1685, 1603, 1521, 1342, 
1055, 753, 701 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.07–8.02 (m, 3H), 7.67–7.53 (m, 3H), 7.40–
7.30 (m, 5H), 6.98 (d, J = 15.3 Hz, 1H), 5.36 (s, 1H), 1.40 (s, 3H), 1.16 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 200.6, 139.4, 137.5, 133.6, 131.4, 130.5, 129.5, 129.2, 128.6, 128.2, 125.8, 125.1, 
68.4, 53.1, 23.1, 20.0; HRMS (ESI) m/z calcd for C19H22ClN2O3 [M + NH4]+ 361.1319, found 
361.1333. 
(1E)-5-Chloro-4,4-dimethyl-1,5-diphenylpent-1-en-3-one (139g) 
 
(1E)-5-Chloro-4,4-dimethyl-1,5-diphenylpent-1-en-3-one (139g) was prepared from 3,3-dimethyl-
4-phenyl-2-methyleneoxetane (62g) (174 mg, 1.00 mmol) using the general procedure with TiCl4 
as the Lewis acid. Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 
95:5) afforded (1E)-5-chloro-4,4-dimethyl-1,5-diphenylpent-1-en-3-one (139g) as colorless oil 
(281 mg, 82%): IR (neat) 3061, 3028, 1680, 1603, 1055, 762, 701 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.73 (d, J = 15.5 Hz, 1H), 7.61–7.57 (m, 2H), 7.42–7.39 (m, 5H), 7.35–7.30 (m, 3H), 7.16 (d, J 
= 15.5 Hz, 1H), 5.44 (s, 1H), 1.41 (s, 3H), 1.15 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 201.2, 144.4, 
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137.7, 137.9, 130.7, 129.2, 129.1, 128.6, 128.5, 128.0, 120.8, 68.4, 52.9, 23.3, 19.9; HRMS (ESI) 
m/z calcd for C19H20ClO [M + H]+ 299.1203, found 299.1212. 
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